{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with widely metastatic cutaneous melanoma, symptomatic with new headaches. Staging: IV with brain metastases confirmed on MRI. PD-L1 reported at 60% TPS. Attempts at comprehensive molecular testing (BRAF/NRAS) were unsuccessful due to insufficient tissue. He received combination immunotherapy with nivolumab + ipilimumab and underwent stereotactic radiosurgery to two intracranial lesions. Short interval MRI shows stable size of most lesions without new disease.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 60%", "treatment": "nivolumab and ipilimumab; stereotactic radiosurgery", "response": "stable disease", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with newly diagnosed metastatic lung adenocarcinoma (right lower lobe). Clinical stage IV with multiple enhancing brain lesions and lytic lesions in the spine. Comprehensive molecular testing performed on biopsy: EGFR L858R detected. PD-L1 TPS reported at 5%. Patient was started on osimertinib 80 mg daily. At 8-week restaging CT chest/abdomen and brain MRI there is a marked reduction in the size of the primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone (spine)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient s/p right hemicolectomy for stage III colon adenocarcinoma (pT3N1) in 2022. Tumor reported as MSI-H on PCR testing. Adjuvant FOLFOX was completed for 6 months with routine surveillance CTs; currently there is no radiographic recurrence.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with metastatic colorectal adenocarcinoma presenting with liver-dominant disease. Tumor sequencing showed KRAS G12D and concurrent TP53 mutation. Mismatch repair testing: MSS (microsatellite stable). He was treated with FOLFOX plus bevacizumab; after 4 cycles imaging demonstrates interval enlargement of hepatic lesions consistent with progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D; TP53 mutation", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX and bevacizumab", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old man with rapidly enlarging pigmented lesion on the back; excisional biopsy showed cutaneous melanoma. Staging scans demonstrate multiple hepatic and pulmonary nodules \u2014 stage IV. Tumor sequencing detected BRAF V600E; tumor mutational burden reported as TMB-high. He was started on dabrafenib and trametinib combination therapy and after two cycles CT shows shrinkage of liver lesions but a new small pulmonary lesion \u2014 overall assessment: partial response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female presenting with metastatic lung adenocarcinoma diagnosed on core biopsy. Molecular testing returned EGFR L858R; patient started osimertinib 80 mg daily. Brain and bone metastases were identified on staging MRI and PET/CT. She had an initial partial response on first restaging at 8 weeks but developed systemic progression at 9 months with new hepatic lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib", "response": "initial partial response then progression", "metastasis_site": "brain, bone, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical summary: 48\u2011year\u2011old male with unresectable cutaneous melanoma of the right thigh. Tumor sequencing confirmed a BRAF V600E mutation. He was initiated on dabrafenib plus trametinib. Early restaging CT at 6 weeks showed a good reduction in tumor burden (partial response), however 6\u2011month imaging revealed new bilateral pulmonary nodules consistent with progression. PD\u2011L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "initial partial response then progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "33-year-old man with a pigmented lesion on the back. Excisional biopsy showed melanoma Breslow 2.8 mm, ulceration absent, sentinel lymph node negative \u2014 staged as stage II (IIA). Tumor sequencing identified BRAF V600E. He underwent wide local excision with clear margins and was observed without adjuvant systemic therapy. Last clinical visit: no evidence of disease on exam.", "output": {"cancer_type": "cutaneous melanoma", "stage": "II", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old with metastatic cutaneous melanoma. Initial molecular testing showed BRAF V600E mutation. Patient received first-line dabrafenib plus trametinib with an early partial response, but after 8 months surveillance imaging documented progression with new hypodense lesions in the liver and sclerotic bone lesions consistent with progression of disease. No PD-L1 or TMB data available in chart.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib", "response": "initial partial response followed by progression", "metastasis_site": "liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old man with high-risk localized prostate adenocarcinoma (Gleason 4+4) underwent radical prostatectomy followed by adjuvant external beam radiation and androgen-deprivation therapy with leuprolide. Germline testing returned a BRCA2 pathogenic variant. Despite local therapy, PSA has risen from undetectable to 0.6 ng/mL on two consecutive checks, consistent with biochemical recurrence. No metastatic disease seen on recent bone scan and CT.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "III", "gene_mutation": "BRCA2 pathogenic variant", "biomarker": "PSA 0.6 ng/mL (biochemical recurrence)", "treatment": "radical prostatectomy, adjuvant radiation, androgen-deprivation therapy (leuprolide)", "response": "biochemical recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed lung adenocarcinoma presenting with progressive cough and weight loss. Staging PET-CT demonstrated bilateral pulmonary nodules, multiple lytic lesions in the thoracic spine and a 1.8 cm enhancing cerebellar lesion consistent with metastasis. Next-generation sequencing detected EGFR L858R. PD-L1 tumor proportion score reported as 15%. He was started on osimertinib 80 mg daily. After 3 months there is marked reduction in size of pulmonary lesions but interval enlargement of the cerebellar metastasis on MRI.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15% (TPS)", "treatment": "osimertinib 80 mg daily", "response": "mixed response (intrathoracic partial response; intracranial progression)", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male presented with obstructing sigmoid mass and underwent urgent colectomy. Final pathology consistent with adenocarcinoma, pathologic stage T3N1 (stage III). Tumor testing identified a KRAS G12D mutation and reported microsatellite stable (MSS). He completed six months of adjuvant FOLFOX and remains on surveillance without radiographic recurrence.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "colectomy, adjuvant FOLFOX", "response": "no evidence of disease / surveillance", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed metastatic lung adenocarcinoma (stage IV). Molecular testing on the biopsy returned EGFR L858R. PD-L1 tumor proportion score reported at 20%. Imaging at presentation showed brain metastases and osseous disease involving the femur. He was started on osimertinib 80 mg daily as first-line treatment. Interval CT/MRI after 8 weeks demonstrates decrease in size of pulmonary and intracranial lesions consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 20%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing revealed EGFR L858R mutation and PD-L1 10%. Brain MRI demonstrated multiple parenchymal metastases; stereotactic radiosurgery was performed to a 1.2 cm lesion. Patient was started on osimertinib 80 mg daily and CT at 8 weeks showed a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with biopsy-proven invasive ductal carcinoma of the right breast, clinical stage II (cT2N0M0). Tumor was ER-positive, PR-negative and HER2-amplified on FISH. She received neoadjuvant doxorubicin and cyclophosphamide x4 cycles followed by paclitaxel with concurrent trastuzumab, then underwent lumpectomy with sentinel node biopsy. Surgical pathology showed no residual invasive carcinoma (ypT0N0) \u2014 pathologic complete response. No distant mets identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II (cT2N0M0)", "gene_mutation": null, "biomarker": "ER-positive; PR-negative; HER2 amplification", "treatment": "neoadjuvant doxorubicin and cyclophosphamide then paclitaxel + trastuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma. Tumor sequencing identified KRAS G12D; microsatellite testing reported MSS and tumor mutational burden low. He was started on FOLFOX with bevacizumab as first-line therapy. Surveillance imaging at 6 months demonstrated new pulmonary nodules and increase in size of existing lesions consistent with disease progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable), TMB-low", "treatment": "FOLFOX and bevacizumab", "response": "progressive disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 43F with locally advanced breast cancer, clinical stage II (T2N1). Core biopsy: invasive ductal carcinoma, ER+, PR+, HER2 amplified by FISH. PIK3CA H1047R mutation detected on targeted panel. She received neoadjuvant paclitaxel with dual HER2 blockade (trastuzumab and pertuzumab) followed by lumpectomy. Surgical pathology reported complete response with no residual invasive carcinoma.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant paclitaxel with trastuzumab and pertuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with cutaneous melanoma originally staged III after wide local excision and positive sentinel node. Molecular testing revealed BRAF V600E. Received adjuvant pembrolizumab for 12 months but developed new pulmonary nodules consistent with metastatic spread. Therapy was switched to dabrafenib plus trametinib with a documented partial response on interval CT.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III (initial)", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab; dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with newly diagnosed lung adenocarcinoma, clinical stage IV. Staging scans revealed multiple brain and bone metastases. Molecular testing returned EGFR L858R positive; PD-L1 TPS 10%. He was started on osimertinib in June. Interval CT and MRI show decrease in size of the primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic colorectal adenocarcinoma who presented with multiple liver lesions. Genomic profiling identified KRAS G12D and tumor testing reported MSI\u2011H. He was started on FOLFOX with bevacizumab. Interval CT after 4 cycles shows no new lesions and overall tumor measurements are unchanged compared with baseline.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Surgical pathology and oncology summary: 54-year-old female underwent lumpectomy for a 1.8 cm invasive ductal carcinoma. Final path shows ER positive, PR positive, HER2 negative. Sentinel nodes negative. Pathologic stage IIA (T1c N0 M0). Patient completed adjuvant whole-breast radiation and was started on tamoxifen. No evidence of distant metastasis on baseline CT. No somatic mutation panel reported in chart.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIA", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy; adjuvant radiation; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy of left breast demonstrates invasive ductal carcinoma, ER negative, PR negative, HER2 IHC 3+ confirmed HER2 amplification by FISH. Clinical stage IIIA tumor. PIK3CA H1047R mutation identified on next-generation sequencing. Patient received neoadjuvant chemotherapy with docetaxel, carboplatin plus trastuzumab and pertuzumab; surgical pathology after mastectomy shows no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "invasive ductal breast cancer", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification (IHC 3+)", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with left-sided metastatic colorectal adenocarcinoma. Comprehensive profiling reported KRAS G12D mutation and high tumor mutational burden (TMB-high); tumor was MSI-H. He began FOLFOX plus bevacizumab and was transitioned to pembrolizumab because of MSI-H status; he is currently on a protocol combining immune checkpoint blockade and VEGF inhibition. Most recent CT shows stable hepatic lesions with small peritoneal nodules.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H, TMB-high", "treatment": "FOLFOX and bevacizumab; pembrolizumab (immunotherapy) with bevacizumab", "response": "stable disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old male diagnosed with metastatic pancreatic ductal adenocarcinoma with liver metastases. Germline and somatic testing demonstrated a pathogenic BRCA2 mutation. He received 8 cycles of FOLFIRINOX with CA19-9 falling from 12,000 to 450 U/mL and radiographic disease control. After good clinical response he was transitioned to olaparib maintenance. Disease has been radiographically stable on follow-up scans.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "CA19-9 elevated (declining on therapy)", "treatment": "FOLFIRINOX followed by olaparib maintenance", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with metastatic lung adenocarcinoma presented with progressive cough and headaches. Molecular testing identified an EGFR L858R substitution; PD-L1 TPS was reported at 5%. Staging CT and MRI demonstrated multiple intracranial lesions consistent with metastases. She was started on osimertinib 80 mg daily. First restaging at 8 weeks showed decrease in size of pulmonary and brain lesions consistent with a partial response and symptomatic improvement.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 62-year-old male with newly diagnosed lung adenocarcinoma, stage IV with multiple brain and bone metastases. Molecular testing returned EGFR L858R (exon 21) and PD-L1 10%. Patient started first-line osimertinib 80 mg daily; stereotactic radiosurgery to intracranial lesions performed. At first restaging CT/MRI at 8 weeks there is interval shrinkage of the primary and brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with metastatic colorectal adenocarcinoma, presenting with multiple liver lesions and several pulmonary nodules. Molecular testing: KRAS G12D positive, MSI-H by PCR and TMB-high reported on panel. He received FOLFOX with bevacizumab as initial therapy and was transitioned to pembrolizumab because of MSI-H; disease has been stable on immunotherapy.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and discharge summary: 62-year-old female with high-grade serous ovarian carcinoma who underwent optimal cytoreductive surgery. Pathology consistent with stage IIIC disease with extensive peritoneal involvement. She completed six cycles of carboplatin and paclitaxel with excellent CA-125 response and is now on niraparib maintenance. Germline and somatic mutation testing results were pending at discharge.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "carboplatin and paclitaxel; niraparib maintenance", "response": "complete response (clinical/biochemical remission)", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with newly staged metastatic prostate adenocarcinoma. Pelvic MRI and CT abdomen/pelvis showed bulky pelvic lymphadenopathy consistent with nodal metastases and no visceral lesions; clinical stage IV (node-positive). No actionable mutations were reported on the tumor panel. He was started on androgen deprivation therapy with leuprolide and received docetaxel \u00d76 cycles. PSA fell substantially and imaging at 3 months shows disease stabilization.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide and docetaxel", "response": "stable disease", "metastasis_site": "pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with newly diagnosed invasive ductal carcinoma of the right breast. Pathology: ER+, PR+, HER2 amplified by FISH. Tumor 2.5 cm, 1/12 nodes positive. Stage IIA disease. Tumor genotyping identified PIK3CA H1047R. Patient underwent breast-conserving surgery (lumpectomy) with sentinel node biopsy and is planned for adjuvant doxorubicin/cyclophosphamide x4 \u2192 paclitaxel x12 with concurrent trastuzumab, followed by endocrine therapy with tamoxifen. Post-op imaging shows no residual disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy; adjuvant doxorubicin/cyclophosphamide followed by paclitaxel; trastuzumab; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman found to have a 1.8 cm invasive ductal carcinoma of the left breast, T1N0 (Stage I). Immunohistochemistry: ER positive, PR positive, HER2 3+ by IHC and confirmed HER2 amplification by FISH. Next-generation sequencing detected PIK3CA H1047R. She underwent lumpectomy with sentinel node biopsy followed by adjuvant paclitaxel and trastuzumab. Surveillance imaging and physical exam show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+, PR+", "treatment": "lumpectomy, paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative pathology: 62-year-old male underwent right hemicolectomy for colon adenocarcinoma, pathologic stage pT3N1 (stage III). MSI testing on the specimen returned MSI-H. Comprehensive mutation panel did not identify actionable KRAS/NRAS/BRAF alterations. Patient completed 6 months adjuvant FOLFOX without complications. Surveillance CT and CEA at 12 months show no evidence of recurrent disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "FOLFOX (adjuvant)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old woman with newly diagnosed invasive ductal carcinoma of the left breast. Tumor is ER positive, PR positive and shows HER2 amplification on FISH. NGS revealed a PIK3CA E545K mutation. Pathology after lumpectomy and sentinel node biopsy reported pT2N1 (stage II). She completed adjuvant chemotherapy with docetaxel and cyclophosphamide and was started on trastuzumab. Follow-up mammogram and PET show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy; docetaxel and cyclophosphamide; trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Case summary: 68-year-old male with metastatic colorectal adenocarcinoma, stage IV with liver and pulmonary metastases. Tumor NGS shows BRAF V600E mutation; MSI testing returned MSI-H and tumor mutational burden described as high. He received first-line FOLFIRI plus bevacizumab with radiographic stable disease, then was started on encorafenib plus cetuximab for BRAF V600E but follow-up scans after 8 weeks demonstrated disease progression.", "output": {"cancer_type": "colorectal (adenocarcinoma)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFIRI + bevacizumab; encorafenib + cetuximab", "response": "progression", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with left-sided invasive ductal carcinoma, pathologic stage IIA (T2N0M0). Tumor is ER positive, PR positive and HER2 negative. Next-generation sequencing identified a PIK3CA H1047R alteration. She underwent lumpectomy with sentinel node biopsy followed by adjuvant radiotherapy and was started on letrozole. At 18-month follow-up she has no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+/PR+/HER2-", "treatment": "lumpectomy, adjuvant radiotherapy, letrozole", "response": "no evidence of disease (NED)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic letter: 65-year-old man with locally advanced pancreatic ductal adenocarcinoma, borderline resectable, clinical stage III. He completed six cycles of FOLFIRINOX followed by consolidative chemoradiation (50.4 Gy with capecitabine). Restaging CT shows the pancreatic mass is stable in size compared with pre-treatment imaging; no distant metastases identified. Tumor was not sent for comprehensive genomic profiling and PD-L1 testing was not performed.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "FOLFIRINOX and chemoradiation", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man diagnosed with clinical stage I prostate adenocarcinoma (Gleason 3+3 = 6) with PSA 6.2 ng/mL. Staging CT and bone scan negative for metastatic disease. Patient elected active surveillance; PSA has remained stable over 18 months and no treatment-related interventions have been performed. No genomic testing was obtained.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "active surveillance", "response": "stable disease (PSA stable)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with locally advanced HER2-positive invasive ductal breast carcinoma, clinical stage IIIB. Core biopsy: HER2 IHC 3+, ER negative, PR negative; NGS identified a PIK3CA H1047R mutation. She received neoadjuvant weekly paclitaxel with trastuzumab and pertuzumab followed by mastectomy. Surgical pathology showed a near-complete pathologic response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+; ER negative; PR negative", "treatment": "paclitaxel with trastuzumab and pertuzumab, mastectomy", "response": "near complete pathologic response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced left breast invasive ductal carcinoma (cT3N1). Core biopsy: HER2 IHC 3+ (FISH positive), ER 80%+, PR 30%+. Targeted panel detected PIK3CA H1047R. She completed 6 cycles of neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab, then lumpectomy. Surgical pathology reported no residual invasive carcinoma (pathologic complete response). Staging CT showed no distant metastases.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification (IHC 3+); ER positive; PR positive", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman with newly diagnosed metastatic lung adenocarcinoma (stage IV). Tissue NGS detected EGFR L858R. PD-L1 tumor proportion score 10%. Patient started osimertinib 80 mg daily in August 2024; interval CT and brain MRI show shrinkage of the primary and decrease in size of multiple brain lesions. Bone lesions are also present on bone scan.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male underwent radical prostatectomy for Gleason 4+4 prostate adenocarcinoma. Pathology showed extraprostatic extension, pT3aN0. He received adjuvant external beam radiation and androgen deprivation with leuprolide. At 18-month follow-up the PSA rose to 1.2 ng/mL, consistent with biochemical recurrence; salvage therapy is being planned.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "pT3a (postoperative staging)", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; adjuvant external beam radiation; androgen deprivation therapy (leuprolide)", "response": "biochemical recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Stage IV metastatic cutaneous melanoma with BRAF V600E on molecular testing and a high tumor mutational burden (TMB-high, 22 muts/Mb). Patient progressed on frontline nivolumab and was switched to targeted therapy with dabrafenib plus trametinib. Follow up imaging showed reduction of several subcentimeter hepatic and nodal lesions but emergence of a new 1.2 cm pulmonary nodule.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high (22 muts/Mb)", "treatment": "dabrafenib and trametinib (after nivolumab)", "response": "mixed response", "metastasis_site": "lung; liver; lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma presenting with multiple pulmonary nodules. Tumor sequencing detected BRAF V600E and high tumor mutational burden. He was initiated on dabrafenib plus trametinib and experienced an initial clinical benefit, but developed radiographic progression in the lungs after approximately 6 months and was switched to pembrolizumab.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib (then switched to pembrolizumab)", "response": "progression after 6 months on BRAF/MEK inhibitors", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "33-year-old F with locally advanced invasive ductal carcinoma of the left breast, clinical stage IIIB. Core biopsy: ER-/PR-; HER2 amplification by FISH. She received neoadjuvant therapy consisting of docetaxel, carboplatin with trastuzumab and pertuzumab. Clinical exam after therapy showed resolution of the palpable mass and she proceeded to mastectomy with pathologic complete response reported in the operative specimen.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma diagnosed March 2024. Comprehensive NGS returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. Baseline PET/CT and brain MRI demonstrate multiple enhancing lesions in the cerebrum and lytic lesions in the thoracic spine consistent with metastatic disease. Clinical stage IV. Patient was started on osimertinib 80 mg daily and received palliative whole-brain radiotherapy to symptomatic sites. Interval CT at 8 weeks shows decrease in target lesion size compared with baseline.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; whole-brain radiotherapy", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old man with metastatic lung adenocarcinoma harboring EGFR L858R. Presented with progressive thoracic pain; MRI brain shows multiple enhancing lesions and PET/CT demonstrates osseous metastases. Staged as IV. PD-L1 tumor proportion score 10%. Osimertinib 80 mg daily was started in July; follow-up CT at 8 weeks demonstrates decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% (TPS)", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old female with metastatic lung adenocarcinoma, diagnosed stage IV. Broad NGS identified EGFR L858R. PD-L1 TPS reported at 10%. Patient started osimertinib 80 mg PO daily; after 8 weeks there is radiographic reduction in intracranial lesions and improvement in osseous pain. Clinically noted as a partial response to therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old with high-grade serous ovarian carcinoma, surgically staged as IIIC with extensive peritoneal carcinomatosis. Germline testing identifies a deleterious BRCA1 mutation; tumor sequencing also shows TP53 mutation. Received debulking surgery followed by carboplatin and paclitaxel with good initial CA-125 decline. Started maintenance olaparib given BRCA1 mutation but two subsequent CT scans show increasing peritoneal implants consistent with progression on maintenance therapy.", "output": {"cancer_type": "ovarian cancer (high-grade serous)", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": "TP53 mutation; HRD (implied by BRCA1)", "treatment": "debulking surgery; carboplatin and paclitaxel; olaparib (maintenance)", "response": "progression", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with recurrent invasive ductal carcinoma of the right breast now with biopsy-proven hepatic metastases. Clinical staging consistent with stage IV disease. Hormone receptor positive (ER+, PR+) and HER2-amplified by FISH. NGS did not reveal actionable somatic mutations. She was treated with first-line trastuzumab, pertuzumab and docetaxel and remains on maintenance trastuzumab/pertuzumab with radiographic stable disease.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "trastuzumab, pertuzumab and docetaxel (maintenance trastuzumab/pertuzumab)", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Tumor sequencing demonstrates KRAS G12D. MSI testing returned MSI-H and TMB reported as high (28 mut/Mb). Given MSI-H status he was started on pembrolizumab monotherapy as first-line systemic therapy. Interval restaging CT at 12 weeks showed overall shrinkage but no new lesions; radiology impression: stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "46-year-old female with locally advanced HER2-positive breast cancer (T3N2). Biopsy: ER positive, PR negative, HER2 amplification by FISH; PIK3CA H1047R mutation identified on NGS. She received neoadjuvant docetaxel, carboplatin with dual HER2 blockade (trastuzumab and pertuzumab). After surgery there was a pathologic complete response in the breast and nodes.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER positive, PR negative", "treatment": "docetaxel + carboplatin + trastuzumab + pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female with metastatic colorectal adenocarcinoma to the liver and peritoneum. Tumor sequencing: KRAS G12D; MSI-H and tumor mutational burden high. First-line therapy was FOLFOX (5-FU/leucovorin/oxaliplatin) with bevacizumab. After four months of chemotherapy disease was radiographically stable and immunotherapy with pembrolizumab was discussed given MSI-H status; patient transitioned to pembrolizumab on study. Best overall response while on chemo + bevacizumab was stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; then pembrolizumab", "response": "stable disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with locally advanced breast cancer (invasive ductal carcinoma). Core biopsy: ER negative, PR negative, HER2 amplified by FISH. PIK3CA E545K mutation identified on NGS. She received neoadjuvant docetaxel and carboplatin with trastuzumab and pertuzumab for 6 cycles followed by mastectomy. Surgical pathology reported pathologic complete response (no residual invasive carcinoma). No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification", "treatment": "neoadjuvant docetaxel and carboplatin with trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 72-year-old male who underwent right hemicolectomy for a colon mass. Final pathology: colon adenocarcinoma, pT3 N0 (stage II). Tumor demonstrated high microsatellite instability (MSI-H) by PCR; mismatch repair proteins absent on IHC. Given stage II MSI-H status, no adjuvant chemotherapy was administered. Surveillance CTs at 12 and 24 months show no recurrence.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "MSI-H (mismatch repair deficient)", "treatment": "right hemicolectomy (surgery); no adjuvant chemotherapy", "response": "no evidence of disease / surveillance negative", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old female with progressive cough and weight loss. Bronchoscopic biopsy confirmed lung adenocarcinoma. Molecular testing returned EGFR L858R positive; ALK and ROS1 negative. PD-L1 tumor proportion score 5%. Staging CT and brain MRI show multiple enhancing cerebral lesions consistent with metastases and bilateral pulmonary nodules. Patient was started on osimertinib 80 mg daily. Interval CT at 8 weeks demonstrates reduction in target lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old woman with metastatic cutaneous melanoma found to have BRAF V600E mutation. She developed multiple new subcutaneous nodules on the trunk consistent with cutaneous metastases. Therapy was initiated with dabrafenib and trametinib. Early PET/CT at 6 weeks shows decreased SUV in the skin lesions and regression of several nodules \u2014 described by oncology as a partial response. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "skin (subcutaneous nodules)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic pancreatic ductal adenocarcinoma found to harbor a germline BRCA2 pathogenic variant. Baseline CA 19-9 elevated. At presentation there were multiple liver metastases (stage IV). She received FOLFIRINOX induction with initial tumor shrinkage, then switched to olaparib maintenance due to BRCA2. After 8 months on maintenance, imaging demonstrated new hepatic lesions and rising CA 19-9 consistent with progressive disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 pathogenic variant", "biomarker": "elevated CA 19-9", "treatment": "FOLFIRINOX followed by olaparib maintenance", "response": "progression after initial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old male with newly diagnosed lung adenocarcinoma presented with headaches and hip pain. Imaging showed multiple cerebral metastases and lytic lesions in the femur. Biopsy confirmed EGFR L858R\u2013positive adenocarcinoma; PD-L1 tumor proportion score 60% and report notes TMB-high. Patient initially started osimertinib but developed hepatic progression after 6 months and was switched to carboplatin/pemetrexed in combination with pembrolizumab. Interval scans after two cycles of chemoimmunotherapy show a partial response with decrease in size of pulmonary and brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 >50%; TMB-high", "treatment": "osimertinib; carboplatin and pemetrexed + pembrolizumab", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing demonstrated EGFR L858R mutation and PD-L1 30% by IHC. Staging CT/PET consistent with stage IV disease with multiple brain metastases; received stereotactic radiosurgery to a cerebellar lesion. Systemic therapy was started with osimertinib in combination with bevacizumab on a compassionate-use basis. Follow-up MRI at 8 weeks shows decrease in size of intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30%", "treatment": "osimertinib + bevacizumab", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with metastatic invasive ductal carcinoma of the breast, ER-/PR-, HER2 amplified by FISH. Staging documented as stage IV with multiple painful axial skeleton lesions. Initiated first-line trastuzumab and pertuzumab with docetaxel; follow-up CT shows decrease in size of several bone lesions and clinical improvement in back pain.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "39-year-old female with locally advanced squamous cervical cancer presented with pelvic pain and vaginal bleeding. Imaging shows parametrial extension and a suspicious osseous lesion in the sacrum. p16 testing is positive consistent with HPV-associated disease; PD-L1 TPS reported at >50%. No actionable somatic mutations were identified on the limited panel. She underwent concurrent cisplatin and external beam radiation followed by consolidative pembrolizumab on a clinical protocol.", "output": {"cancer_type": "squamous cervical cancer", "stage": "IVA", "gene_mutation": null, "biomarker": "p16 positive (HPV-associated); PD-L1 >50%", "treatment": "concurrent cisplatin and external beam radiation followed by pembrolizumab", "response": null, "metastasis_site": "sacrum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old man with recurrent cutaneous melanoma. Molecular testing positive for BRAF V600E. Staging PET/CT shows multiple bilateral pulmonary nodules and mediastinal nodal uptake. He was started on dabrafenib plus trametinib; unfortunately at 3 months there is interval progression in the lungs with several new nodules. PD-L1 2% and TMB-high (18 mut/Mb) were noted on prior testing.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 2%; TMB-high", "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old male with metastatic cutaneous melanoma. PCR sequencing identified a BRAF V600E mutation. He progressed on first-line ipilimumab + nivolumab and was switched to dabrafenib with trametinib. Recent PET/CT demonstrates new lytic lesions in the left femur consistent with osseous metastasis. Overall response to targeted therapy is described as a mixed response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib (prior ipilimumab + nivolumab)", "response": "mixed response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: patient with cutaneous melanoma harboring a BRAF V600E mutation confirmed on NGS. PD-L1 staining low (~5%). He was started on targeted combination therapy with dabrafenib plus trametinib after wide local excision and sentinel node biopsy. Clinical course is currently stable disease by RECIST on two consecutive scans.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 ~5%", "treatment": "dabrafenib + trametinib", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with high-grade serous ovarian carcinoma, stage IIIC. At presentation there were extensive peritoneal implants and malignant ascites. Germline testing returned a deleterious BRCA1 mutation. She received neoadjuvant carboplatin and paclitaxel, underwent interval cytoreductive surgery followed by adjuvant chemotherapy; CA-125 normalized and follow-up CT shows no measurable disease consistent with a complete clinical response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": "CA-125 normalized (previously elevated)", "treatment": "neoadjuvant carboplatin and paclitaxel, interval cytoreductive surgery, adjuvant chemotherapy", "response": "complete clinical response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old woman with newly diagnosed stage IV lung adenocarcinoma. Molecular testing returned EGFR L858R; T790M was negative. PD-L1 tumor proportion score 10%. MRI brain showed two small enhancing lesions consistent with metastatic disease. Patient started osimertinib 80 mg daily with good CNS penetration. Interval CT and brain MRI after 8 weeks demonstrate reduction in pulmonary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "39-year-old woman with stage IIIC high-grade serous ovarian carcinoma. Germline testing returned a pathogenic BRCA1 variant and tumor was HRD-positive. She underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel with complete clinical remission on post-treatment imaging; maintenance olaparib was started thereafter.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "HRD-positive", "treatment": "cytoreductive surgery; carboplatin and paclitaxel x6; maintenance olaparib", "response": "complete clinical remission", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 52-year-old man with stage IV cutaneous melanoma harboring BRAF V600E. Initial therapy with dabrafenib and trametinib produced a good partial response in pulmonary and nodal disease, but new bone pain and imaging confirmed osseous lesions with progression after 8 months. He subsequently received palliative radiotherapy to the symptomatic vertebral metastasis and was referred for immunotherapy (nivolumab/ipilimumab). PD-L1 reported as 1%.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 1%", "treatment": "dabrafenib and trametinib; palliative radiotherapy; nivolumab/ipilimumab planned", "response": "initial partial response, then progression in bone", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with left-sided colorectal adenocarcinoma presenting with multiple hepatic lesions on CT consistent with liver metastases. Tumor testing returned MSI-H by IHC. Given the MSI-H status, pembrolizumab monotherapy was initiated with shrinkage of liver metastases at first restaging. Extended RAS/BRAF testing results were still pending at time of note.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma, stage IV with a solitary symptomatic brain metastasis. Molecular report positive for BRAF V600E. PD-L1 by IHC 5% and tumor sequencing noted TMB-high. Treated initially with dabrafenib plus trametinib with extracranial control but growth of the brain lesion; subsequently switched to nivolumab. Overall course documented progression of intracranial disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%; TMB-high", "treatment": "dabrafenib and trametinib followed by nivolumab", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right-sided invasive ductal carcinoma, ER-/PR-, HER2 IHC 3+ on core biopsy. Clinical stage prior to therapy: IIB (T2N1M0). NGS panel detected a PIK3CA H1047R mutation. She received neoadjuvant paclitaxel and carboplatin with trastuzumab and pertuzumab for 6 cycles followed by breast-conserving surgery; surgical pathology showed no residual invasive carcinoma (pCR). No distant disease identified on staging scans.", "output": {"cancer_type": "invasive ductal breast cancer", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+; ER-/PR-", "treatment": "neoadjuvant paclitaxel + carboplatin with trastuzumab and pertuzumab; surgery", "response": "complete pathological response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old man with sigmoid adenocarcinoma, stage III (T3N2M0). Tumor testing showed KRAS G12D and concurrent TP53 mutation; MSI testing was MSS. He underwent colectomy but developed unresectable regional nodal recurrence and was treated with FOLFOX. Interval CTs demonstrate persistent, unchanged nodal disease \u2014 overall assessment: stable disease on chemotherapy.", "output": {"cancer_type": "adenocarcinoma of the sigmoid colon", "stage": "III", "gene_mutation": "KRAS G12D; TP53 mutation", "biomarker": "MSI-stable (MSS)", "treatment": "colectomy; FOLFOX", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old man presents with newly diagnosed stage IV lung adenocarcinoma from RUL core biopsy. Molecular testing identified an EGFR exon 21 L858R mutation. MRI brain demonstrated two small enhancing lesions and PET/CT showed lytic lesions in the thoracic spine. He was started on osimertinib 80 mg daily and had a partial response on CT at 8 weeks.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma reported to clinic. Molecular panel returned KRAS G12D; microsatellite testing shows MSS (microsatellite stable). Multiple bilobar liver metastases on staging CT consistent with stage IV disease. Patient started FOLFOX with bevacizumab two cycles ago; scans after 8 weeks indicate overall stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old male with newly diagnosed prostate adenocarcinoma, clinical stage II (T2bN0M0). Pre-treatment PSA 12 ng/mL. No genomic testing was performed. He underwent definitive external beam radiation with concurrent androgen deprivation therapy (leuprolide depot). At 6-month follow-up PSA fell to 0.3 ng/mL.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 12 ng/mL", "treatment": "external beam radiation and leuprolide (androgen deprivation therapy)", "response": "biochemical response (PSA decline)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old woman with high-grade serous ovarian carcinoma. At initial debulking there were omental and diffuse peritoneal implants (FIGO IIIC). Germline testing returned positive for BRCA1 mutation. She completed six cycles of carboplatin and paclitaxel followed by maintenance olaparib and currently has no radiographic evidence of disease on CT.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": "BRCA1 mutation (germline)", "treatment": "carboplatin and paclitaxel followed by olaparib maintenance", "response": "complete response", "metastasis_site": "peritoneum, omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing demonstrated EGFR L858R on PCR. Staged IV at diagnosis with multiple enhancing cerebral metastases on MRI. She was started on osimertinib 80 mg daily for systemic and CNS disease; after 3 months MRI shows decreased size and number of lesions consistent with a partial response. PD-L1 reported at 10%.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with progressive cough and weight loss. Bronchoscopy with biopsy: lung adenocarcinoma. Staging PET/CT: multiple bilateral pulmonary nodules and lytic lesions in the thoracic spine consistent with metastases. Molecular testing positive for EGFR L858R. PD-L1 by IHC 10%. Patient started osimertinib 80 mg daily with marked shrinkage of pulmonary lesions and decreased enhancement of spinal lesions on first follow-up\u2014clinical partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone (thoracic spine), lung (bilateral pulmonary nodules)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with locally advanced pancreatic ductal adenocarcinoma found to have liver metastases on staging CT \u2014 consistent with Stage IV disease. Tumor sequencing identified a deleterious BRCA2 mutation. CA19-9 markedly elevated at diagnosis. He received 8 cycles of FOLFIRINOX with radiographic partial response in the liver and pancreas, then was transitioned to olaparib maintenance due to BRCA2 mutation with continued disease control on recent scans.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 deleterious mutation", "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX followed by olaparib maintenance", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: Patient with metastatic melanoma presented with symptomatic pulmonary nodules and brain metastases. Molecular profile: BRAF V600E positive; PD-L1 ~5%. Initially treated with pembrolizumab monotherapy but restaging at 12 weeks showed clinical progression. Therapy was switched to dabrafenib plus trametinib with subsequent tumor shrinkage on CT and partial radiographic response documented.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "pembrolizumab followed by dabrafenib and trametinib", "response": "progression on pembrolizumab then partial response to dabrafenib/trametinib", "metastasis_site": "lung and brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old man with a 1.8 cm pigmented lesion on the forearm. Excisional biopsy showed cutaneous melanoma with one positive sentinel node; final pathologic stage IIIA. BRAF V600E mutation was detected. He underwent wide local excision and completion lymphadenectomy and was started on adjuvant nivolumab. Surveillance PET/CT at 6 months is negative and the patient remains clinically disease-free.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIA", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision, lymphadenectomy, adjuvant nivolumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with newly diagnosed prostate adenocarcinoma, Gleason 9 (4+5) on biopsy. Cross-sectional imaging and bone scan show enlarged pelvic lymph nodes without visceral metastases. Androgen deprivation therapy with leuprolide was initiated and patient is planned for external beam radiation to the prostate and pelvic nodes. No tumor molecular testing was performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV (N1)", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide and external beam radiation", "response": "not yet assessed", "metastasis_site": "pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with metastatic colorectal adenocarcinoma. CT shows multiple liver lesions and peritoneal implants. Tumor profiling demonstrates MSI-H and TMB-high (22 muts/Mb) consistent with mismatch repair deficiency. No actionable RAS/RAF alterations were identified on the PCR panel. He received FOLFOX plus bevacizumab up front and was transitioned to pembrolizumab in the second line; serial scans show a sustained reduction in tumor burden.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H, TMB-high", "treatment": "FOLFOX plus bevacizumab; pembrolizumab", "response": "partial response / sustained reduction", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman with high-grade serous ovarian carcinoma presenting with omental caking and extensive peritoneal implants consistent with stage IIIC disease. CA-125 markedly elevated preoperatively. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel with clinical improvement and radiographic reduction of peritoneal disease (partial response). BRCA testing results pending at the time of discharge; maintenance PARP inhibitor was being considered.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "CA-125 elevated", "treatment": "cytoreductive surgery; carboplatin and paclitaxel", "response": "partial response", "metastasis_site": "peritoneum, omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "34-year-old female underwent left hemithyroidectomy for a 0.8 cm papillary thyroid carcinoma identified incidentally. Pathologic stage pT1a, overall stage I. No lymphovascular invasion, no nodes sampled, no distant disease on staging; no molecular testing was performed. Post-operative course uneventful and patient is currently without evidence of disease.", "output": {"cancer_type": "papillary thyroid carcinoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "left hemithyroidectomy (surgery)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and operative note: 47-year-old female with palpable left breast mass. Core biopsy: invasive ductal carcinoma, ER negative, PR negative, HER2 IHC 3+; FISH confirms HER2 amplification. Clinical stage reported as IIB (cT2N1). She received neoadjuvant paclitaxel and carboplatin with trastuzumab and pertuzumab. Imaging prior to surgery showed complete clinical response. No distant disease identified on staging CT.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant paclitaxel, carboplatin, trastuzumab, pertuzumab", "response": "complete clinical response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient underwent sigmoid colectomy for stage III (T3N1M0) adenocarcinoma of the colon. Tumor testing by PCR showed high microsatellite instability (MSI-H) / mismatch repair deficient. No actionable single-gene drivers were identified on the NGS panel. The patient completed 6 months of adjuvant FOLFOX and is currently without radiographic evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "sigmoid colectomy; adjuvant FOLFOX x6 months", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "42-year-old M with metastatic cutaneous melanoma, stage IV. NGS identified NRAS Q61K. PD-L1 reported at 30% by IHC. He received combination immunotherapy with nivolumab and ipilimumab as first-line. After four cycles surveillance imaging demonstrated new brain metastases and progressive pulmonary nodules. Therapy was changed to MEK inhibitor (trametinib) on a compassionate basis, but overall assessment is disease progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "NRAS Q61K", "biomarker": "PD-L1 30%", "treatment": "nivolumab + ipilimumab; trametinib (subsequent)", "response": "progression", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with high-grade serous ovarian carcinoma presenting with bulky pelvic disease and carcinomatosis. Clinical stage IIIC at presentation. Germline testing returned BRCA1 pathogenic variant. CA-125 markedly elevated at diagnosis. She received neoadjuvant carboplatin and paclitaxel with partial radiographic response, underwent optimal debulking and has been started on maintenance olaparib. Residual peritoneal implants noted at surgery.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": "CA-125 elevated", "treatment": "neoadjuvant carboplatin + paclitaxel, debulking surgery, maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old female with high-grade serous ovarian carcinoma. Germline testing positive for BRCA1 pathogenic variant (c.5266dupC). At presentation she had bulky pelvic disease with omental cake and diffuse peritoneal implants consistent with peritoneal metastasis; disease was staged IIIC. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel. Maintenance olaparib was started given the BRCA1 mutation. CA-125 normalized and CT at 12 months shows no radiographic evidence of disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 c.5266dupC (pathogenic)", "biomarker": "HRD positive (BRCA1-associated)", "treatment": "cytoreductive surgery; carboplatin; paclitaxel; olaparib (maintenance)", "response": "complete response / no evidence of disease", "metastasis_site": "peritoneum (omental/peritoneal implants)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48F with a 1.8 cm palpable right breast mass. Core biopsy: invasive ductal carcinoma, ER positive, PR positive, HER2 amplified by FISH. Clinical stage reported as Stage I (T1cN0M0). She underwent lumpectomy with sentinel node biopsy; margins negative. Plan for adjuvant paclitaxel followed by trastuzumab. Current post-op assessment: no evidence of disease.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "I", "gene_mutation": null, "biomarker": "ER+, PR+, HER2 amplification", "treatment": "lumpectomy with sentinel node biopsy; planned adjuvant paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant chemotherapy for locally advanced left breast cancer: patient with HER2-amplified invasive ductal carcinoma, clinical stage IIIB. Received three cycles of docetaxel and carboplatin with trastuzumab prior to mastectomy. Surgical pathology reported no residual invasive carcinoma (pCR). ER/PR were weakly positive on initial core, HER2 confirmed by FISH.", "output": {"cancer_type": "breast cancer (HER2-amplified invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER weakly positive; PR weakly positive", "treatment": "neoadjuvant docetaxel and carboplatin with trastuzumab, followed by surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with metastatic cutaneous melanoma. NGS showed BRAF V600E mutation; PD-L1 10%. She initially started on dabrafenib plus trametinib with a partial response that was durable for 11 months, then developed progression with new pulmonary and hepatic lesions. Therapy was changed to pembrolizumab; after three cycles repeat imaging demonstrates stable disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib + trametinib; pembrolizumab", "response": "stable disease (after immunotherapy); prior partial response to targeted therapy", "metastasis_site": "lung, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic note: 58-year-old man with metastatic colorectal adenocarcinoma with multiple liver lesions. Biopsy shows adenocarcinoma of colon; molecular testing: KRAS G12D mutation. Tumor was microsatellite stable (MSI-stable) on PCR. He initiated FOLFOX with bevacizumab; CT at first restaging shows no new lesions and minor shrinkage of one lesion \u2014 radiology impression: overall stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male diagnosed with high-volume metastatic prostate adenocarcinoma (Gleason 4+5). Bone scan shows widespread osseous metastases. Started on androgen deprivation with leuprolide plus docetaxel for castration-sensitive metastatic disease. PSA has declined and symptoms improved; current assessment is disease stable on therapy. No tumor genomic testing was performed and no molecular biomarkers available.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with muscle-invasive bladder cancer underwent radical cystectomy. Pathology was pT2N0 at the time of surgery. No tumor genomic testing was performed and there is no documentation of PD-L1 or FGFR testing in the chart. He received adjuvant gemcitabine and cisplatin given high-risk features. At 6-month follow-up there is no radiographic evidence of distant disease.", "output": {"cancer_type": "bladder cancer (muscle-invasive)", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical cystectomy; adjuvant gemcitabine and cisplatin", "response": "no evidence of disease (disease-free at 6 months)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with right-sided metastatic colorectal adenocarcinoma, stage IV with multiple liver and peritoneal implants. Molecular testing showed BRAF V600E mutation; tumor was MSI-H with high tumor mutational burden. He was treated with FOLFOX plus bevacizumab initially with mixed response, then switched to encorafenib plus cetuximab with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX and bevacizumab; encorafenib and cetuximab", "response": "partial response", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "34-year-old male with a 0.8 mm superficial spreading cutaneous melanoma on the left forearm. Wide local excision performed with negative margins and negative sentinel lymph node sampling. Final pathologic stage IA. No adjuvant systemic therapy was recommended and patient remains on surveillance.", "output": {"cancer_type": "cutaneous melanoma (superficial spreading)", "stage": "IA", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision (surgery); surveillance", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with locally advanced left invasive ductal carcinoma of the breast. Core biopsy: ER+, PR-, HER2 amplified by FISH. Clinical staging consistent with IIIB disease with fixed axillary nodes. Molecular profiling on the core showed a PIK3CA E545K mutation. She received neoadjuvant therapy (dose-dense doxorubicin/cyclophosphamide followed by paclitaxel with concurrent trastuzumab) with marked tumor reduction but persistent palpable nodal disease.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant doxorubicin/cyclophosphamide \u2192 paclitaxel + trastuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman with high-grade serous ovarian carcinoma, stage IIIC, presented with bulky pelvic disease and extensive peritoneal carcinomatosis. Germline testing identified a deleterious BRCA2 mutation. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel for six cycles and is now on olaparib maintenance. CA-125 normalized and latest CT shows no measurable disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA2 deleterious mutation", "biomarker": null, "treatment": "optimal cytoreductive surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "complete clinical response / no measurable disease on CT", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic note: 64-year-old female with metastatic lung adenocarcinoma diagnosed 03/2023. Biopsy confirmed EGFR L858R positive tumor with acquired MET amplification on repeat NGS. PD-L1 tumor proportion score 60%. Initial therapy was osimertinib 80 mg daily with CNS-directed stereotactic radiosurgery for a solitary cerebellar lesion. After extracranial progression, patient was transitioned to pembrolizumab in combination with carboplatin and pemetrexed. Imaging after 3 cycles shows decrease in size of lung primary and bone lesions consistent with a partial response. Sites of disease at progression included bone and brain metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; MET amplification", "biomarker": "PD-L1 60%", "treatment": "osimertinib; pembrolizumab + carboplatin + pemetrexed; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with castration-resistant prostate adenocarcinoma and extensive sclerotic bone metastases. Treated with six cycles of docetaxel followed by androgen receptor blockade with enzalutamide; received palliative radiotherapy to the lumbar spine for pain control. No actionable genomic alterations were reported on the standard panel. PSA is slowly rising but cross-sectional imaging shows predominantly stable osseous disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "docetaxel; enzalutamide; palliative radiotherapy (lumbar spine)", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with newly diagnosed stage IV lung adenocarcinoma. Biopsy showed EGFR L858R mutation and PD-L1 10% by IHC. MRI brain demonstrates multiple small enhancing lesions consistent with metastatic disease. Patient was started on osimertinib 80 mg daily; first restaging CT at 8 weeks documents decrease in size of pulmonary and intracranial lesions, consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Gynecologic oncology note: 62-year-old female with high-grade serous ovarian carcinoma. At laparotomy she had bulky omental and peritoneal disease; optimal cytoreduction achieved. Pathologic stage IIIC. Germline BRCA1 pathogenic variant identified; tumor HRD-high. She completed neoadjuvant and adjuvant carboplatin/paclitaxel and was placed on maintenance olaparib. Follow-up CT shows decreased peritoneal implants consistent with partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1", "biomarker": "HRD-high", "treatment": "carboplatin and paclitaxel; maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum; omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 57-year-old male with metastatic colorectal adenocarcinoma with dominant hepatic metastases. Initial therapy was FOLFOX plus bevacizumab (first-line) with radiographic disease control. Broad NGS returned BRAF V600E mutation and tumor was MSI-H, prompting switch to pembrolizumab after mixed progression in lung nodules. PD-L1 by IHC was 5%. Current best overall response on pembrolizumab is stable disease by RECIST; ongoing therapy tolerated.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; PD-L1 5%", "treatment": "FOLFOX + bevacizumab (first-line), then pembrolizumab", "response": "stable disease", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 58-year-old female with newly diagnosed lung adenocarcinoma presented with headaches and back pain. Imaging and biopsy consistent with stage IV disease. Molecular profiling identified EGFR L858R. PD-L1 by IHC reported as <1%. She was started on osimertinib 80 mg daily two weeks ago; interval MRI shows shrinkage of intracranial lesions and improvement of spinal metastatic burden.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 <1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male underwent right hemicolectomy for colon cancer. Pathology: moderately differentiated adenocarcinoma, pathologic stage III (T3N1). Tumor sequencing demonstrated KRAS G12D; mismatch repair proteins intact (MSS). He completed 6 months of adjuvant FOLFOX without complications and surveillance CTs show no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS (MMR intact)", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Metastatic cutaneous melanoma with multiple pulmonary nodules. Molecular testing shows a BRAF V600E mutation. The patient was started on dabrafenib and trametinib with dramatic clinical improvement; PET-CT after 10 weeks demonstrates complete metabolic response of all lung lesions. No formal stage was documented in the consulted note.", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with metastatic lung adenocarcinoma referred for targeted therapy. Molecular testing returned EGFR L858R mutation and PD-L1 tumor proportion score 10%. Staged IV at diagnosis with multiple enhancing brain metastases on MRI. Patient was started on osimertinib 80 mg daily as first-line therapy. Interval CT and brain MRI at 8 weeks demonstrate marked reduction in size of pulmonary nodules and decreased enhancement of cerebral lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male diagnosed with metastatic pancreatic ductal adenocarcinoma with multiple liver metastases. Tumor sequencing revealed BRCA2 6174delT and a concurrent TP53 R248Q mutation. He received FOLFIRINOX with radiographic partial response and was transitioned to maintenance olaparib for the BRCA2 alteration. PD-L1 testing and serum tumor marker results were not available in the chart.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 6174delT; TP53 R248Q", "biomarker": null, "treatment": "FOLFIRINOX; olaparib (maintenance)", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male status post right hemicolectomy for colon adenocarcinoma, pathologic stage III (T3N1). Molecular studies show BRAF V600E mutation; tumor was MSI-H by PCR. He completed adjuvant FOLFOX without complications and is currently on routine surveillance with no radiographic evidence of recurrence.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 59-year-old male with metastatic colorectal adenocarcinoma, known KRAS G12D on prior testing. Staging CT shows multiple liver lesions consistent with disease progression. MSI testing: microsatellite stable. He received FOLFOX plus bevacizumab x6 cycles but interval imaging demonstrates new hepatic lesions and rising CEA.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with metastatic colorectal adenocarcinoma. PCR-based genotyping identified KRAS G12D; tumor is microsatellite stable (MSS). CT abdomen revealed diffuse peritoneal implants consistent with peritoneal carcinomatosis and omental caking. He was started on FOLFOX with bevacizumab as first-line palliative chemotherapy \u2014 interim restaging shows disease stabilization.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX (5-FU/leucovorin/oxaliplatin) with bevacizumab", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant oncology note: 48-year-old woman with locally advanced invasive ductal carcinoma of the left breast, clinical stage IIIB. Core biopsy: ER-/PR-, HER2 amplification by FISH; NGS reported PIK3CA H1047R. She received 6 cycles of docetaxel plus trastuzumab and then underwent lumpectomy. Surgical pathology: no residual invasive carcinoma (pathologic complete response). No distant mets identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-/PR-", "treatment": "docetaxel and trastuzumab (neoadjuvant) followed by surgery", "response": "complete response (pathologic complete response)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hematology note: 54-year-old diagnosed with acute myeloid leukemia after presenting with pancytopenia. Bone marrow biopsy: 45% blasts. NGS detected FLT3-ITD mutation and NPM1 wild type. Patient received induction with cytarabine and daunorubicin (7+3) with midostaurin added for FLT3-ITD. Bone marrow at day 28 shows morphologic complete remission. No staging assigned for leukemia.", "output": {"cancer_type": "acute myeloid leukemia", "stage": null, "gene_mutation": "FLT3-ITD", "biomarker": null, "treatment": "7+3 (cytarabine and daunorubicin) with midostaurin", "response": "complete remission", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman with metastatic cutaneous melanoma. NGS on the tumor showed BRAF V600E. She was started on dabrafenib plus trametinib after resection of the primary. After 6 months she developed progression with new pulmonary nodules and hepatic metastases. PD-L1 testing was not done and is not available in the chart.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung; liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology consult: 58-year-old male with metastatic colon adenocarcinoma presenting with right upper quadrant pain. CT abdomen shows multiple hypodense lesions in the liver consistent with metastatic disease. Tumor profiling returned BRAF V600E mutation and high microsatellite instability (MSI-H). Given MSI-H status patient initiated pembrolizumab monotherapy; after four cycles there is a radiographic partial response of hepatic metastases and improvement in transaminases.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma. PET/CT and brain MRI at diagnosis showed multiple intracranial metastases with a 1.8 cm cerebellar lesion and scattered osseous disease. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 10%. Staged as IV. Patient started first-line osimertinib 80 mg daily and underwent stereotactic radiosurgery to the cerebellar lesion. Interim CT after 8 weeks demonstrates decrease in chest and brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with recurrent invasive ductal carcinoma of the breast now with multiple hepatic lesions on PET/CT. Tumor FISH demonstrated HER2 amplification; ER 80% positive, PR 40% positive. No actionable hotspot mutations were reported on the targeted panel. She was started on first-line trastuzumab and pertuzumab with weekly paclitaxel. Interval imaging and tumor marker CA 15-3 are stable; oncology note documents stable disease in the liver metastases.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER+, PR+", "treatment": "trastuzumab, pertuzumab and paclitaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old woman with high-grade serous ovarian carcinoma, stage IIIC, presenting with bulky pelvic disease and omental caking. Germline testing positive for pathogenic BRCA1 alteration. CA-125 was elevated at 820 U/mL at diagnosis. She underwent primary debulking with optimal cytoreduction followed by adjuvant carboplatin and paclitaxel with normalization of CA-125 and no radiographic residual disease on CT \u2014 documented complete clinical response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "CA-125 820 U/mL (elevated at diagnosis)", "treatment": "primary debulking surgery; adjuvant carboplatin and paclitaxel", "response": "complete clinical response", "metastasis_site": "peritoneum (omental caking)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced left breast cancer. Core biopsy: invasive ductal carcinoma, HER2 IHC 3+ with confirmed HER2 amplification by FISH, ER/PR negative. Clinical stage was IIIC (fixed axillary nodes). She received neoadjuvant docetaxel and carboplatin with trastuzumab x 6 cycles followed by mastectomy. Surgical pathology after chemo revealed no residual invasive carcinoma (pCR). No distant disease on staging CT prior to surgery.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIC", "gene_mutation": null, "biomarker": "HER2 amplification, ER negative, PR negative", "treatment": "neoadjuvant docetaxel and carboplatin with trastuzumab; mastectomy", "response": "pathologic complete response (pCR)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Radiology/progress note: 71-year-old man with metastatic melanoma presenting with multiple pulmonary nodules and several enhancing intracranial lesions. Biopsy of a skin lesion confirmed melanoma with BRAF V600E mutation. PD-L1 was reported as 30%. He was started on dabrafenib and trametinib combination therapy. Interim MRI brain and CT chest after 8 weeks demonstrate shrinkage of brain and lung lesions consistent with a partial response; continues on targeted therapy with clinical improvement in headaches.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 30%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of metastatic breast cancer, ER positive / PR negative, HER2 amplified. Patient presents with progressive hepatic lesions on imaging. She is receiving first-line trastuzumab and pertuzumab with docetaxel q3 weeks. No somatic NGS mutations were reported in the chart. Recent oncology note: disease has been radiographically stable after three cycles.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": null, "biomarker": "ER positive; PR negative; HER2 amplification", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of metastatic colorectal adenocarcinoma with multiple hepatic metastases at diagnosis. Tumor testing reported KRAS G12D mutation and high microsatellite instability (MSI-H) with elevated tumor mutational burden. Patient received pembrolizumab monotherapy given MSI-H/TMB-high status. Follow-up CT at 12 weeks: target hepatic lesions stable in size compared with baseline \u2014 overall stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colon adenocarcinoma presenting with multiple liver lesions. Comprehensive tumor profiling detected KRAS G12D and high microsatellite instability (MSI-H) with an elevated tumor mutational burden. He was started on pembrolizumab as first-line therapy with a documented partial response on interval imaging.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female diagnosed with high-grade serous ovarian carcinoma, FIGO stage IIIC with extensive peritoneal carcinomatosis. Germline testing returned positive for a pathogenic BRCA1 mutation. CA-125 was elevated at presentation. She underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel with complete clinical and radiographic response and was transitioned to maintenance olaparib. No liver, lung or bone metastases identified outside the peritoneal cavity.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": "CA-125 elevated", "treatment": "cytoreductive surgery; carboplatin + paclitaxel x6; olaparib maintenance", "response": "complete clinical and radiographic response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female diagnosed with metastatic lung adenocarcinoma in 2019. Comprehensive genomic testing identified EGFR L858R and acquired EGFR T790M. PD-L1 tumor proportion score reported as 10%. Patient started osimertinib 80 mg daily with symptomatic improvement; interval CT chest/abdomen shows decrease in size of pulmonary nodules and osseous lesions consistent with partial response. Brain MRI demonstrates two previously treated small metastases after stereotactic radiosurgery.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 10%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 49 y/o F with HER2-positive breast cancer (invasive ductal). Staging PET/CT showed osseous uptake in the spine and pelvis consistent with bone metastases; overall stage IV. NGS on the tumor identified a PIK3CA H1047R mutation. ER IHC was positive, PR negative, and HER2 amplification confirmed by FISH. Patient received first-line trastuzumab with weekly paclitaxel and monthly zoledronic acid; repeat imaging after 3 months documents a partial response with decreased size of bony lesions.", "output": {"cancer_type": "HER2-positive breast cancer", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab and paclitaxel; zoledronic acid", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op clinic: 48-year-old woman with locally advanced right breast invasive ductal carcinoma, clinical stage IIIB. Core biopsy: ER negative, PR negative, HER2 amplification by FISH; NGS shows PIK3CA H1047R. She received neoadjuvant carboplatin and docetaxel with trastuzumab and proceeded to mastectomy \u2014 final pathology: no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification", "treatment": "neoadjuvant carboplatin and docetaxel with trastuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Post-op note: 58-year-old male with resected sigmoid adenocarcinoma, pathologic stage III (pT3 N1). Tumor profiling returned KRAS G12D and was microsatellite stable (MSS). Patient completed adjuvant FOLFOX for 6 cycles and is currently NED at 12-month surveillance imaging.", "output": {"cancer_type": "colon adenocarcinoma (sigmoid)", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "microsatellite stable (MSS)", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female with newly diagnosed lung adenocarcinoma, stage IV. Staging CT and MRI demonstrate multiple cerebral and osseous metastases. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 10%. She was started on osimertinib 80 mg daily as first-line targeted therapy. Follow-up scans at 8 weeks show reduction in size of pulmonary and brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic summary: 71-year-old male with metastatic right-sided colon adenocarcinoma, biopsy proven. Baseline CT shows multiple liver lesions and peritoneal nodularity. Molecular testing: KRAS G12D mutation; tumor is MSI-H and TMB-high. He completed 8 cycles of FOLFOX with bevacizumab with partial radiographic response in the liver, then transitioned to pembrolizumab given MSI-high status. Tolerating immunotherapy well with ongoing shrinkage of peritoneal implants.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H, TMB-high", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "partial response", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man with cutaneous melanoma of the back, stage IIIC at time of wide local excision and sentinel node dissection. Tumor testing positive for BRAF V600E. PD-L1 TPS was 15%. He was started on adjuvant dabrafenib and trametinib; six months later developed an FDG-avid brain lesion consistent with metastatic progression and was transitioned to ipilimumab plus nivolumab. Clinical course described mixed response on subsequent imaging.", "output": {"cancer_type": "melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 15%", "treatment": "dabrafenib and trametinib; later ipilimumab and nivolumab", "response": "mixed response / progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with metastatic lung adenocarcinoma found to harbor EGFR L858R with acquired T790M on repeat NGS. She progressed on first-line erlotinib and was started on osimertinib 80 mg daily. Brain MRI demonstrated two small parenchymal metastases. After 3 months of osimertinib there is a decrease in size of pulmonary and intracranial lesions consistent with a partial response. PD-L1 reported at 10%.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 10%", "treatment": "erlotinib (prior), osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with cutaneous melanoma underwent wide local excision. Staging PET/CT demonstrated increased uptake in ipsilateral axillary lymph nodes consistent with regional nodal involvement; no distant visceral metastases identified. BRAF testing not performed. He was started on adjuvant nivolumab and follow-up PET shows decreased nodal uptake.", "output": {"cancer_type": "melanoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "nivolumab", "response": "partial response (decreased nodal uptake)", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced right breast invasive ductal carcinoma, ER-negative/PR-negative, HER2 amplification by FISH. Clinical stage IIIB with dermal involvement. Received neoadjuvant carboplatin and docetaxel with concurrent trastuzumab, followed by mastectomy and axillary dissection. Final pathology showed pathologic complete response with no residual invasive carcinoma.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification, ER-negative, PR-negative", "treatment": "neoadjuvant carboplatin and docetaxel, trastuzumab; mastectomy and axillary dissection", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 58-year-old woman diagnosed with high\u2011grade serous ovarian carcinoma, stage IIIC with extensive peritoneal disease. Germline testing identified a pathogenic BRCA2 mutation and tumor was HRD-positive. She underwent optimal cytoreductive surgery followed by combination chemotherapy with carboplatin and paclitaxel and was transitioned to maintenance olaparib. CT after six months of maintenance demonstrates a partial radiographic response of peritoneal nodules.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA2 (pathogenic)", "biomarker": "HRD-positive", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma (diagnosed 2019). Molecular testing demonstrated EGFR L858R and PD-L1 10%. She was started on osimertinib first-line and achieved an initial partial response; at 14 months brain metastases were identified with subsequent intracranial progression. Stereotactic radiosurgery was given to a cerebellar lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response then progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with intermediate-risk prostate adenocarcinoma (Gleason 3+4) underwent radical prostatectomy. Postoperative PSA was 0.02 ng/mL. Germline testing was negative for BRCA1/2 and tumor NGS was not performed. Androgen deprivation therapy with leuprolide was discussed for biochemical recurrence but was deferred. Currently there is no radiographic evidence of disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 0.02 ng/mL", "treatment": "radical prostatectomy (ADT with leuprolide discussed, deferred)", "response": "no evidence of disease / remission", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced breast cancer. Core biopsy: invasive ductal carcinoma, ER positive, PR negative, HER2 amplified by FISH. PIK3CA H1047R detected on panel. Clinical stage was IIIB with fixed axillary nodes. She received neoadjuvant trastuzumab and pertuzumab with docetaxel for six cycles followed by surgery; pathology showed no residual invasive carcinoma (pathologic complete response). No distant metastases identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma, HER2-amplified)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER positive, PR negative", "treatment": "trastuzumab + pertuzumab + docetaxel (neoadjuvant); surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced invasive ductal carcinoma of the left breast. Tumor is ER positive, PR positive and HER2 amplification confirmed by FISH; NGS reports a PIK3CA H1047R mutation. Clinical stage documented as IIIB (T4bN1M0). She received neoadjuvant paclitaxel with concurrent trastuzumab and is scheduled for mastectomy. Staging CT showed no evidence of distant disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "paclitaxel and trastuzumab (neoadjuvant)", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 59-year-old with metastatic colorectal adenocarcinoma, liver-dominant disease. Molecular testing: BRAF V600E and high microsatellite instability (MSI-H). Initially treated with FOLFOX with modest shrinkage, then transitioned to pembrolizumab due to MSI-H status; interval scans after 12 weeks demonstrated a marked reduction in hepatic lesions consistent with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX (initial) then pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 63-year-old man diagnosed with metastatic pancreatic ductal adenocarcinoma, KRAS G12D positive. CA19-9 at diagnosis was 1,200 U/mL. Imaging demonstrates multiple hepatic lesions consistent with liver metastases. He was treated with gemcitabine plus nab-paclitaxel and received palliative radiotherapy to the porta hepatis; after two cycles there was interval growth of liver lesions and rising CA19-9 consistent with disease progression.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "CA19-9 1200 U/mL", "treatment": "gemcitabine and nab-paclitaxel, palliative radiotherapy", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Gynecologic oncology note: 62-year-old with high-grade serous ovarian carcinoma, intraoperative findings consistent with bulky peritoneal disease and involvement of the omentum. Final stage assigned IIIC. Germline testing identified BRCA1 pathogenic variant. Baseline CA-125 was >500 U/mL. She received neoadjuvant carboplatin and paclitaxel with addition of bevacizumab and had radiographic stable disease after three cycles.", "output": {"cancer_type": "ovarian carcinoma (high-grade serous)", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": "CA-125 >500 U/mL", "treatment": "carboplatin and paclitaxel; bevacizumab", "response": "stable disease", "metastasis_site": "peritoneum, omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic cutaneous melanoma presenting with new symptomatic brain metastases. Tumor tested positive for BRAF V600E. He received induction ipilimumab plus nivolumab and, due to intracranial progression early on, was transitioned to BRAF/MEK targeted therapy with dabrafenib and trametinib. Follow-up MRI shows complete resolution of intracranial lesions and PET/CT shows no active extracranial disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "ipilimumab + nivolumab; dabrafenib + trametinib", "response": "complete response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man presenting with obstructive jaundice found to have pancreatic ductal adenocarcinoma with multiple liver lesions at diagnosis. Germline and somatic testing identified a BRCA2 pathogenic variant. He received 8 cycles of FOLFIRINOX with an initial partial response and was transitioned to olaparib maintenance given the BRCA2 variant; subsequent CT at 6 months showed progression in the liver and he was treated with gemcitabine/nab-paclitaxel with limited benefit. Most recent imaging documents progressive disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 pathogenic variant", "biomarker": "BRCA2 (germline)", "treatment": "FOLFIRINOX; olaparib (maintenance); gemcitabine/nab-paclitaxel", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Mr. S, age 68, diagnosed with intermediate-risk prostate adenocarcinoma (Gleason 3+4) on biopsy. Underwent robotic-assisted radical prostatectomy; final pathology pT2 with negative margins. Post-op PSA undetectable. No adjuvant systemic therapy planned; referral for consideration of salvage radiation only if PSA rises.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy", "response": "no evidence of disease (undetectable PSA)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman presented with obstructive jaundice and was found to have a pancreatic head mass. Diagnostic laparoscopy revealed diffuse peritoneal seedlings consistent with metastatic pancreatic adenocarcinoma. Due to limited tissue sampling, no molecular testing was performed. She was started on gemcitabine plus nab\u2011paclitaxel but clinical course was marked by rapid decline and radiographic progression on first restaging.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine and nab-paclitaxel", "response": "progression", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female diagnosed with metastatic lung adenocarcinoma in 2021. Biopsy confirmed adenocarcinoma of the lung; comprehensive NGS revealed EGFR L858R. PD-L1 by IHC reported at 10%. Staging workup consistent with stage IV disease with multiple brain and osseous lesions on MRI/PET. Patient was started on osimertinib 80 mg daily in January 2022 and underwent stereotactic radiosurgery to two brain metastases. First follow-up CT showed shrinkage of thoracic lesions and decreased size of brain nodules \u2014 assessed as a partial response per RECIST.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic lung adenocarcinoma. Molecular testing from plasma cell-free DNA detected EGFR L858R mutation. PD-L1 by IHC 10%. Staging consistent with stage IV disease with multiple pulmonary nodules and a single enhancing cerebellar metastasis. He was started on osimertinib 80 mg daily. At first restaging (8 weeks) there is a decrease in size of measurable lung lesions and partial response of the brain lesion on MRI.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic colorectal adenocarcinoma, NGS showed KRAS G12D. MSI testing is stable (MSI-stable). CT chest/abdomen reveals multiple pulmonary metastases. Treated with FOLFOX plus bevacizumab as first-line; after 6 cycles scans demonstrate interval enlargement of lung lesions and new nodules \u2014 clinical progression; patient transitioned to irinotecan-based salvage therapy.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab; then irinotecan-based salvage", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Urology operative summary and follow-up: 62-year-old man with clinically localized prostate adenocarcinoma (Gleason 4+4) underwent radical prostatectomy. Pathology pT2 (stage II). Germline testing returned positive for pathogenic BRCA2. He subsequently received adjuvant external beam radiation and has been on androgen deprivation therapy with leuprolide. PSA is undetectable on follow-up (<0.1 ng/mL). No evidence of metastatic disease on bone scan.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": "BRCA2 (germline pathogenic)", "biomarker": "PSA <0.1 ng/mL", "treatment": "radical prostatectomy; adjuvant external beam radiation; androgen deprivation therapy (leuprolide)", "response": "complete biochemical response (undetectable PSA)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with left-sided invasive ductal breast cancer, clinical stage IIB. ER/PR negative on IHC and HER2 FISH positive with clear HER2 amplification; NGS revealed PIK3CA H1047R. She received neoadjuvant paclitaxel with trastuzumab followed by lumpectomy. Surgical pathology reported no residual invasive carcinoma (pathologic complete response). No distant disease identified on staging.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER/PR negative", "treatment": "paclitaxel and trastuzumab; surgery", "response": "pathological complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Left breast invasive ductal carcinoma, ER+, PR+, HER2 amplified on FISH. Clinical stage IIIA at presentation. Received neoadjuvant doxorubicin/cyclophosphamide x4 followed by paclitaxel with concurrent trastuzumab. Underwent lumpectomy and sentinel node biopsy; surgical pathology: no residual invasive carcinoma identified \u2014 pathologic complete response. No distant disease on staging PET/CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant doxorubicin/cyclophosphamide then paclitaxel with trastuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Unresectable cutaneous melanoma of the right shoulder. Molecular profiling positive for BRAF V600E; PD-L1 by IHC 20%; tumor mutational burden reported as TMB-high (18 muts/Mb). Patient was started on combination targeted therapy with dabrafenib plus trametinib and had a rapid partial response on CT with reduction of pulmonary nodules. Note: staging not documented in this consult note.", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 20%; TMB-high (18 muts/Mb)", "treatment": "dabrafenib + trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient diagnosed with stage II (T2N0M0) invasive ductal carcinoma of the left breast. Tumor was ER positive, PR positive and HER2 amplified by FISH. Tumor sequencing identified a PIK3CA H1047R variant. She received neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel with concurrent trastuzumab, then underwent lumpectomy and sentinel node biopsy. Final pathology showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER+, PR+", "treatment": "doxorubicin and cyclophosphamide then paclitaxel with trastuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced left breast cancer. Core biopsy: invasive ductal carcinoma, HER2 amplified by FISH, ER and PR negative. Clinical stage IIIC with fixed axillary nodes. She received neoadjuvant trastuzumab and pertuzumab with docetaxel; after three cycles the primary increased in size and nodal disease progressed on exam and ultrasound.", "output": {"cancer_type": "breast cancer", "stage": "IIIC", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "trastuzumab, pertuzumab and docetaxel (neoadjuvant)", "response": "progressive disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic colorectal adenocarcinoma. Liver-dominant disease on CT with multiple hepatic lesions and rising CEA to 120 ng/mL. Molecular report: KRAS G12D, microsatellite stable (MSS). He was initiated on FOLFOX with bevacizumab; first restaging at 8 weeks shows no new lesions and minimal change in size consistent with stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "CEA elevated (120 ng/mL); MSS", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with locally advanced pancreatic ductal adenocarcinoma, unresectable mass abutting the SMA \u2014 staged as III. Germline testing returned BRCA2 pathogenic variant. He completed 8 cycles of FOLFIRINOX with radiographic disease stabilization and symptomatic improvement, then received consolidative radiation and was placed on PARP inhibitor maintenance (olaparib). Most recent CT shows stable disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": "BRCA2 pathogenic variant", "biomarker": null, "treatment": "FOLFIRINOX, radiation, maintenance olaparib", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old male with metastatic colorectal adenocarcinoma diagnosed in 2019. Current staging is IV with multiple liver lesions and peritoneal implants. Tumor profiling: MSI-H, BRAF V600E mutation, KRAS wild-type and TMB-high (18 muts/Mb). He received first-line pembrolizumab for MSI-H disease with an initial clinical benefit but progressed in the liver and was switched to encorafenib plus cetuximab combination therapy, with subsequent partial radiologic response on follow-up CT.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; KRAS wild-type; TMB-high (18 muts/Mb)", "treatment": "pembrolizumab; encorafenib + cetuximab", "response": "partial response", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colon adenocarcinoma presenting with multiple hepatic lesions. Next-generation sequencing reported KRAS G12D. Treated with FOLFOX plus bevacizumab in the palliative setting. Interval CT shows increase in size and number of liver lesions consistent with disease progression.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Impression: metastatic colon adenocarcinoma with liver-dominant disease. Biopsy of hepatic lesion positive for BRAF V600E. Initial management was FOLFOX plus bevacizumab with disease control for 5 months; on progression the patient was transitioned to encorafenib and cetuximab per molecular tumor board recommendations. Current restaging CT: size-stable hepatic lesions compared with prior scan.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "FOLFOX and bevacizumab; then encorafenib and cetuximab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with metastatic cutaneous melanoma (stage IV) who had BRAF V600E identified on tumor sequencing. He was started on pembrolizumab 200 mg every 3 weeks as first-line systemic therapy. After 6 cycles PET/CT demonstrates complete metabolic resolution of previously FDG-avid pulmonary and nodal disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 not specified", "treatment": "pembrolizumab", "response": "complete response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "61-year-old male with newly diagnosed metastatic lung adenocarcinoma. Staging CT chest/abdomen and brain MRI demonstrate a right upper lobe primary with multiple supratentorial metastases and lytic lesions in the spine. Comprehensive NGS identified an EGFR exon 19 deletion. PD-L1 by IHC was 5%. Patient was started on osimertinib 80 mg daily in July and reports symptomatic improvement. First restaging at 8 weeks showed decrease in size of target lesions and resolution of several brain mets consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: pt with metastatic cutaneous melanoma, BRAF V600E positive. Initially received single-agent nivolumab with mixed benefit; after progression in the chest and new brain metastases the patient was switched to combination dabrafenib plus trametinib. Baseline PD-L1 by IHC was 5%. After 2 months of targeted therapy the patient had an initial partial response in intracranial lesions but developed new pulmonary nodules consistent with a mixed response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "nivolumab (prior); dabrafenib plus trametinib", "response": "mixed response (initial partial response then new lesions)", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 52F with stage IIA invasive ductal carcinoma of the right breast, ER positive, PR positive, HER2 amplified on FISH. Surgical management included lumpectomy with sentinel node biopsy; margins negative. Adjuvant plan: weekly paclitaxel followed by trastuzumab for one year. PIK3CA H1047R identified on next-generation sequencing. At 18-month follow-up patient remains with no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy; adjuvant paclitaxel and trastuzumab", "response": "complete response (no evidence of disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma, stage IV with multiple hepatic lesions. NGS demonstrates KRAS G12D mutation. Treated with FOLFOX plus bevacizumab as first-line therapy. Interval CT shows increase in size and number of liver lesions consistent with progression. MSI status not reported and PD-L1 not assessed.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old premenopausal woman with Stage II (T2N1) invasive ductal breast carcinoma, ER+, PR+, HER2 amplified by FISH. She received neoadjuvant docetaxel and carboplatin plus trastuzumab with a clinical partial response, proceeded to lumpectomy and sentinel node dissection; final pathology showed pathologic complete response. Adjuvant radiation is planned.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "neoadjuvant docetaxel and carboplatin with trastuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant oncology note: 48-year-old woman with clinical T2N1 invasive ductal breast cancer, stage II. Tumor is ER+, PR+, HER2 amplified by FISH. No germline BRCA mutation identified. Patient received 4 cycles of carboplatin and docetaxel with trastuzumab and pertuzumab prior to surgery. Sentinel node biopsy and mastectomy pathology shows complete eradication of invasive tumor (pCR).", "output": {"cancer_type": "breast cancer", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant carboplatin and docetaxel with trastuzumab and pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old woman with newly diagnosed lung adenocarcinoma presenting with cough and headaches. Molecular testing identified EGFR L858R mutation; PD-L1 tumor proportion score 10%. Brain MRI confirmed a 1.2 cm cerebellar metastasis. She was started on osimertinib 80 mg daily in March and interval CT/PET shows decrease in primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man underwent resection of a sigmoid mass; pathology consistent with stage III (T3N1) colorectal adenocarcinoma. Tumor genotyping identified KRAS G12D and microsatellite stable (MSS) status. He completed 6 months of adjuvant FOLFOX without complications and is currently without radiologic evidence of distant disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "microsatellite stable (MSS)", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old female with metastatic lung adenocarcinoma diagnosed after MRI showed multiple enhancing lesions. Molecular testing returned EGFR L858R and MET amplification; PD-L1 tumor proportion score 10%. She was started on osimertinib in combination with crizotinib on a compassionate-use protocol. Interval imaging at 8 weeks demonstrated shrinkage of pulmonary and intracranial lesions with improvement of bone pain.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; MET amplification", "biomarker": "PD-L1 10%", "treatment": "osimertinib + crizotinib", "response": "partial response", "metastasis_site": "brain, bone, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 48-year-old male with metastatic cutaneous melanoma initially resected from the right shoulder. Restaging revealed pulmonary nodules and a solitary cerebellar lesion. Tumor genotyping: BRAF V600E. He was treated with dabrafenib and trametinib; extracranial disease shrank (partial systemic response) but interval MRI showed a new enhancing cerebellar metastasis requiring stereotactic radiosurgery. Oncology notes describe an overall mixed response with intracranial progression despite systemic benefit.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; stereotactic radiosurgery (for brain lesion)", "response": "mixed response (systemic partial response with intracranial progression)", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with metastatic colorectal adenocarcinoma. Liver-dominant metastatic disease on CT. Tumor genotyping: KRAS G12D mutation; MSI-stable. He completed 6 cycles of FOLFOX combined with bevacizumab but interval imaging shows increase in size and number of hepatic lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX + bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old with metastatic cutaneous melanoma harboring BRAF V600E and high tumor mutational burden. Baseline PD-L1 was 10%. He initially received targeted combination therapy with dabrafenib plus trametinib and achieved a partial response, but after 8 months developed new brain and pulmonary lesions and was transitioned to combination immunotherapy with nivolumab and ipilimumab, with subsequent progression.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high, PD-L1 10%", "treatment": "dabrafenib + trametinib; nivolumab + ipilimumab", "response": "initial partial response then progression", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma, FIGO IIIC with diffuse peritoneal implants and elevated CA-125. BRCA testing was negative for germline and somatic variants, but genomic scarring indicated HRD-positive status. She underwent optimal cytoreductive surgery followed by standard carboplatin and paclitaxel combination chemotherapy and was placed on maintenance olaparib. Imaging after completion of chemo showed complete radiologic response and normalization of CA-125.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "HRD-positive; CA-125 elevated", "treatment": "cytoreductive surgery followed by carboplatin and paclitaxel; maintenance olaparib", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "38-year-old male with metastatic cutaneous melanoma, BRAF V600E positive with TMB-high on NGS. He underwent wide local excision of the primary and subsequently developed multiple pulmonary nodules. Treatment with dabrafenib and trametinib was initiated and the chest CT after 6 weeks demonstrated a partial response of the lung metastases.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old male presented with a pigmented lesion on the left forearm. Excisional biopsy: superficial spreading melanoma, Breslow 0.6 mm, no ulceration. Clinical stage I (IA). Wide local excision performed with negative margins; no sentinel node biopsy was done per guidelines and patient declined further testing. No molecular testing was performed. Patient remains clinically NED at 18-month follow-up.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 62-year-old female with stage IV lung adenocarcinoma complicated by multiple supratentorial brain metastases and lytic lesions in the T6 vertebral body. NGS of the tumor revealed EGFR L858R mutation; PD-L1 TPS reported at 10%. Patient was started on osimertinib 80 mg daily three weeks ago. Interval chest CT demonstrates decrease in the size of the primary and extracranial metastases consistent with a partial response, while a new 6 mm enhancing cerebellar lesion is suspicious for intracranial progression.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response (extracranial); progression (intracranial) / mixed response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with castration-resistant prostate adenocarcinoma, status post radical prostatectomy (2010). Now presents with progressive bone pain and new sclerotic bone metastases on bone scan (stage IV). Previously received docetaxel; currently on enzalutamide for symptomatic control. No actionable genomic alterations reported in chart.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "docetaxel followed by enzalutamide", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma presented with multiple hypodense liver lesions on CT. Tumor genotyping: KRAS G12D; mismatch repair proficient (MSS). Clinical stage IV. Started FOLFOX plus bevacizumab. Follow-up CT after 3 months shows decrease in size of hepatic lesions consistent with partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (mismatch repair proficient)", "treatment": "FOLFOX plus bevacizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female diagnosed with high-grade serous ovarian carcinoma, stage IIIC with bulky pelvic disease and diffuse peritoneal implants. She underwent primary debulking surgery followed by six cycles of carboplatin and paclitaxel. Post-treatment CT and CA-125 demonstrate no radiographic evidence of disease and biochemical normalization. Limited somatic/germline panel showed no pathogenic mutations.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "primary debulking surgery followed by carboplatin and paclitaxel", "response": "complete response / no radiographic disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Admission note: 58-year-old female with metastatic colorectal adenocarcinoma. Tumor genotyping returned KRAS G12D. Imaging shows multiple hepatic lesions consistent with liver metastases. Tumor was reported microsatellite stable. Systemic therapy with FOLFOX (5-FU/leucovorin/oxaliplatin) plus bevacizumab was started; CT after three cycles demonstrates stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "microsatellite stable (MSS)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced breast cancer: ER negative, PR negative, HER2 amplified on FISH. Core biopsy also noted a PIK3CA H1047R mutation. She completed neoadjuvant chemotherapy with docetaxel and carboplatin plus trastuzumab and pertuzumab with good clinical reduction in tumor size. No distant mets identified on PET/CT prior to surgery.", "output": {"cancer_type": "breast cancer (HER2-positive)", "stage": "II (locally advanced) ", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel and carboplatin; trastuzumab and pertuzumab", "response": "clinical response / tumor shrinkage", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Cutaneous melanoma, stage IIIC on staging PET/CT. Tumor harbors BRAF V600E mutation. Initial adjuvant therapy with pembrolizumab was given but patient developed symptomatic brain metastases 8 months later. Therapy was changed to targeted therapy with dabrafenib plus trametinib with subsequent reduction in size of intracranial lesions. PD-L1 by IHC reported as 10%.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "pembrolizumab; dabrafenib plus trametinib", "response": "partial response (intracranial lesions)", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Urology postoperative summary: 71-year-old male underwent radical prostatectomy for clinically localized prostate adenocarcinoma (Gleason 4+3). Pathology consistent with organ-confined disease, postoperative plan included adjuvant external beam radiation and androgen deprivation with leuprolide because of adverse features. PSA is undetectable at 12 months follow-up.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; adjuvant radiation; androgen deprivation therapy (leuprolide)", "response": "no evidence of disease (undetectable PSA)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic lung adenocarcinoma diagnosed on core biopsy. Tumor harbors EGFR L858R mutation; PD-L1 tumor proportion score ~5%. MRI brain shows multiple small enhancing lesions. He was started on osimertinib 80 mg daily as first-line targeted therapy with stereotactic radiotherapy to dominant brain met. At 8-week follow-up there is a radiographic partial response in the lung and reduction in size of intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib; stereotactic radiotherapy", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old with metastatic cutaneous melanoma. Molecular testing detected BRAF V600E. She was started on targeted therapy with dabrafenib plus trametinib and had a brisk clinical and radiographic shrinkage of pulmonary nodules. After 6 months she developed symptomatic brain metastases requiring stereotactic radiosurgery and was transitioned to combination immunotherapy with nivolumab + ipilimumab. Recent scans show mixed response with intracranial control but new small pulmonary nodules.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib; nivolumab + ipilimumab; stereotactic radiosurgery", "response": "mixed response (intracranial control, new pulmonary nodules)", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with newly diagnosed glioblastoma (left temporal). He underwent subtotal resection; molecular testing shows MGMT promoter methylation positive and IDH1 R132H was negative. He was started on concurrent radiotherapy with temozolomide per the Stupp regimen. No extracranial metastatic disease was identified on staging.", "output": {"cancer_type": "glioblastoma (GBM)", "stage": "IV", "gene_mutation": null, "biomarker": "MGMT promoter methylation positive; IDH1 wild-type", "treatment": "radiotherapy + temozolomide (concurrent)", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Surgical pathology and clinic note: 48-year-old premenopausal woman with a 2.5 cm invasive ductal carcinoma of the left breast. Core biopsy showed HER2 3+, ER positive, PR negative. She received neoadjuvant doxorubicin/cyclophosphamide \u00d74 followed by paclitaxel with concurrent trastuzumab and pertuzumab. Left lumpectomy performed with sentinel node biopsy; no residual invasive carcinoma identified (pCR). No evidence of distant metastasis.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+; ER positive; PR negative", "treatment": "neoadjuvant doxorubicin/cyclophosphamide then paclitaxel with trastuzumab and pertuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old woman diagnosed with high-grade serous ovarian carcinoma, FIGO stage IIIC with extensive peritoneal disease. Germline testing returned a deleterious BRCA1 mutation. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel. Because of BRCA1 positivity she was placed on maintenance olaparib after chemotherapy and has had no evidence of disease on the most recent CT (complete clinical response).", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": null, "treatment": "cytoreductive surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man presented with cough and weight loss. CT chest revealed a right upper lobe mass and biopsy confirmed lung adenocarcinoma. Staging workup consistent with stage IV disease. Molecular testing identified EGFR exon 21 L858R mutation. PD-L1 tumor proportion score 10%. Brain MRI demonstrated multiple small enhancing lesions and PET showed osseous uptake consistent with bone metastases. He was started on osimertinib 80 mg daily as first-line therapy and interval scans at 8 weeks showed a 60% reduction in target lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic castration-resistant prostate adenocarcinoma presenting with diffuse sclerotic bone metastases. He remains on androgen deprivation therapy and was started on docetaxel chemotherapy. Over three cycles his PSA has been elevated but stable and imaging shows no new lesions \u2014 clinical status interpreted as stable disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "androgen deprivation therapy; docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma, KRAS G12D identified on molecular testing. Initial presentation included shortness of breath; CT chest/abdomen shows pulmonary nodules consistent with lung metastases. Treated with FOLFOX plus bevacizumab in the community setting. Despite therapy the most recent imaging documented progression of multiple lung lesions and new pleural effusion.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Gynecologic oncology record: 61-year-old with high-grade serous ovarian carcinoma, FIGO stage IIIC at presentation with bulky peritoneal disease and omental cake. Germline testing positive for BRCA1 pathogenic variant (185delAG). Underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel x6 cycles, achieved partial radiographic response with residual peritoneal implants; CA-125 fell from 980 to 120 U/mL. Patient started maintenance olaparib. Plan for interval imaging in 3 months.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 185delAG (pathogenic)", "biomarker": "CA-125 elevated (declining on treatment)", "treatment": "cytoreductive surgery, carboplatin and paclitaxel, maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum, omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman underwent lumpectomy for a 1.8 cm invasive ductal carcinoma. Pathology: ER positive, PR positive, HER2 negative; sentinel nodes negative. Final stage pT1cN0 \u2014 Stage I. She completed adjuvant whole-breast radiation and was started on tamoxifen. No evidence of disease at 6-month follow-up.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy, adjuvant radiation, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 60-year-old man with newly diagnosed prostate adenocarcinoma, clinical stage T2b (stage II). Preoperative PSA was 12 ng/mL. No genomic testing was performed. He elected definitive surgery and underwent radical prostatectomy; postoperative PSA is undetectable.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 12 ng/mL (preoperative)", "treatment": "radical prostatectomy", "response": "undetectable PSA", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with newly diagnosed metastatic lung adenocarcinoma. Imaging revealed multiple cerebral and vertebral lesions consistent with metastatic disease. Molecular testing detected EGFR L858R mutation; PD-L1 by IHC was 10%. Patient started osimertinib first-line with symptomatic improvement and interval scans show a partial response after 8 weeks.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old female with newly diagnosed lung adenocarcinoma. Molecular testing of the biopsy detected EGFR L858R. PD-L1 TPS was 10%. Staging workup consistent with stage IV disease with a single cerebellar metastasis and lytic lesions in the thoracic spine. She was started on osimertinib 80 mg PO daily. First restaging CT at 12 weeks demonstrates interval decrease in size of pulmonary and bony lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic colorectal adenocarcinoma, liver-predominant disease. Staging consistent with Stage IV. Tumor genotyping: KRAS G12D; microsatellite testing MSI-stable. He was started on FOLFOX plus bevacizumab. Follow-up CT at 8 weeks shows no new lesions and slight decrease in size of hepatic lesions consistent with stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female presented with rectal bleeding. Colonoscopy revealed a sigmoid mass; pathology: moderately differentiated adenocarcinoma, pT3N1 (stage III). MSI testing returned MSI-H. She underwent low anterior resection with regional lymphadenectomy and completed 6 months of adjuvant FOLFOX. Follow-up CT chest/abdomen/pelvis shows no evidence of distant disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "surgery (low anterior resection) followed by adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with right-sided colon adenocarcinoma with multiple hypodense hepatic lesions on CT. Molecular testing: BRAF V600E mutation and high microsatellite instability (MSI-H) on PCR. Given MSI-H status he was started on pembrolizumab monotherapy. Restaging at 12 weeks demonstrates no new lesions and overall tumor measurements are unchanged \u2014 stable disease by RECIST.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma. Staging CT demonstrates multiple bilateral pulmonary nodules and enhancing lesions in the cerebellum and thoracic spine consistent with metastatic disease \u2014 clinical stage IV. Molecular testing returned EGFR L858R mutation; ALK and ROS1 negative. PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily and received stereotactic radiosurgery to the cerebellar lesion. First follow-up CT at 8 weeks shows a partial response with shrinkage of the lung primary and decreased size of brain and spinal metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; spine"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score approximately 10%. He was started on osimertinib as first-line therapy and had a radiographic partial response at the 8-week scan. Brain and bone metastases were present on staging MRI and PET/CT.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma, stage IIIC at cytoreduction with extensive peritoneal carcinomatosis. Germline BRCA1 pathogenic variant was reported. Patient underwent optimal debulking followed by carboplatin and paclitaxel with near-complete radiographic response; placed on maintenance olaparib and remains in clinical remission.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": null, "treatment": "carboplatin and paclitaxel followed by maintenance olaparib", "response": "clinical remission", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "39-year-old man with a pigmented lesion on the upper arm found to be stage IIIc cutaneous melanoma with bulky axillary nodal involvement. Tumor panel detected BRAF V600E. He underwent wide local excision and axillary lymphadenectomy and then started adjuvant dabrafenib plus trametinib. Early postsurgical CT shows no distant disease; plan is close surveillance.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIc", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; axillary lymphadenectomy; dabrafenib and trametinib", "response": "no evidence of distant disease", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with right-sided invasive ductal carcinoma. ER/PR negative, HER2 amplified by FISH. Clinical stage IIIB based on chest wall involvement and fixed axillary nodes. Next-generation sequencing identified a PIK3CA H1047R variant. She received neoadjuvant paclitaxel in combination with trastuzumab and pertuzumab, then underwent modified radical mastectomy. Surgical pathology shows near-complete response with only focal residual tumor.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "paclitaxel; trastuzumab; pertuzumab; surgery (modified radical mastectomy)", "response": "near-complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47F presented with a 2.5 cm left breast mass. Core biopsy: invasive ductal carcinoma, ER+/PR+, HER2 amplified by FISH. Pathologic stage after lumpectomy and sentinel node biopsy was Stage IIA (T2N0). Tumor sequencing showed PIK3CA H1047R. She completed adjuvant paclitaxel with trastuzumab and remains without evidence of disease on follow up.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "lumpectomy, adjuvant paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma to the liver. Tumor sequencing: KRAS G12D. MSI testing returned MSI-H and tumor mutational burden reported as TMB-high. Given MSI-H status, patient was started on pembrolizumab monotherapy. After 12 weeks on treatment, scans show stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic lung adenocarcinoma diagnosed in 2020. Molecular testing showed EGFR L858R; PD-L1 TPS 15%. He initially received carboplatin and pemetrexed, then was switched to osimertinib after progression. Recent MRI shows shrinkage of the primary and decreased size of the brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "carboplatin and pemetrexed; osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old with biopsy-proven pancreatic ductal adenocarcinoma, stage IV with multiple liver metastases. Tumor profiling identified KRAS G12V and a pathogenic germline BRCA2 mutation. CA 19-9 was markedly elevated (>1000 U/mL) at presentation. He received 6 cycles of FOLFIRINOX with initial stable disease, then progression on restaging scans; subsequently treated with gemcitabine/nab\u2011paclitaxel and later olaparib maintenance because of the BRCA2 mutation, but scans ultimately demonstrated progressive disease.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12V; BRCA2 pathogenic mutation (germline)", "biomarker": "CA19-9 markedly elevated (>1000 U/mL)", "treatment": "FOLFIRINOX; gemcitabine/nab-paclitaxel; olaparib", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical note: 48-year-old woman with stage IIA invasive ductal carcinoma of the left breast, ER positive, PR positive and HER2 amplification by FISH. She received neoadjuvant chemotherapy (dose-dense doxorubicin/cyclophosphamide followed by paclitaxel) with trastuzumab. Surgical pathology after lumpectomy and sentinel node biopsy showed no residual invasive tumor (pathologic complete response). No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant doxorubicin/cyclophosphamide followed by paclitaxel and trastuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Follow-up note: 62-year-old female with metastatic lung adenocarcinoma (EGFR L858R positive) diagnosed 03/2024. Staging: IV with multiple brain metastases on MRI. PD-L1 reported at 5%. She was started on osimertinib 80 mg daily; first restaging CT shows decreased size of pulmonary and nodal disease consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "49-year-old female with locally advanced invasive ductal carcinoma of the left breast, clinical stage IIIB (T4bN1). Hormone receptors: ER positive, PR positive. HER2 amplification by FISH. NGS panel detected PIK3CA H1047R. She received neoadjuvant paclitaxel then carboplatin with trastuzumab; subsequent mastectomy showed pathologic complete response. No distant metastases were identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant paclitaxel, carboplatin, trastuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology / Oncology summary: 48-year-old woman with palpable left breast mass. Core biopsy: invasive ductal carcinoma, ER 90%+, PR 5%+, HER2 IHC 3+ with confirmed HER2 amplification on FISH. Clinical stage cT2N1 (breast MRI demonstrates 2.5 cm primary and suspicious axillary nodes). Neoadjuvant regimen: dose-dense AC followed by paclitaxel with trastuzumab initiated. Post-op report: mastectomy with axillary dissection reveals no residual invasive carcinoma \u2014 pathologic complete response. BRCA testing pending.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "cT2N1 (clinical)", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR low", "treatment": "dose-dense doxorubicin and cyclophosphamide then paclitaxel with trastuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with metastatic colorectal adenocarcinoma, stage IV with multiple liver and bilateral lung metastases. Tumor profiling: MSI-H and TMB-high on tumor sequencing; KRAS G12D reported. He received first-line FOLFOX with bevacizumab but progressed after 8 cycles and was started on pembrolizumab monotherapy, achieving a durable stable disease for 10 months on imaging.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic colorectal adenocarcinoma, stage IV with multiple hepatic lesions. Molecular testing returned positive for BRAF V600E and MSI-H. He was started on FOLFOX plus bevacizumab. Interval imaging at 12 weeks demonstrates no new lesions and measurements are stable.", "output": {"cancer_type": "colorectal (colon) adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant clinical note: 48F with locally advanced invasive ductal carcinoma of the left breast, ER positive, PR negative, HER2 amplification on FISH. Clinical stage cT3N1 (stage IIIA). She completed 6 cycles of dose-dense paclitaxel and carboplatin with concurrent trastuzumab and had no measurable disease on pre-op imaging. Underwent mastectomy and nodes negative on final pathology \u2014 pathologic complete response. No distant metastases identified.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant paclitaxel and carboplatin with trastuzumab, surgery (mastectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with palpable left breast mass. Core biopsy: invasive ductal carcinoma, ER positive, PR negative, HER2 IHC 3+; clinical stage II (T2N0M0). Neoadjuvant AC followed by paclitaxel was administered with trastuzumab started concurrent with taxane. Post-op pathology showed no residual invasive carcinoma (pathologic complete response). PIK3CA H1047R was found on panel testing.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+, ER positive, PR negative", "treatment": "neoadjuvant doxorubicin + cyclophosphamide then paclitaxel with trastuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology: invasive ductal carcinoma of the right breast, clinical stage IIB (T2N1). ER positive, PR negative, HER2 amplified by FISH. NGS panel returned PIK3CA H1047R mutation. Patient received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) followed by lumpectomy; surgical specimen showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab (neoadjuvant TCHP)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male with metastatic colorectal adenocarcinoma. Tumor profiling identified KRAS G12D by NGS. Microsatellite testing reported MSI-H and tumor mutational burden high (TMB-high, 25 mut/Mb). CT abdomen shows multiple lesions in the liver consistent with metastatic disease. Patient was started on FOLFOX plus bevacizumab; interval imaging after 8 weeks demonstrates stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high (25 mut/Mb)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48F with locally advanced left breast cancer. Core biopsy confirmed invasive ductal carcinoma, HER2 IHC 3+ and FISH positive for HER2 amplification. ER and PR were negative. Clinical exam and MRI consistent with fixed tumor and skin involvement\u2014stage IIIB. She received neoadjuvant trastuzumab in combination with weekly paclitaxel followed by modified radical mastectomy. Pathology after surgery showed no residual invasive carcinoma.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "trastuzumab and paclitaxel (neoadjuvant), surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man diagnosed with lung adenocarcinoma after biopsy of a right upper lobe mass. Staging workup revealed brain metastases on MRI. Molecular testing returned positive for EGFR L858R; PD-L1 TPS reported as 10%. Patient staged as IV and started osimertinib 80 mg PO daily. First restaging at 8 weeks showed marked reduction in measurable disease consistent with a partial response. Whole brain radiation was discussed but deferred.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 62-year-old female with newly diagnosed lung adenocarcinoma. Molecular testing returned EGFR L858R mutation; PD-L1 10% by IHC. Staging workup consistent with stage IV disease with brain and bone metastases. Patient was started on osimertinib 80 mg daily. Eight-week restaging CT/MRI demonstrates reduction in thoracic nodules and decreased enhancement of several brain metastases consistent with a partial response to therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Case summary: 58-year-old female with high-grade serous ovarian carcinoma, optimally debulked at exploratory laparotomy (Stage IIIC) with diffuse omental and peritoneal disease. Germline testing positive for BRCA1 mutation. CA-125 at diagnosis was 620 U/mL. She completed six cycles of adjuvant carboplatin and paclitaxel with partial radiographic and CA-125 response, and was transitioned to maintenance olaparib. Most recent assessment documents disease control on maintenance (stable disease).", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": "CA-125 620 U/mL", "treatment": "debulking surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "stable disease (after partial response to chemo)", "metastasis_site": "peritoneum, omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma (stage IV) presented with headaches and back pain. NGS returned EGFR L858R mutation. PD-L1 by 22C3 reported at 10%. Brain MRI showed multiple enhancing lesions and PET/CT confirmed osseous metastases. She was started on osimertinib 80 mg daily; 3-month restaging CT chest/abdomen showed decrease in pulmonary nodules and partial response clinically and radiographically.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man presenting with metastatic prostate adenocarcinoma with diffuse sclerotic bone lesions on bone scan. Treated with androgen deprivation therapy (leuprolide) and docetaxel x6. On follow-up PSA and imaging there is rising PSA and new bone lesions concerning for progression. Somatic genomic testing not performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide (androgen deprivation therapy) and docetaxel", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of present illness: 62-year-old female with progressive dyspnea. Biopsy-proven lung adenocarcinoma diagnosed 03/2024. Staging workup demonstrates stage IV disease with multiple brain and vertebral lesions. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. Patient started osimertinib 80 mg daily in April and has interval MRI showing decrease in size of intracranial lesions. Treatment response documented as partial response on RECIST.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of present illness: 62-year-old female diagnosed with lung adenocarcinoma in January 2024. Staging workup consistent with stage IV disease with multiple intracranial lesions on MRI. Molecular testing returned EGFR L858R and no ALK/ROS1 rearrangement. PD-L1 by IHC reported 10%. Patient started osimertinib 80 mg daily in February and stereotactic radiosurgery to two symptomatic brain mets. At 8-week restaging CT/MRI there is a marked decrease in size of both intracranial and pulmonary lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Radiology report: PET/CT and brain MRI for a 55-year-old man with advanced melanoma. Prior molecular testing positive for BRAF V600E and high tumor mutational burden (TMB-high). Patient started on dabrafenib plus trametinib three months ago. Current imaging shows decrease in size of several pulmonary nodules but enlargement of a cerebellar lesion; overall impression consistent with a mixed response. Disease is managed as metastatic (stage IV) melanoma with known brain and lung involvement.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "mixed response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with bulky cervical lymphadenopathy diagnosed as diffuse large B-cell lymphoma. Staging workup indicated stage II disease. He completed 6 cycles of R-CHOP with PET-CT after therapy showing complete metabolic response. No molecular driver mutations were reported in the chart and PD-L1/other biomarkers were not sent.", "output": {"cancer_type": "diffuse large B-cell lymphoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "R-CHOP (6 cycles)", "response": "complete metabolic response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with castration-resistant prostate cancer and extensive osteoblastic bone metastases. Germline and somatic testing identified a deleterious BRCA2 mutation. PSA is 42 ng/mL. He progressed on first-line androgen deprivation plus abiraterone and received docetaxel; most recently started on olaparib for BRCA2-associated disease with stable PSA and radiographic stable disease at first assessment.", "output": {"cancer_type": "prostate adenocarcinoma (castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2", "biomarker": "PSA 42 ng/mL", "treatment": "androgen deprivation + abiraterone; docetaxel; olaparib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced invasive ductal carcinoma of the right breast. Core biopsy: ER positive, PR positive, HER2 amplification by FISH. PIK3CA H1047R mutation detected on NGS. She received neoadjuvant docetaxel with trastuzumab and pertuzumab prior to mastectomy; surgical pathology showed no residual invasive carcinoma in the breast or nodes.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel with trastuzumab and pertuzumab (neoadjuvant), surgery", "response": "complete pathologic response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "78-year-old man with metastatic prostate cancer, stage IV at diagnosis with multiple bone metastases on bone scan. Germline testing identified a BRCA2 pathogenic variant. He initially received androgen deprivation therapy with leuprolide plus docetaxel; on progression with rising PSA and radiographic progression after a trial of enzalutamide, he was transitioned to the PARP inhibitor olaparib. Recent imaging shows new pelvic nodal and additional bony lesions consistent with progression; PSA is 320 ng/mL.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "PSA 320 ng/mL", "treatment": "androgen deprivation therapy (leuprolide) and docetaxel; later enzalutamide then olaparib", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with unresectable metastatic cutaneous melanoma presenting with symptomatic brain metastases. Molecular profiling positive for BRAF V600E. PD-L1 10% and tumor shows high TMB. He was started on dabrafenib plus trametinib with an initial partial response of intracranial and extracranial disease, later progressing and enrolled on combination immunotherapy with ipilimumab and nivolumab. Best documented response to targeted therapy was partial response. Stage IV at presentation.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%, TMB-high", "treatment": "dabrafenib + trametinib; later ipilimumab + nivolumab", "response": "partial response (to dabrafenib + trametinib)", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man diagnosed with lung adenocarcinoma presenting with cough and weight loss. Staging scans demonstrate multiple bilateral pulmonary nodules and two enhancing brain lesions consistent with metastases \u2014 overall stage IV disease. Tumor genotyping returned EGFR L858R; PD-L1 TPS 10%. He was started on osimertinib 80 mg daily and interval CT/MRI at 3 months showed a partial response with shrinkage of intracranial and pulmonary lesions. Continues on osimertinib with clinical improvement.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female with biopsy-proven lung adenocarcinoma, stage IV. Molecular testing returned EGFR L858R (exon 21) and PD-L1 20% by IHC. PET/CT demonstrated metastatic disease to the brain and liver. She was started on osimertinib 80 mg daily as first-line targeted therapy with symptomatic improvement; CT chest/brain after 8 weeks showed a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 20%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 54-year-old with metastatic cutaneous melanoma. Initial molecular testing revealed BRAF V600E mutation. Patient began combination targeted therapy with dabrafenib and trametinib; achieved partial response at 3 months. After 8 months of therapy there was clinical progression with new pulmonary nodules and increasing LDH; therapy changed to ipilimumab and nivolumab. PD-L1 status was not reported in records.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib (then switched to ipilimumab + nivolumab)", "response": "initial partial response then progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op clinic note: 47-year-old with locally advanced invasive ductal carcinoma, clinical stage cT3N2M0 (stage IIIC). Core biopsy: HER2 amplification by FISH; ER positive (80%), PR positive (30%). FoundationOne NGS identified PIK3CA E545K mutation. Patient completed 6 cycles neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab and pertuzumab) followed by modified radical mastectomy. Surgical pathology indicates pathologic complete response (no residual invasive carcinoma). No distant mets identified.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIC", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with locally advanced pancreatic ductal adenocarcinoma involving the superior mesenteric vein (borderline resectable). Baseline tumor marker CA19-9 was 1,200 U/mL. Molecular profiling returned KRAS G12D. He received 6 cycles of neoadjuvant FOLFIRINOX with decrease in tumor size and CA19-9, making him a candidate for surgical resection. Underwent distal pancreatectomy; pathology showed marked treatment effect.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "CA19-9 1,200 U/mL", "treatment": "neoadjuvant FOLFIRINOX then distal pancreatectomy", "response": "partial response enabling resection", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 63-year-old female with metastatic lung adenocarcinoma. NGS revealed EGFR L858R mutation; PD-L1 by 22C3 was 1%. She started osimertinib 80 mg daily in January and has had symptomatic improvement. Interval MRI shows shrinkage of multiple intracranial lesions and decreased size of a lytic T8 lesion. Assessment: Stage IV lung adenocarcinoma with brain and bone metastases; current best response: partial response on systemic therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "46-year-old woman with locally advanced left breast invasive ductal carcinoma, ER positive, PR positive. HER2 amplification confirmed by FISH. Clinical stage recorded as IIIB due to fixation to chest wall and bulky axillary nodes. She received neoadjuvant doxorubicin and cyclophosphamide x4 followed by paclitaxel with trastuzumab; modified radical mastectomy performed. Surgical pathology reported no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Tumor profiling returned MSI-H. He received first-line FOLFOX with progression and was switched to pembrolizumab monotherapy; restaging after 4 cycles demonstrated a partial response which is ongoing at eight months.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "FOLFOX; pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with sigmoid colon adenocarcinoma found to have KRAS G12D on tumor profiling. Tumor was microsatellite stable (MSS) on PCR. CT shows multiple liver lesions consistent with liver-predominant metastatic disease. After progression on adjuvant capecitabine, the patient received FOLFOX plus bevacizumab but interval scans demonstrate enlarging hepatic metastases.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "38-year-old male with a superficial spreading melanoma of the right forearm, Breslow depth 0.8 mm without ulceration. Wide local excision with 1 cm margins was performed; sentinel node biopsy negative. Pathologic staging reported stage I. No targeted or immunotherapy was recommended and patient will be followed with dermatology and oncology surveillance.", "output": {"cancer_type": "cutaneous melanoma (superficial spreading)", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision (surgery)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic colorectal adenocarcinoma to the liver. KRAS mutation testing returned positive for KRAS G12D; microsatellite testing reported MSS. He was treated with FOLFOX plus bevacizumab for six cycles. Restaging CT shows minimal shrinkage of hepatic lesions and CEA decreased modestly; disease has been radiographically stable.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female presented with high-grade serous ovarian carcinoma, clinical stage IIIC with bulky peritoneal disease. Pre-op CA-125 was 860 U/mL. She underwent optimal cytoreductive debulking followed by six cycles of carboplatin and paclitaxel and was placed on olaparib maintenance. BRCA testing was not performed prior to starting maintenance. Imaging after 3 cycles of chemo showed a partial radiographic response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "CA-125 860 U/mL", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "partial response after chemotherapy", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and follow-up note: 34-year-old with cutaneous melanoma of the left forearm, Breslow 2.1 mm, sentinel node positive \u2014 overall stage IIIA. Wide local excision and completion lymphadenectomy completed. Adjuvant pembrolizumab started. PD-L1 reported as 10%. BRAF testing was not available in the chart. At 12-month surveillance imaging there is no evidence of disease.", "output": {"cancer_type": "cutanous melanoma", "stage": "IIIA", "gene_mutation": null, "biomarker": "PD-L1 10%", "treatment": "pembrolizumab (adjuvant); surgical excision and lymphadenectomy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female diagnosed with lung adenocarcinoma. Staging revealed stage IV disease with multiple enhancing lesions on MRI consistent with brain metastases. Comprehensive NGS returned EGFR L858R activating mutation. PD-L1 by IHC was 10%. She was started on osimertinib 80 mg daily and follow-up CT/MRI demonstrated a confirmed partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed stage IV lung adenocarcinoma. Molecular testing returned an EGFR exon 19 deletion. PD-L1 tumor proportion score 10%. Patient started first-line osimertinib 80 mg daily in June. Follow-up MRI brain and PET-CT at 3 months show reduction in size of intracranial lesions and partial regression of bone lesions \u2014 overall partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic lung adenocarcinoma. Tissue biopsy positive for EGFR L858R. PD-L1 by IHC reported at 10%. He was started on osimertinib 80 mg daily. Baseline brain MRI showed multiple small cerebral metastases. Systemic disease demonstrated a partial response to osimertinib at first restaging, but he developed intracranial progression at month 9.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response then intracranial progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with newly diagnosed metastatic prostate adenocarcinoma with extensive symptomatic bony disease. No molecular testing performed. He was started on androgen deprivation therapy with leuprolide and given concurrent docetaxel chemotherapy per CHAARTED protocol. PSA has stabilized on therapy.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide + docetaxel", "response": "stable disease (PSA stabilization)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with cutaneous melanoma, stage IV with pulmonary and intracranial involvement. Molecular profiling positive for BRAF V600E and high tumor mutational burden (TMB-high). He was initially treated with pembrolizumab but developed new brain lesions (mixed response). Switched to dabrafenib plus trametinib with partial response of extracranial disease; CNS progression required stereotactic radiosurgery.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "pembrolizumab; dabrafenib and trametinib; stereotactic radiosurgery", "response": "mixed response (initial); partial response extracranially with CNS progression", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with intermediate-risk prostate adenocarcinoma (Gleason 4+3), clinical stage IIB. Germline testing positive for BRCA2 mutation. Underwent radical prostatectomy followed by adjuvant external beam radiation and androgen deprivation therapy with leuprolide. PSA remains undetectable and scans show no evidence of distant disease; clinical status described as stable disease on ADT.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IIB", "gene_mutation": "BRCA2", "biomarker": null, "treatment": "radical prostatectomy, adjuvant radiation, androgen deprivation therapy (leuprolide)", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with metastatic colorectal adenocarcinoma diagnosed on liver biopsy. Molecular testing returned BRAF V600E mutation. Tumor is MSI-H and reported as TMB-high on NGS. Patient received pembrolizumab monotherapy as first-line immunotherapy but imaging after three cycles showed enlargement of hepatic lesions and new ascites consistent with progression. Stage at presentation: IV with dominant liver metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced breast cancer. Core biopsy triple negative for ER/PR but FISH positive for HER2 amplification. Clinical stage IIIB with fixed supraclavicular adenopathy. She received neoadjuvant paclitaxel with dual anti-HER2 therapy (trastuzumab and pertuzumab) followed by mastectomy; pathology showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification", "treatment": "neoadjuvant paclitaxel with trastuzumab and pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Emergency admission: 68-year-old with abdominal pain and weight loss. Imaging shows a pancreatic head mass encasing the superior mesenteric artery with small-volume peritoneal nodularity. Endoscopic biopsy reported pancreatic ductal adenocarcinoma. No actionable mutations were reported on limited panel at the time; genomic data pending. Patient was started on systemic chemotherapy with gemcitabine and nab-paclitaxel. After two cycles there is minor radiographic tumor shrinkage but persistent peritoneal disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IIB", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine and nab-paclitaxel", "response": "stable disease / minor shrinkage", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing identified an EGFR L858R mutation; T790M was not detected. PD-L1 tumor proportion score reported at 10%. PET/CT at diagnosis showed multiple bony lesions and two enhancing brain metastases. Patient initiated osimertinib 80 mg daily in September 2019 with radiographic partial response on first follow-up and symptomatic improvement.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 58-year-old with cutaneous melanoma originally treated with wide local excision and sentinel node biopsy (node positive). Developed pulmonary nodules and a symptomatic solitary brain metastasis. PD-L1 by IHC reported at 60%. Patient received pembrolizumab 200 mg q3w; lung lesions showed partial shrinkage but brain lesion progressed requiring stereotactic radiosurgery. BRAF testing was not informative / no actionable mutation reported at this time. Final assessment: mixed response with intracranial progression.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 60%", "treatment": "pembrolizumab", "response": "mixed response with intracranial progression", "metastasis_site": "brain and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology summary: 64-year-old with high-grade serous ovarian carcinoma, stage IIIC at laparotomy with extensive peritoneal carcinomatosis. Germline testing positive for BRCA1 pathogenic variant. Patient received debulking surgery followed by adjuvant carboplatin and paclitaxel x6 cycles and was transitioned to maintenance olaparib. CA-125 decreased into the normal range and CT shows no new peritoneal implants; disease is currently assessed as stable on maintenance therapy.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": null, "treatment": "debulking surgery; carboplatin; paclitaxel; olaparib (maintenance)", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic colorectal adenocarcinoma with numerous liver lesions and nodular peritoneal implants. Biopsy shows poorly differentiated adenocarcinoma. Molecular profile: BRAF V600E mutation; tumor is MSI-H with high tumor mutational burden. He was started on pembrolizumab given MSI status, but after 12 weeks scans demonstrated progression in the liver. He was switched to encorafenib plus cetuximab on a compassionate-use protocol with subsequent decrease in target lesions (partial response).", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab; encorafenib + cetuximab", "response": "progression on pembrolizumab then partial response to encorafenib + cetuximab", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note (oncology): 48-year-old with metastatic cutaneous melanoma diagnosed last year. BRAF V600E mutation identified on tumor panel. Initially responded to combination targeted therapy (dabrafenib + trametinib) but developed clinical decline with enlarging hepatic lesions on interval CT. Impression: progressive disease in the liver after 6 months of targeted therapy. Will consider switching to immunotherapy or clinical trial.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with biopsy-proven lung adenocarcinoma. Staging workup demonstrated stage IV disease with brain and bone metastases. Tumor NGS returned EGFR L858R mutation and PD-L1 tumor proportion score 5%. Patient was started on osimertinib 80 mg daily as first-line therapy; interval MRI/CT at 8 weeks shows a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma, AJCC stage IV. Molecular testing: BRAF V600E mutation and MSI-H (loss of MLH1/PMS2). Liver-dominant metastases on CT abdomen. Prior FOLFOX plus bevacizumab achieved minimal shrinkage; due to MSI-H status patient was transitioned to pembrolizumab monotherapy. Most recent CT shows no significant change in target lesions \u2014 assessment: stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman presents with locally advanced invasive ductal carcinoma of the right breast. ER/PR negative, HER2 amplified on FISH. Clinical stage IIIB with fixed axillary nodes. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) followed by mastectomy. Surgical pathology reported no residual invasive carcinoma consistent with a pathologic complete response. No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab; surgery (mastectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Discharge summary: 67-year-old male with metastatic castration-resistant prostate cancer, bone-predominant metastases. Germline testing identified a deleterious BRCA2 frameshift mutation. He received androgen-deprivation therapy followed by docetaxel; due to continued progression he was started on olaparib 300 mg PO BID. PSA was 120 ng/mL prior to olaparib and declined to 45 ng/mL at 12 weeks. Radiographs show stable osseous disease.", "output": {"cancer_type": "prostate cancer (castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 frameshift mutation", "biomarker": "PSA elevated (baseline 120 ng/mL; decreased to 45 ng/mL)", "treatment": "olaparib (prior docetaxel, androgen-deprivation therapy)", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female diagnosed with high-grade serous ovarian carcinoma, FIGO stage IIIC with bulky omental and diffuse peritoneal disease. Germline BRCA1 mutation (c.5266dupC) was identified and tumor was HRD-positive. She had optimal cytoreductive surgery followed by systemic chemotherapy with carboplatin and paclitaxel; CT after 4 cycles demonstrates a partial radiographic response with decreased peritoneal implants.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 c.5266dupC (germline)", "biomarker": "HRD-positive", "treatment": "cytoreductive surgery followed by carboplatin and paclitaxel", "response": "partial response", "metastasis_site": "peritoneum, omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: Patient with widely metastatic cutaneous melanoma, AJCC stage IV, with pulmonary and cerebral metastases. BRAF testing pending at the time of treatment decision (no actionable mutation documented). PD-L1 tumor proportion score 5%. Started combination immunotherapy with nivolumab plus ipilimumab as first-line therapy. Interval imaging after 3 cycles demonstrates stable disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 5%", "treatment": "nivolumab plus ipilimumab", "response": "stable disease", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Medical oncology letter: 74-year-old male with metastatic castration-resistant prostate adenocarcinoma (mCRPC), bone-predominant metastases. Germline and tumor testing identified a deleterious BRCA2 alteration consistent with HRR deficiency. Prior exposure included docetaxel and enzalutamide with subsequent progression; patient was started on olaparib with stable disease on 3-month bone scan review.", "output": {"cancer_type": "prostate adenocarcinoma (mCRPC)", "stage": "IV", "gene_mutation": "BRCA2 deleterious", "biomarker": "HRR deficiency (BRCA2)", "treatment": "olaparib (after docetaxel and enzalutamide)", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology consult: 62-year-old man with metastatic cutaneous melanoma, presented with symptomatic headache. MRI: multiple enhancing parenchymal lesions and pulmonary nodules. Prior tumor genotyping: BRAF V600E positive. PD-L1 reported as <1%. He was started on nivolumab monotherapy but had radiographic progression after 8 weeks. He was switched to dabrafenib plus trametinib with subsequent reduction in size of brain and lung lesions on first restaging scan.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 <1%", "treatment": "nivolumab then dabrafenib and trametinib", "response": "progression on nivolumab, partial response to dabrafenib/trametinib", "metastasis_site": "brain and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old man with metastatic lung adenocarcinoma (stage IV) found to harbor an EGFR L858R mutation on next-generation sequencing. Baseline PD-L1 tumor proportion score reported as 10%. He was started on osimertinib 80 mg daily as first-line therapy in March 2025. Staging MRI brain and PET/CT demonstrated metastases to the cerebellum and multiple lytic bone lesions. After three months on therapy, interval imaging demonstrated a partial response with shrinkage of pulmonary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "38-year-old male with cutaneous melanoma on the left forearm. Wide local excision and sentinel lymph node biopsy revealed one positive node consistent with stage IIIA disease. Tumor was BRAF V600E positive. He completed 12 months of adjuvant dabrafenib plus trametinib and remains on clinical follow-up without recurrence.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIA", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; sentinel lymph node biopsy; adjuvant dabrafenib and trametinib", "response": "no evidence of disease / no recurrence on follow-up", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "28-year-old man with a 1.2 mm superficial spreading melanoma on the right forearm, staged as IB. Wide local excision with negative sentinel node was performed. No tumor genomic sequencing was performed and no adjuvant therapy was given. Patient is on surveillance with no evidence of recurrence.", "output": {"cancer_type": "superficial spreading melanoma", "stage": "I (IB)", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision (surgery)", "response": "no evidence of recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with pancreatic ductal adenocarcinoma presenting with extensive liver metastases. Baseline CA 19-9 was markedly elevated (>1000 U/mL). Tumor sequencing identified a KRAS G12V mutation. He received first-line FOLFIRINOX but progressed after 4 months and was switched to second-line gemcitabine plus nab\u2011paclitaxel. Restaging CT following second-line therapy demonstrated interval growth of hepatic lesions.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12V", "biomarker": "CA 19-9 >1000 U/mL", "treatment": "FOLFIRINOX; then gemcitabine + nab-paclitaxel", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with a 1.1 cm invasive ductal carcinoma of the left breast, clinical stage I. Tumor is ER positive, PR positive and HER2 negative on IHC/FISH. Lumpectomy with sentinel node biopsy was performed; margins negative. Tumor sequencing showed a PIK3CA H1047R mutation. She was started on adjuvant tamoxifen. At 6-month surgical follow-up there is no clinical or radiographic evidence of disease.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "I", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+; PR+; HER2-negative", "treatment": "lumpectomy and adjuvant tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with newly diagnosed lung adenocarcinoma found to harbor EGFR L858R on diagnostic NGS. Staging PET/CT showed contralateral pulmonary nodules and enhancing lesions in the cerebellum and liver consistent with metastatic disease; overall stage IV. PD-L1 by IHC reported at 10%. He was started on osimertinib 80 mg daily in June and after 8 weeks repeat imaging demonstrated marked decrease in target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of metastatic castration-resistant prostate adenocarcinoma with bone pain and rising PSA. Germline and somatic testing identified a deleterious BRCA2 mutation. Patient was started on olaparib 300 mg twice daily after failing androgen-deprivation therapy and abiraterone. Imaging shows partial radiographic improvement of multiple osseous metastases and decrease in size of pelvic nodal disease.", "output": {"cancer_type": "prostate adenocarcinoma (metastatic castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": null, "treatment": "olaparib", "response": "partial response", "metastasis_site": "bone, pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male with locally advanced squamous cell carcinoma of the oropharynx. Exam and imaging consistent with stage III disease. He underwent definitive concurrent chemoradiation with high-dose cisplatin per institutional protocol. On follow-up clinic visit the physical exam and post-treatment PET/CT showed no residual disease. No molecular testing was performed.", "output": {"cancer_type": "squamous cell carcinoma of the oropharynx", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "concurrent chemoradiation with high-dose cisplatin", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant plan for a 48-year-old with locally advanced invasive ductal carcinoma of the right breast, clinically T4bN1. Tumor is HER2 IHC 3+ with FISH-confirmed HER2 amplification; ER and PR negative. Patient started on neoadjuvant chemotherapy with docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP). After three cycles there is significant tumor shrinkage; clinical partial response noted. No distant disease on staging CT and bone scan.", "output": {"cancer_type": "invasive ductal breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced invasive ductal carcinoma of the breast, clinical stage III (cT3N2M0). Core biopsy: ER 20%, PR 0%, HER2 IHC 3+ and FISH confirmed HER2 amplification. She received neoadjuvant doxorubicin/cyclophosphamide x4 followed by docetaxel with trastuzumab, then underwent modified radical mastectomy with final pathology ypT0N0 \u2014 pathologic complete response. No tumor sequencing performed.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "III", "gene_mutation": null, "biomarker": "HER2 amplification; ER 20%; PR 0%", "treatment": "neoadjuvant doxorubicin/cyclophosphamide -> docetaxel + trastuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Emergency department note: 56-year-old male with history of cutaneous melanoma now with cough and hemoptysis. CT chest shows multiple pulmonary nodules. Excisional biopsy months prior reported BRAF V600E mutation. He was treated systemically with dabrafenib and trametinib but follow-up CT demonstrates interval growth of pulmonary metastases consistent with progression. PD-L1 on archival tissue was 5%.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Bronchoscopic biopsy confirmed lung adenocarcinoma. Comprehensive NGS returned EGFR L858R mutation. PD-L1 by IHC was 10% TPS. Staging PET/CT demonstrated multiple enhancing brain lesions and lytic lesions in the thoracic spine consistent with metastases; overall assessment stage IV. Patient was started on osimertinib 80 mg daily and tolerated therapy well. Interval brain MRI at 8 weeks showed shrinkage of the dominant intracranial metastasis and decrease in metabolic activity on PET \u2014 assessed as a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% TPS", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 59-year-old male with metastatic colorectal adenocarcinoma presenting with right upper quadrant pain. CT shows multiple hepatic lesions and a solitary pulmonary nodule. Biopsy confirmed colorectal primary; molecular panel revealed KRAS G12D. Microsatellite testing reported microsatellite stable (MSS). He was started on FOLFOX with bevacizumab. Interval imaging after 3 cycles shows no new lesions and overall size measurements stable compared with baseline \u2014 treatment ongoing with clinical benefit (stable disease).", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Surgical oncology visit: 72-year-old woman with pancreatic ductal adenocarcinoma of the pancreatic head, 3.2 cm. CA19-9 is 980 U/mL. Imaging shows a T3 N1 lesion without radiographic distant spread \u2014 clinical stage IIB (T3 N1 M0). Biopsy submitted for genomic testing; results pending. She has completed two cycles of gemcitabine with nab\u2011paclitaxel with interval CT demonstrating stable disease. Plan: continue systemic therapy and reassess for resection or chemoradiation.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IIB", "gene_mutation": null, "biomarker": "CA19-9 980 U/mL", "treatment": "gemcitabine and nab-paclitaxel", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old with metastatic colorectal adenocarcinoma. At presentation had liver and peritoneal disease (stage IV). Tumor harbors BRAF V600E and high microsatellite instability (MSI-H) with TMB-high on NGS. Patient started on FOLFOX + bevacizumab with initial disease stabilization for 4 months, then progression of hepatic lesions. Because of MSI-H status he was transitioned to pembrolizumab but ultimately had progressive disease after 6 cycles.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with metastatic invasive ductal breast carcinoma, ER positive, PR negative. FISH demonstrated HER2 amplification. Next-generation sequencing identified a PIK3CA H1047R mutation. Patient presented with liver lesions on staging CT consistent with hepatic metastases. She was started on first-line trastuzumab, pertuzumab and docetaxel with interval imaging showing a partial response in the liver.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive", "treatment": "trastuzumab + pertuzumab + docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female diagnosed with pancreatic ductal adenocarcinoma with CT showing both liver and peritoneal metastases. Germline testing revealed a pathogenic BRCA2 variant. Baseline CA19-9 markedly elevated. She received 6 cycles of FOLFIRINOX with good partial response in hepatic lesions and was transitioned to maintenance olaparib. Subsequent imaging, however, demonstrated progression of peritoneal disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline pathogenic variant)", "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX; maintenance olaparib", "response": "initial partial response then progression", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male diagnosed with metastatic colon adenocarcinoma with bulky peritoneal carcinomatosis and several hepatic metastases. Tumor profiling revealed KRAS G12D and MSI-H status. Given MSI-H, patient was treated with pembrolizumab monotherapy; PET-CT after 4 cycles documents a partial metabolic and radiographic response.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "peritoneum, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic castration-resistant prostate cancer (stage IV) with multiple bone metastases. Germline testing positive for BRCA2 mutation. He received androgen deprivation with leuprolide plus docetaxel initially with a transient PSA decline, followed by radiographic progression at 6 months. Switched to PARP inhibitor olaparib and first follow-up imaging showed a partial radiographic response.", "output": {"cancer_type": "prostate cancer (metastatic castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2", "biomarker": "PSA rise (clinical biomarker)", "treatment": "androgen deprivation (leuprolide); docetaxel; olaparib", "response": "partial response (to olaparib)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old woman diagnosed with high-grade serous ovarian carcinoma after papillary serous tumor found at diagnostic laparoscopy. Disease involved pelvic peritoneum and omentum; CA-125 was markedly elevated preop. Germline testing demonstrated a pathogenic BRCA2 mutation (c.6174delT). She underwent debulking surgery followed by adjuvant carboplatin and paclitaxel with a partial radiographic and biochemical response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA2 c.6174delT", "biomarker": "CA-125 elevated", "treatment": "debulking surgery followed by carboplatin and paclitaxel", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old man with localized prostate adenocarcinoma, Gleason 3+4 on biopsy, clinical stage II. Baseline PSA 12 ng/mL. He elected definitive therapy and underwent external beam radiotherapy with concurrent androgen deprivation (leuprolide). Follow-up PSA at 6 months is 0.8 ng/mL.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 12 ng/mL (baseline)", "treatment": "external beam radiation; leuprolide (androgen deprivation therapy)", "response": "biochemical response (PSA decreased to 0.8 ng/mL)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with newly diagnosed lung adenocarcinoma presented with headaches and back pain. Staging PET/CT showed multiple pulmonary nodules and enhancing lesions in the cerebellum and T8 vertebral body consistent with metastatic disease. Biopsy confirmed adenocarcinoma with EGFR L858R mutation; PD-L1 by IHC was 10%. He was started on osimertinib 80 mg daily with stereotactic radiosurgery to the brain lesions. Interval imaging at 8 weeks demonstrated decrease in size of thoracic nodules and partial regression of the intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone (T8)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with sigmoid colon cancer underwent anterior resection. Pathology: stage IIIA (pT2 N1) moderately differentiated adenocarcinoma. Molecular testing identified KRAS G12D. MSI testing not available in the report. He received adjuvant FOLFOX x 6 cycles and remains on surveillance with normal CTs and CEA undetectable at 12 months.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IIIA", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "surgery (anterior resection); adjuvant FOLFOX", "response": "no evidence of disease on surveillance", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman with newly diagnosed lung adenocarcinoma presenting with cough and weight loss. Staging workup demonstrated stage IV disease with multiple brain and bone metastases. Molecular testing returned EGFR exon 19 deletion; PD-L1 tumor proportion score 10%. She was started on osimertinib 80 mg daily as first-line targeted therapy and noted radiographic partial response at first restaging scan.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Post-operative note for 62-year-old man: sigmoid colon adenocarcinoma, pathologic stage III (pT3 N1). Tumor testing returned MSI-high. KRAS testing was not performed. Patient completed 6 cycles of adjuvant FOLFOX. Surveillance CT abdomen/pelvis shows expected post-op changes and no distant disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "adjuvant FOLFOX (6 cycles)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology correspondence: 45-year-old man with metastatic cutaneous melanoma. BRAF V600E mutation detected on PCR; PD-L1 by IHC reported >50%. Started on dabrafenib and trametinib combination therapy. After 12 weeks of treatment PET/CT shows decreased metabolic activity of pulmonary nodules and partial shrinkage of target lesions \u2014 assessment: partial response. No CNS involvement identified.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >50%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology / post-op note: 48F with invasive ductal carcinoma of the left breast, tumor 2.2 cm, sentinel nodes negative. Final stage pT2N0 \u2014 clinical stage IIA. Biomarkers: ER positive, PR positive, HER2 amplification confirmed by FISH. Targeted sequencing detected PIK3CA H1047R. She underwent lumpectomy with clear margins and completed adjuvant weekly paclitaxel with concurrent trastuzumab; endocrine therapy (tamoxifen) was initiated. Last clinic visit: no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+, PR+, HER2 amplification", "treatment": "lumpectomy, paclitaxel, trastuzumab, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male presents with metastatic lung adenocarcinoma (Stage IV) diagnosed on core biopsy. Molecular testing identified EGFR L858R. He was started on osimertinib 80 mg daily last month. Interim CT chest shows decrease in size of multiple pulmonary nodules consistent with a partial response; brain MRI demonstrates two small asymptomatic enhancing lesions consistent with metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right breast invasive ductal carcinoma, ER positive / PR negative, HER2 amplified by FISH. Core biopsy also showed a PIK3CA H1047R mutation. Clinical exam and imaging consistent with T4bN1 \u2014 clinical stage IIIB. Neoadjuvant therapy: paclitaxel with trastuzumab and pertuzumab x6 cycles followed by right mastectomy. Surgical pathology reported no residual invasive carcinoma \u2014 pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR-", "treatment": "neoadjuvant paclitaxel, trastuzumab and pertuzumab; mastectomy", "response": "complete pathological response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and operative note: Core biopsy consistent with invasive ductal carcinoma, HER2-positive. Clinically bulky axillary nodes and chest wall involvement; clinical stage IIIB. ER and PR reported negative. FoundationOne panel identified a PIK3CA H1047R mutation. Neoadjuvant regimen given: trastuzumab and pertuzumab with docetaxel x 6 cycles prior to surgery. Post-op report documents no residual invasive carcinoma in the breast or nodes \u2014 pathologic complete response.", "output": {"cancer_type": "breast cancer (HER2-positive)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "neoadjuvant trastuzumab, pertuzumab and docetaxel", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male presented with obstructive jaundice. Imaging revealed a pancreatic head mass with multiple hypodense liver lesions. ERCP with stent placed; biopsy confirmed pancreatic ductal adenocarcinoma. Germline and somatic testing identified a BRCA2 truncating mutation. Baseline CA 19-9 was markedly elevated at 12,000 U/mL. Patient started FOLFIRINOX and after six cycles was transitioned to maintenance olaparib. Most recent CT shows no interval growth of target lesions (stable disease).", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 truncating mutation", "biomarker": "CA 19-9 elevated", "treatment": "FOLFIRINOX followed by maintenance olaparib", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with newly diagnosed metastatic invasive ductal carcinoma of the breast. Tumor is ER-negative, PR-negative and HER2 amplified by FISH. Staging PET-CT demonstrated osseous metastases only. Next-generation sequencing detected PIK3CA H1047R. She was started on first-line trastuzumab, pertuzumab and docetaxel. Interval scans demonstrate disease control with no new lesions.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with metastatic lung adenocarcinoma diagnosed in 2019. Comprehensive NGS showed EGFR L858R and secondary T790M. PD-L1 by IHC 5%, tumor mutational burden low. MRI brain demonstrated multiple small enhancing metastases. He was started on osimertinib and later received bevacizumab for rapidly progressive hepatic disease; stereotactic radiosurgery was delivered to dominant brain lesions. Most recent CT chest/abdomen shows partial response of the pulmonary and hepatic lesions; bone scan identified new osteoblastic lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; T790M", "biomarker": "PD-L1 5%; TMB-low", "treatment": "osimertinib; bevacizumab; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "liver; bone; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Surgical pathology: 2.1 cm invasive ductal carcinoma, margins negative. ER negative, PR negative, HER2 IHC 3+ (confirmed by FISH as HER2 amplification). Tumor staged pT2 N1 \u2014 clinical stage IIB. Patient underwent lumpectomy followed by adjuvant doxorubicin/cyclophosphamide then paclitaxel with concurrent trastuzumab; completed 1 year trastuzumab and currently NED on surveillance.", "output": {"cancer_type": "invasive ductal breast cancer", "stage": "IIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "lumpectomy; adjuvant doxorubicin/cyclophosphamide; paclitaxel; trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with newly diagnosed pancreatic ductal adenocarcinoma in the head of the pancreas. Imaging shows local vascular involvement with SMA encasement, no distant metastasis. Multidisciplinary tumor board staged the disease as III (locally advanced). He received gemcitabine plus nab-paclitaxel for four cycles with concurrent external beam radiation. Post-treatment CT showed no significant change from baseline and the radiology report described stable disease. No tumor genomic testing was performed locally and molecular results are unavailable.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine and nab-paclitaxel with concurrent radiation", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male underwent left hemicolectomy for a sigmoid mass. Pathology: adenocarcinoma, pT3 N1 (stage III). Tumor genotyping returned KRAS G12D. He completed 6 months of adjuvant FOLFOX. One-year surveillance CT and CEA are negative for recurrence.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "surgery (left hemicolectomy), adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old F with newly diagnosed lung adenocarcinoma presenting with headaches and back pain. Staging workup consistent with stage IV disease with multiple brain metastases and lytic lesions in the thoracic spine. Comprehensive genomic profiling returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. Patient received whole-brain radiation followed by osimertinib 80 mg PO daily as first-line targeted therapy after a short cycle of carboplatin/pemetrexed for symptomatic control. Interval CT and MRI at 8 weeks demonstrate decrease in size of the pulmonary primary and brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "whole-brain radiation; carboplatin/pemetrexed (short course); osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with metastatic colorectal adenocarcinoma presenting with weight loss and right upper quadrant pain. CT shows multiple liver lesions consistent with metastases. Molecular testing revealed BRAF V600E and high microsatellite instability (MSI-H) with high tumor mutational burden (TMB-high). He declined immediate cytotoxic chemotherapy; immunotherapy with pembrolizumab was started and disease remained stable on scans for six months.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced HER2-positive invasive ductal carcinoma of the right breast, clinical stage IIIB. Core biopsy: ER positive (80%), PR negative, HER2 amplification by FISH. NGS detected PIK3CA E545K. She received neoadjuvant docetaxel, carboplatin with trastuzumab and pertuzumab for six cycles. Imaging after four cycles showed marked reduction in tumor size and she is scheduled for mastectomy. No distant disease on staging CT.", "output": {"cancer_type": "breast cancer (HER2-positive invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+; PR-", "treatment": "docetaxel; carboplatin; trastuzumab; pertuzumab (neoadjuvant)", "response": "significant tumor shrinkage (partial response)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma (stage IV) found to harbor BRAF V600E on next-generation sequencing. After rapid progression on first-line pembrolizumab with new pulmonary nodules, therapy was switched to dabrafenib plus trametinib. Nine-week imaging documented a partial response; brain MRI remained negative.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab (prior); dabrafenib + trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female diagnosed with high-grade serous ovarian carcinoma, FIGO stage IIIC with bulky omental and peritoneal disease. Germline testing identified a pathogenic BRCA1 variant and HRD testing was positive. Preoperative CA-125 was markedly elevated. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel; maintenance olaparib was initiated given the BRCA1 mutation. She achieved a complete clinical response but recurred in the pelvis after 18 months.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "HRD positive; elevated CA-125", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "complete response followed by recurrence", "metastasis_site": "peritoneum (omental disease); pelvis at recurrence"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female with metastatic lung adenocarcinoma (Stage IV) found to harbor EGFR L858R on molecular testing. PD-L1 tumor proportion score 5%. She was started on osimertinib 80 mg daily in July. Interval CT chest in September shows a marked decrease in size of the primary and multiple pulmonary nodules consistent with a partial response; MRI brain demonstrates a new 8 mm cerebellar metastasis.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5% (TPS)", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "61-year-old female presented with right-sided abdominal pain. Colonoscopy revealed adenocarcinoma of the sigmoid; staging CT showed multiple hepatic metastases consistent with stage IV disease. Tumor testing returned MSI-H by PCR; initial report did not list an actionable RAS/BRAF mutation. Given MSI-H status she was started on pembrolizumab monotherapy. Follow-up imaging at 9 months demonstrates complete radiographic resolution of the liver lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "complete response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 71-year-old male with metastatic colorectal adenocarcinoma, KRAS G12D detected on molecular panel. CT chest/abdomen/pelvis shows multiple bilateral pulmonary nodules consistent with lung metastases. Patient was started on FOLFOX with bevacizumab; CT after 4 months shows no new lesions and stable size of known nodules \u2014 assessment: stable disease. MSI testing reported microsatellite stable; PD-L1 not reported.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with high-risk prostate adenocarcinoma, clinical stage III with pelvic nodal involvement. Preoperative PSA was 18 ng/mL. Germline and somatic testing identified a pathogenic BRCA2 mutation. He underwent radical prostatectomy with pelvic lymph node dissection followed by adjuvant intensity-modulated radiation therapy and androgen deprivation therapy. At 12-month follow up his PSA is undetectable and imaging shows no residual disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "III", "gene_mutation": "BRCA2", "biomarker": "PSA 18 ng/mL (preoperative)", "treatment": "radical prostatectomy, pelvic lymph node dissection, adjuvant radiation, androgen deprivation therapy", "response": "no evidence of disease (undetectable PSA at 12 months)", "metastasis_site": "pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with metastatic pancreatic ductal adenocarcinoma. Initial presentation included weight loss and a pancreatic head mass; current staging indicates stage IV disease after development of peritoneal nodules. CA 19-9 elevated at 4,200 U/mL. Tumor panel did not identify any actionable alterations on targeted sequencing. He received FOLFIRINOX followed by consolidative chemoradiation but was noted to have radiographic progression with increasing peritoneal disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "CA 19-9 elevated", "treatment": "FOLFIRINOX followed by chemoradiation", "response": "progression", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female diagnosed with stage IV lung adenocarcinoma in 2023. Initial testing showed EGFR exon 21 L858R; re-biopsy after progression identified T790M. PD-L1 TPS reported at 60%. She was started on osimertinib with excellent intracranial and thoracic shrinkage; interval CT and MRI demonstrate a partial response. Documented metastatic sites include multiple brain lesions and vertebral bone deposits.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; T790M", "biomarker": "PD-L1 60% (TPS >50%)", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 67-year-old female with metastatic lung adenocarcinoma. Initial molecular testing demonstrated EGFR L858R; repeat biopsy after progression showed acquired EGFR T790M. PD-L1 reported at 10%. Patient was started on osimertinib 80 mg daily after cranial radiation for a symptomatic brain metastasis. Most recent imaging notes a shrinkage of pulmonary and osseous lesions compared with baseline.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "49-year-old with newly diagnosed invasive ductal carcinoma of the left breast. Pathology: ER positive, PR positive, HER2 amplified by FISH; PIK3CA E545K mutation identified on NGS. Clinical stage after lumpectomy and sentinel node biopsy reported as T1cN1M0 (stage IIA). Patient completed adjuvant paclitaxel x12 weekly doses with trastuzumab; currently on maintenance trastuzumab with no evidence of disease on recent mammogram and chest imaging.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "lumpectomy; adjuvant paclitaxel and trastuzumab; maintenance trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old man with metastatic cutaneous melanoma found to harbor BRAF V600E mutation. He was treated with combination targeted therapy (dabrafenib plus trametinib) with rapid symptom improvement and shrinkage of extracranial disease. After 6 months MRI showed new small cerebellar lesions despite extracranial control; note: PD-L1 testing was not performed. The oncology note documents a mixed response with intracranial progression.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "mixed response (intracranial progression)", "metastasis_site": "brain (cerebellum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with high-grade serous ovarian carcinoma presenting with ascites and radiologic peritoneal carcinomatosis and hepatic implants. Staged as IV. Germline testing positive for BRCA1 185delAG; somatic testing confirmed the same BRCA1 frameshift. She received neoadjuvant carboplatin and paclitaxel with partial response, underwent interval debulking, and is now on olaparib maintenance. CA-125 declined but remains above normal.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IV", "gene_mutation": "BRCA1 185delAG", "biomarker": "CA-125 elevated", "treatment": "carboplatin and paclitaxel; interval debulking; olaparib maintenance", "response": "partial response", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man with unresectable cutaneous melanoma, stage IV with pulmonary nodules on CT. Tumor sequencing positive for BRAF V600E; tumor mutational burden reported as TMB-high (15 muts/Mb). Therapy initiated with dabrafenib plus trametinib. Clinical course showed regression of several skin lesions but interval appearance of new small lung nodules \u2014 overall mixed response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high (15 muts/Mb)", "treatment": "dabrafenib plus trametinib", "response": "mixed response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "A 38-year-old woman diagnosed with glioblastoma (WHO grade IV) following craniotomy for a frontal lobe mass. Molecular workup demonstrated IDH1 R132H and MGMT promoter methylation. She completed concurrent radiotherapy with daily temozolomide followed by adjuvant temozolomide. Interval MRI at 3 months shows no new enhancing disease and stable post-operative changes.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": "IDH1 R132H", "biomarker": "MGMT promoter methylation", "treatment": "concurrent radiotherapy with temozolomide followed by adjuvant temozolomide", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic letter: Unresectable cutaneous melanoma diagnosed on excisional biopsy. BRAF V600E mutation identified on tumor sequencing. Patient began targeted therapy with dabrafenib plus trametinib. At the 3-month PET/CT there is no fluorodeoxyglucose-avid disease and the oncologist documents a complete metabolic response. No distant visceral mets were documented on staging; follow-up planned q8 weeks.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III (unresectable)", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with a 2.2 mm pigmented lesion on the left forearm diagnosed as cutaneous melanoma. Wide local excision and sentinel lymph node biopsy were performed; sentinel node was negative and final pathologic stage was II. NGS panel detected BRAF V600E. No adjuvant systemic therapy was recommended; patient is under surveillance and at 12 months shows no recurrence on clinical exam.", "output": {"cancer_type": "cutaneous melanoma", "stage": "II", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision, sentinel lymph node biopsy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 67-year-old male with metastatic colon adenocarcinoma diagnosed after presentation with obstructive symptoms. Imaging shows multiple hepatic lesions consistent with metastatic disease (stage IV). Tumor sequencing identified BRAF V600E and tumor testing reported MSI-high (MSI-H). Given MSI-H status he was started on pembrolizumab monotherapy; at first restaging after 12 weeks CT shows no significant shrinkage but no new lesions.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic colorectal adenocarcinoma. Initial presentation with obstructing sigmoid mass; CT abdomen shows multiple hypodense lesions in the liver consistent with metastases. Pathology: moderately differentiated adenocarcinoma. Molecular profile: KRAS G12D mutation; MSI testing shows MSI-stable; tumor mutational burden low. Started FOLFOX plus bevacizumab as first-line systemic therapy. Follow-up CT at 12 weeks demonstrates stable size of hepatic lesions compared to baseline.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable, TMB-low", "treatment": "FOLFOX plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "61-year-old female with newly diagnosed metastatic lung adenocarcinoma (stage IV). Biopsy showed EGFR L858R mutation. PD-L1 by 22C3 was 10%. She was started on osimertinib 80 mg PO daily. Eight-week brain MRI demonstrated decreased contrast-enhancing lesions consistent with a partial response; imaging also noted a new sclerotic focus in the T-spine concerning for bone metastasis.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% (22C3)", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology/surgical oncology note: Core biopsy of the right breast shows invasive ductal carcinoma, ER positive, PR positive. HER2 IHC 3+ with confirmatory FISH revealing HER2 amplification. Tumor sequencing detected PIK3CA H1047R. Clinically staged as IIIB with matted axillary nodes. Patient received neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) x6 cycles and achieved a clinical complete response prior to planned mastectomy. No evidence of distant metastasis on staging PET/CT.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab (neoadjuvant)", "response": "clinical complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "78-year-old male with newly diagnosed metastatic colorectal adenocarcinoma. CT shows multiple hepatic metastases; colonoscopy biopsy confirmed adenocarcinoma. Tumor profiling: KRAS G12D mutation detected; microsatellite testing shows MSI-stable. Started on FOLFOX with bevacizumab. After 3 months of therapy, scans show progression in the liver with rising CEA.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable; CEA elevated", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with metastatic breast cancer. Core biopsy: ER positive, PR positive, HER2 IHC 3+ with FISH-confirmed HER2 amplification; NGS detected PIK3CA H1047R. Staging at presentation: stage IV with diffuse osteoblastic bone metastases. She was started on first-line docetaxel in combination with trastuzumab and pertuzumab; after six cycles interval CT shows stable disease.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel, trastuzumab and pertuzumab", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 59-year-old male with metastatic colorectal adenocarcinoma diagnosed after presentation with weight loss and RUQ pain. CT abdomen showed multiple hepatic lesions and bilateral pulmonary nodules. Biopsy confirmed metastatic colon cancer. Molecular panel: KRAS G12D; microsatellite stable (MSS). He received first-line FOLFOX with bevacizumab. After 6 cycles restaging showed new enlarging liver lesions and rising CEA consistent with progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX and bevacizumab", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Melanoma patient, 62-year-old female, originally stage IIIB on excision, now with recurrent metastatic disease to brain and lung. Tumor testing: BRAF V600E mutation detected, NRAS negative. PD-L1 by IHC 5%. She received combined targeted therapy with dabrafenib and trametinib and stereotactic radiosurgery to two cerebellar metastases, with interval shrinkage of intracranial lesions. On extracranial progression she was started on combination immunotherapy with nivolumab plus ipilimumab.", "output": {"cancer_type": "melanoma", "stage": "IV (recurrent metastatic)", "gene_mutation": "BRAF V600E", "biomarker": "NRAS negative; PD-L1 5%", "treatment": "dabrafenib + trametinib; stereotactic radiosurgery; nivolumab + ipilimumab", "response": "intracranial lesion shrinkage (partial response)", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 59-year-old with high-grade serous ovarian carcinoma presenting with bulky peritoneal carcinomatosis and ascites. Germline testing returned a pathogenic BRCA1 variant. She underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel. Post-treatment CT shows decreased size and number of peritoneal implants consistent with a partial response. CA-125 declined into the normal range.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "CA-125 elevated (declined post-treatment)", "treatment": "debulking surgery followed by carboplatin and paclitaxel", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 48-year-old woman with metastatic invasive ductal carcinoma of the breast. Biopsy of a sternal lesion confirms carcinoma, ER positive, PR negative, HER2 amplified by FISH. No actionable somatic mutation reported on the targeted panel. Disease is metastatic to bone. Treatment plan: start trastuzumab and pertuzumab combined with weekly paclitaxel. On assessment after 3 cycles patient had clinical benefit with pain improvement; radiology shows stable disease.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab; pertuzumab; paclitaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma diagnosed in 2023. NGS identified an EGFR L858R mutation. PD-L1 TPS reported at 10%. MRI brain demonstrates two small enhancing lesions and PET/CT shows a lytic lesion in T8. She was started on osimertinib 80 mg daily in August and first restaging CT demonstrates a partial response with shrinkage of pulmonary and nodal disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: Patient with metastatic cutaneous melanoma with pulmonary and brain involvement. Baseline testing: BRAF V600E positive, PD-L1 >50%, tumor mutational burden reported as TMB-high. Initially received pembrolizumab but had radiographic progression after 12 weeks; switched to dabrafenib plus trametinib with subsequent decrease in extracranial disease burden. Current status: mixed course \u2014 progression on immunotherapy then partial response to BRAF/MEK inhibition.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >50%; TMB-high", "treatment": "pembrolizumab; then dabrafenib and trametinib", "response": "progression on pembrolizumab then partial response to dabrafenib+trametinib", "metastasis_site": "lung and brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with a large left breast mass diagnosed as invasive ductal carcinoma, ER+/PR+, HER2-amplified on FISH. Clinical stage IIIA. Tumor sequencing identified PIK3CA H1047R. She received neoadjuvant carboplatin, docetaxel, trastuzumab and pertuzumab for six cycles followed by lumpectomy. Surgical pathology showed no residual invasive carcinoma (pathologic complete response). No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant carboplatin, docetaxel, trastuzumab, pertuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced right breast invasive ductal carcinoma, clinical stage IIIB. Core biopsy: ER positive, PR positive, HER2 amplification by FISH. NGS identified a PIK3CA H1047R mutation. She received neoadjuvant trastuzumab + pertuzumab with weekly paclitaxel, proceeded to lumpectomy with sentinel node biopsy, and was started on adjuvant tamoxifen. Pathology showed a pathologic complete response. No distant metastases were identified on staging scans.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab + pertuzumab + paclitaxel; lumpectomy; tamoxifen", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant clinic note: 48-year-old woman with locally advanced left breast cancer, clinical T3N1 (stage IIIB). Tumor is HER2 amplified by FISH, ER positive and PR positive. Tumor sequencing identified a PIK3CA H1047R mutation. She received neoadjuvant trastuzumab and pertuzumab with docetaxel for 6 cycles with shrinkage of the primary mass (partial response) and is scheduled for surgery next month.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab and pertuzumab with docetaxel (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology consult: 72-year-old M with metastatic lung adenocarcinoma, stage IV (T2N3M1c). Molecular testing positive for EGFR L858R. PD-L1 by IHC 5%. Started osimertinib 80 mg daily; stereotactic radiosurgery to a single cerebellar metastasis was also delivered. First restaging CT and brain MRI show shrinkage of the primary and pulmonary nodules and radiographic response of the cerebellar lesion \u2014 overall assessed as a partial response. Bone scan was equivocal for small sclerotic focus under further evaluation.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; possible bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic colorectal adenocarcinoma diagnosed with multiple liver lesions. Molecular testing: BRAF V600E mutation and MSI-high (MSI-H). He initially received FOLFOX plus bevacizumab but had progression in the liver; subsequently started pembrolizumab. Follow-up cross-sectional imaging after 12 weeks on pembrolizumab shows decrease in some lesions and overall disease control consistent with stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Metastatic cutaneous melanoma with BRAF V600E mutation and high tumor mutational burden (TMB-high). Patient developed symptomatic brain metastases and multiple pulmonary nodules. After progression on single-agent pembrolizumab, started combined BRAF/MEK inhibition with dabrafenib and trametinib and underwent stereotactic radiosurgery to intracranial lesions. Systemic imaging shows extracranial partial response; intracranial lesions decreased in size.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib; prior pembrolizumab; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old man found to have localized prostate adenocarcinoma on biopsy (Gleason 3+4). Preoperative PSA was 7.8 ng/mL. Clinical stage cT1c (stage I). He underwent robotic radical prostatectomy. Postoperative PSA is undetectable. No tumor genomic testing was performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": "PSA 7.8 ng/mL (preoperative)", "treatment": "robotic radical prostatectomy", "response": "undetectable PSA post-op", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology: invasive ductal carcinoma, ER positive, PR positive, HER2 amplified by FISH. Clinical stage IIIB (T3N2M0). Neoadjuvant regimen of docetaxel, carboplatin and trastuzumab was administered for 6 cycles with clinical reduction of the breast mass. No distant disease identified on staging imaging.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel, carboplatin and trastuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female diagnosed with high-grade serous ovarian carcinoma, FIGO stage IV with peritoneal carcinomatosis and liver metastases. Germline testing returned BRCA1 185delAG pathogenic variant. Baseline CA-125 was 650 U/mL. She received 6 cycles of carboplatin and paclitaxel with partial radiographic response and decline in CA-125, and was transitioned to maintenance olaparib.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IV", "gene_mutation": "BRCA1 185delAG", "biomarker": "CA-125 650 U/mL (baseline, elevated)", "treatment": "carboplatin and paclitaxel; maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old male with metastatic melanoma harboring BRAF V600E. He was started on pembrolizumab but after 4 months developed worsening bone pain and PET/CT showed new lytic bone lesions consistent with progression. He was transitioned to targeted therapy with dabrafenib and trametinib with marked symptomatic improvement and partial radiographic response. PD-L1 on the archival sample was reported as 60%.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 60%", "treatment": "pembrolizumab; then dabrafenib + trametinib", "response": "progression on pembrolizumab; partial response on dabrafenib + trametinib", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and oncology notes: 48-year-old woman with right breast invasive ductal carcinoma, clinical stage II (pT2N1). Tumor is ER-positive, PR-positive and HER2 3+ by IHC consistent with HER2 amplification. She underwent lumpectomy with sentinel node biopsy followed by adjuvant dose-dense AC-T and concurrent trastuzumab; planned endocrine therapy with tamoxifen. BRCA testing was negative. Current status: post-adjuvant surveillance, no palpable disease and imaging without evidence of recurrence.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy; dose-dense AC-T (adriamycin/cyclophosphamide then paclitaxel); trastuzumab; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Urology note: 65-year-old male with organ-confined prostate adenocarcinoma (Gleason 3+4) diagnosed on TRUS biopsy. Clinical stage I (cT1c). PSA at diagnosis 7.0 ng/mL. Patient elected active surveillance with PSA checks q3 months and repeat MRI/biopsy planned in 12 months. No systemic therapy or genetic testing performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": "PSA 7.0 ng/mL", "treatment": "active surveillance", "response": "stable disease / under surveillance", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with right-sided colon adenocarcinoma metastatic to the liver and peritoneum. Tumor genotyping identified BRAF V600E and PCR-based testing returned MSI-H. She received FOLFOX plus bevacizumab initially; on radiographic progression therapy was switched to pembrolizumab because of MSI-H status. Current scans show stable disease in the liver with some new peritoneal nodularity.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "61-year-old male with newly diagnosed lung adenocarcinoma, stage IV with multiple brain and bone metastases. Comprehensive NGS returned EGFR L858R mutation. PD-L1 tumor proportion score reported as 10%. Patient was started on osimertinib 80 mg daily; follow-up CT and brain MRI at 8 weeks demonstrate symptomatic improvement and a radiographic partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Newly diagnosed glioblastoma multiforme (subtotal resection performed). Pathology reports MGMT promoter methylation positive. No actionable driver mutation was reported on the panel. Patient started concurrent radiotherapy with temozolomide per Stupp protocol.", "output": {"cancer_type": "glioblastoma multiforme", "stage": "IV", "gene_mutation": null, "biomarker": "MGMT promoter methylation", "treatment": "radiation and temozolomide (concurrent)", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic castration-resistant prostate cancer. He initially received androgen deprivation therapy and six cycles of docetaxel. Upon progression his regimen was escalated to continuous ADT with the addition of abiraterone acetate and prednisone (combination systemic therapy). Germline and tumor genomic testing were not performed / not available. Recent bone scan and CT show new progressive osseous lesions with pelvic nodal enlargement.", "output": {"cancer_type": "metastatic castration-resistant prostate cancer", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "Androgen deprivation therapy + docetaxel; subsequently abiraterone acetate + prednisone", "response": "progression", "metastasis_site": "bone, pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "35-year-old male with metastatic cutaneous melanoma. Resection of primary scalp lesion showed BRAF V600E mutation. He was started on dabrafenib and trametinib with an initial partial response; after 7 months there is radiographic progression with new subcentimeter pulmonary nodules and enlarging cerebellar lesion. Patient was discussed at tumor board; plans to switch to ipilimumab/nivolumab and refer for stereotactic radiosurgery. PD-L1 testing not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib (followed by planned ipilimumab/nivolumab)", "response": "progression after initial partial response", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology note: 45-year-old male with metastatic cutaneous melanoma. Molecular testing positive for BRAF V600E. PD-L1 by IHC reported at 5%. Patient was started on dabrafenib and trametinib and had clinical improvement; interval PET/CT shows reduction of nodal and subcutaneous disease consistent with a partial response. Brain MRI for new headaches identified a single small metastasis.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with metastatic cutaneous melanoma. MRI brain demonstrated a 1.5 cm right frontal metastasis; extracranial CT showed pulmonary nodules. Tumor sequencing identified BRAF V600E; NRAS was wild-type. PD-L1 reported ~5\u201310% and the tumor had high TMB. She underwent stereotactic radiosurgery to the brain lesion and was started on combination targeted therapy with dabrafenib and trametinib. Follow-up scans show a partial response in extracranial disease and shrinkage of the brain lesion.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5\u201310%; TMB-high", "treatment": "dabrafenib + trametinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with newly diagnosed stage IV lung adenocarcinoma. Molecular testing identified EGFR L858R. PD-L1 expression reported at 10%. Osimertinib 80 mg daily was started in March 2024. Interval CT chest/abdomen demonstrates decrease in size of pulmonary nodules and mediastinal nodes consistent with partial response. MRI brain shows a few enhancing lesions consistent with metastases; bone scan positive for osseous disease in the thoracic spine.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Discharge summary: 56-year-old female with high-grade serous ovarian carcinoma, FIGO stage IIIC, extensive omental and peritoneal disease at laparotomy. Germline testing returned a pathogenic BRCA1 variant. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel with good clinical response and was started on maintenance olaparib. CA-125 normalized post-treatment.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "CA-125 normalized", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "complete clinical response", "metastasis_site": "peritoneum/omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced breast cancer, inflammatory features. Biopsy: invasive ductal carcinoma, HER2 amplification by FISH, ER positive, PR negative. PIK3CA H1047R identified on NGS. Neoadjuvant therapy with weekly paclitaxel plus dual HER2 blockade (trastuzumab and pertuzumab) was initiated. Clinical exam after 8 weeks shows marked decrease in tumor size but residual palpable mass.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma, HER2-positive)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "paclitaxel + trastuzumab + pertuzumab (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old woman underwent exploratory laparotomy and optimal cytoreduction for high-grade serous ovarian carcinoma with omental caking and widespread peritoneal disease. Final pathology staged disease as IIIC. She completed six cycles of adjuvant carboplatin and paclitaxel with excellent clinical and CA-125 response and was started on olaparib maintenance. Germline BRCA1 testing was ordered but results are pending and no somatic panel was performed yet.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "CA-125 normalized", "treatment": "debulking surgery, carboplatin and paclitaxel, olaparib maintenance", "response": "excellent clinical response", "metastasis_site": "peritoneum, omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man referred for progressive cough and weight loss. CT chest and PET/CT demonstrated a right upper lobe mass with widespread osseous uptake. Biopsy: lung adenocarcinoma. Molecular testing positive for EGFR L858R. PD-L1 tumor proportion score 10%. MRI brain revealed two enhancing lesions. He was started on osimertinib; 3-month restaging CT and brain MRI show decrease in size of primary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "32-year-old woman with papillary thyroid carcinoma, clinical stage I (T1aN0M0). Molecular testing by NGS identified a BRAF V600E mutation. She underwent total thyroidectomy followed by radioactive iodine ablation. Post-treatment thyroglobulin is undetectable and ultrasound shows no residual disease. PD-L1 testing not assessed.", "output": {"cancer_type": "papillary thyroid carcinoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "total thyroidectomy, radioactive iodine", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with metastatic cutaneous melanoma harboring a BRAF V600E mutation. Baseline testing reported high tumor mutational burden and PD-L1 expression ~1%. He was started on targeted combination therapy with dabrafenib plus trametinib and had a brisk clinical partial response. At 9 months he developed intracranial progression and was transitioned to nivolumab for systemic control. Brain metastases were documented on MRI.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high, PD-L1 1%", "treatment": "dabrafenib plus trametinib; nivolumab", "response": "partial response then intracranial progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic lung adenocarcinoma diagnosed 03/2024. Comprehensive NGS on the lung biopsy identified EGFR L858R with a concurrent TP53 mutation. PD-L1 tumor proportion score reported as 10%. He was started on first-line osimertinib with symptomatic improvement and a partial radiographic response on chest CT. After 9 months he developed new cerebellar lesions and worsening bone pain; treatment was switched to pembrolizumab plus carboplatin and pemetrexed on progression.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; TP53 mutation", "biomarker": "PD-L1 10%", "treatment": "osimertinib; pembrolizumab + carboplatin and pemetrexed", "response": "initial partial response; subsequent progression", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old man underwent right hemicolectomy for colon adenocarcinoma; final pathology pT3N1 (stage III). Tumor genotyping identified KRAS G12D. He completed 6 months of adjuvant FOLFOX without complications. MSI status was not reported in the chart. Surveillance CT at 12 months shows no evidence of recurrence.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative note: 44-year-old woman with high-grade invasive ductal carcinoma of the right breast, clinical T3N1 (overall stage IIIA). Tumor is ER-negative, PR-negative, HER2 3+ by IHC with HER2 amplification confirmed by FISH. She received neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) for 6 cycles. Post-neoadjuvant imaging showed marked reduction in size; surgical specimen reported a pathologic complete response (pCR). No distant disease identified on staging scans.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "III A", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "neoadjuvant docetaxel, carboplatin and trastuzumab (TCH)", "response": "pathologic complete response (pCR)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with stage II invasive ductal breast cancer (2.4 cm, 1/16 nodes). ER and PR positive, HER2 amplified on IHC/FISH. Tumor sequencing identified a PIK3CA E545K mutation. She underwent lumpectomy followed by adjuvant paclitaxel and trastuzumab, and was started on adjuvant letrozole. Six-month clinic note documents no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy, paclitaxel, trastuzumab, letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with newly diagnosed lung adenocarcinoma. Staging CT shows multiple pulmonary nodules and enhancing lesions in the cerebellum and T10 vertebral body consistent with metastases; clinical stage IV. Molecular testing returned EGFR L858R mutation; ALK and ROS1 negative. PD-L1 tumor proportion score 10%. Started first-line osimertinib 80 mg daily with improvement in cough. First restaging scan at 8 weeks demonstrates 40% reduction in target lesions\u2014partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Primary invasive ductal carcinoma of the right breast, HER2-positive by FISH with HER2 amplification; ER and PR negative. Clinical exam and imaging consistent with locally advanced disease, clinical stage IIIB with fixed nodal involvement. Patient received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) and proceeded to mastectomy \u2014 final pathology reported a pathologic complete response (pCR).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) followed by mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man diagnosed with metastatic castration-sensitive prostate adenocarcinoma with bone-predominant disease. He was started on androgen deprivation with leuprolide plus docetaxel. Somatic NGS reported no actionable genomic alterations. On follow-up PSA rose and bone scan showed new sclerotic lesions consistent with progression.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide and docetaxel", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "A 42-year-old male with recurrent nodal melanoma in the left axilla, biopsy confirming malignant melanoma, stage IIIB. Molecular profiling detected BRAF V600E. PD-L1 testing not contributory. He was enrolled on adjuvant targeted therapy with dabrafenib plus trametinib following nodal dissection. Follow-up PET/CT at 6 months shows complete metabolic response in the axilla.", "output": {"cancer_type": "melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 not contributory", "treatment": "nodal dissection; dabrafenib; trametinib", "response": "complete response", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Surgical pathology: Invasive ductal carcinoma of the right breast, grade 2. ER positive, PR positive, HER2 amplification by FISH. Clinical stage before therapy was IIB (T2 N1 M0). Patient received neoadjuvant dose-dense AC followed by paclitaxel and concurrent trastuzumab; final surgical specimen showed no residual invasive carcinoma \u2014 pathologic complete response. Somatic PIK3CA H1047R was identified on targeted panel.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant doxorubicin + cyclophosphamide (AC), paclitaxel, trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 64-year-old female with newly diagnosed lung adenocarcinoma. Staging workup consistent with Stage IV disease with multiple cerebral metastases. Molecular testing returned EGFR L858R mutation. PD-L1 was 10% by IHC. She was started on osimertinib 80 mg daily as first-line systemic therapy and achieved a radiographic partial response at 8 weeks.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "53-year-old male with a pigmented lesion on the left forearm excised last week. Final pathology: cutaneous melanoma, Breslow depth consistent with stage II (T3a). Molecular testing identified BRAF V600E mutation. Wide local excision with negative margins was performed; no adjuvant systemic therapy was given. Patient will be followed with dermatology and oncology. Sentinel node biopsy was not positive.", "output": {"cancer_type": "cutaneous melanoma", "stage": "II", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology consult: 62-year-old with rapidly enlarging pigmented scalp lesion. Excisional biopsy: metastatic melanoma, BRAF V600E positive. PET/CT reported multiple FDG-avid cervical nodes; brain MRI negative. He was started on pembrolizumab but had mixed radiographic response after 3 cycles with shrinkage of some nodal disease and growth of a dominant left cervical node; therapy was switched to dabrafenib plus trametinib with subsequent partial response.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab; then dabrafenib and trametinib", "response": "mixed response to pembrolizumab then partial response to BRAF/MEK therapy", "metastasis_site": "cervical lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with prostate adenocarcinoma initially treated with radical prostatectomy. Following biochemical recurrence he was placed on androgen deprivation therapy with leuprolide. He now has castrate-resistant PSA rise despite ADT but imaging has not identified any distant metastases to date. No tumor genomic testing was performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "androgen deprivation therapy (leuprolide)", "response": "PSA progression / castration-resistant", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colon adenocarcinoma. Tumor profiling: KRAS G12D mutation and high microsatellite instability (MSI-H). He has extensive peritoneal carcinomatosis on PET/CT. After progression on FOLFOX/bevacizumab he was transitioned to pembrolizumab for MSI-H disease; interval imaging after 12 weeks shows stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX, bevacizumab (prior); pembrolizumab", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old female with biopsy-proven pancreatic ductal adenocarcinoma. CT abdomen shows locally advanced disease with peritoneal implants; formal TNM/stage not recorded in this consult note. BRCA testing negative; no actionable gene mutation identified in the available report. CA19-9 markedly elevated at 900 U/mL. Received 4 cycles of gemcitabine/nab-paclitaxel followed by consolidative chemoradiation. Interval imaging demonstrates decreased tumor bulk and stable peritoneal nodularity.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": null, "gene_mutation": null, "biomarker": "CA19-9 900 U/mL", "treatment": "gemcitabine/nab-paclitaxel and chemoradiation", "response": "stable disease (decreased primary tumor size)", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic prostate adenocarcinoma presenting with diffuse osteoblastic lesions on bone scan and PSA of 128 ng/mL. He was started on androgen deprivation with leuprolide and abiraterone; PSA fell and repeat imaging showed stable skeletal disease. Somatic and germline genomic testing were ordered and results are pending.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 128 ng/mL", "treatment": "leuprolide and abiraterone", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman with high-grade serous ovarian carcinoma presenting with bulky peritoneal disease and omental caking. Surgical staging and imaging consistent with stage IIIC disease. Germline testing identified a pathogenic BRCA1 variant; CA-125 markedly elevated pre-treatment. She received neoadjuvant carboplatin and paclitaxel with partial radiologic response, underwent interval debulking with optimal cytoreduction, and was started on olaparib maintenance. Recent CT shows no measurable disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "elevated CA-125", "treatment": "neoadjuvant carboplatin and paclitaxel, interval debulking surgery, olaparib maintenance", "response": "complete response (no measurable disease)", "metastasis_site": "peritoneum, omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative oncology note: 43-year-old woman with T3N1 invasive ductal carcinoma of the breast, HER2-positive by IHC 3+ and confirmatory FISH demonstrating HER2 amplification. ER/PR negative. She received neoadjuvant weekly paclitaxel x12 with concurrent trastuzumab, followed by doxorubicin and cyclophosphamide (AC). Patient underwent mastectomy; pathology shows no residual invasive carcinoma in breast or nodes (pathologic complete response). No distant disease on staging CT.", "output": {"cancer_type": "breast cancer", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification", "treatment": "paclitaxel, trastuzumab, doxorubicin and cyclophosphamide (AC)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man diagnosed with sigmoid colon adenocarcinoma with multiple hepatic lesions on CT. Molecular testing demonstrated KRAS G12D. He was started on FOLFOX plus bevacizumab for metastatic disease. Restaging CT after 4 cycles showed enlarging liver metastases consistent with disease progression. MSI testing was not available in the chart.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with newly diagnosed metastatic lung adenocarcinoma. Staging workup consistent with stage IV disease. Comprehensive NGS identified EGFR L858R mutation. PD-L1 tumor proportion score reported as 10%. She was started on osimertinib 80 mg daily with symptomatic improvement; first restaging CT at 8 weeks showed decrease in target lesions consistent with a partial response. Brain MRI demonstrated a 1.2 cm cerebellar metastasis.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "35-year-old male with cutaneous melanoma of the posterior trunk. Molecular testing positive for BRAF V600E. Initially underwent wide local excision; later developed pulmonary and small brain metastases. Started on dabrafenib plus trametinib with brisk tumor shrinkage, documented as a partial response, but interval imaging at 9 months demonstrated clinical progression in the brain requiring stereotactic radiosurgery.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "initial partial response then progression", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with metastatic lung adenocarcinoma diagnosed 2019. Molecular testing demonstrated EGFR L858R mutation; PD-L1 tumor proportion score 10%. Brain metastases were noted on staging MRI and she received stereotactic radiosurgery to a solitary cerebellar lesion. Patient was started on osimertinib 80 mg daily with symptomatic improvement and interval CT shows shrinkage of pulmonary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male presented with sigmoid colon adenocarcinoma with synchronous pulmonary nodules. Molecular testing showed KRAS G12D mutation. Clinical stage recorded as IV. He was started on FOLFOX with bevacizumab; after 6 cycles surveillance CT demonstrates no new lesions and essentially unchanged size of existing lung metastases \u2014 oncology assessment documents stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology consult: Patient with metastatic cutaneous melanoma positive for BRAF V600E by PCR. He was started on dabrafenib plus trametinib with symptomatic improvement and shrinkage of several subcutaneous nodules (initial PR), however surveillance MRI recently showed a new enhancing cerebellar metastasis despite extracranial disease control. Received stereotactic radiosurgery to the brain lesion and systemic therapy continued. Stage not documented in outside records. PD-L1 reported at ~20%.", "output": {"cancer_type": "cutaneous melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 20%", "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "mixed response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology report: CT-guided core biopsy of right upper lobe mass shows lung adenocarcinoma. Tumor profiling returned positive for EGFR L858R. PD-L1 TPS reported at 10%. Staging scans demonstrate multiple intracranial lesions and lytic osseous lesions consistent with metastatic spread \u2014 patient staged as AJCC IV. Oncology started osimertinib 80 mg PO daily; interval imaging and clinical assessment show symptomatic improvement and a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed glioblastoma (grade IV). Underwent subtotal resection; MGMT promoter methylation was reported positive. No comprehensive systemic gene panel was performed and IDH1 was not mutated on limited testing. He completed concurrent radiation with temozolomide per Stupp protocol; subsequent MRI at 6 months showed progression at the resection cavity and bevacizumab was started.", "output": {"cancer_type": "glioblastoma (grade IV)", "stage": "IV", "gene_mutation": null, "biomarker": "MGMT promoter methylation", "treatment": "surgery, radiation and temozolomide; later bevacizumab", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with metastatic colorectal adenocarcinoma. Tumor testing: MSI-High by PCR and loss of MLH1/PMS2 on IHC. Somatic testing detected BRAF V600E mutation. Liver-dominant metastatic disease on CT. Given MSI-H status the patient received pembrolizumab as first-line systemic therapy; initial radiographic partial response at 3 months but progressive hepatic disease documented at 10 months.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response followed by progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with newly diagnosed prostate adenocarcinoma, Gleason 9, presenting with severe lower back pain. PSA on presentation 120 ng/mL. Bone scan reveals multiple sclerotic metastases in the lumbar spine and pelvis. Diagnosed with metastatic (stage IV) prostate cancer. He was started on leuprolide depot and docetaxel for systemic control. No tumor genomic testing was performed. After 6 months PSA decreased to 10 ng/mL and symptoms are controlled.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 120 ng/mL (decreased to 10 ng/mL after treatment)", "treatment": "leuprolide; docetaxel", "response": "stable disease (PSA response; symptomatic improvement)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with metastatic melanoma with multiple pulmonary nodules. Molecular testing identified BRAF V600E; he was started on dabrafenib plus trametinib with marked radiographic shrinkage of lung lesions on first follow-up. Chart does not document a formal AJCC stage.", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response (radiographic shrinkage)", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Breast oncology note: 49-year-old female with ER+/PR+/HER2-amplified invasive ductal carcinoma of the left breast, clinical stage II (cT2N0). She completed neoadjuvant paclitaxel with trastuzumab followed by lumpectomy and sentinel node biopsy. Pathology reports a pathologic complete response (no residual invasive carcinoma). BRCA testing not performed pre-op.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant paclitaxel and trastuzumab; lumpectomy and sentinel node biopsy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed metastatic lung adenocarcinoma. Core biopsy positive for EGFR L858R mutation; PD-L1 reported as <1%. Staging workup demonstrates stage IV disease with brain and bony lesions. Patient was started on osimertinib 80 mg daily and tolerated therapy well. Follow-up MRI after 8 weeks shows decrease in size of intracranial lesion consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 <1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 54-year-old man referred for stage IV lung adenocarcinoma with multifocal pulmonary lesions and multiple enhancing brain metastases on MRI. Molecular profiling identified EGFR L858R (exon 21); ALK and ROS1 were negative. PD-L1 tumor proportion score ~10%. He was started on osimertinib 80 mg daily with marked symptomatic improvement and interval tumor shrinkage on first CT \u2014 documented partial response; brain lesions also decreased in size.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old male with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing showed an EGFR exon 19 deletion and a co-occurring TP53 R273H mutation. PD-L1 TPS 10%. He was started on first-line osimertinib with initial radiographic benefit but developed intracranial and osseous progression after 11 months. He was switched to combination chemo-immunotherapy with carboplatin and pemetrexed plus pembrolizumab and achieved a partial response on first restaging CT. Metastatic sites at progression included brain and bone.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion; TP53 R273H", "biomarker": "PD-L1 10%", "treatment": "osimertinib; carboplatin and pemetrexed + pembrolizumab", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Medical oncology summary: 66-year-old female with metastatic pancreatic ductal adenocarcinoma diagnosed 02/2023. Germline testing positive for BRCA2 deleterious mutation. Baseline CA19-9 was 1,200 U/mL. Imaging at diagnosis showed multiple liver lesions and peritoneal nodularity consistent with metastatic disease. Treated with FOLFIRINOX x 6 cycles with marked CA19-9 decline and shrinkage of liver mets (partial response), switched to olaparib maintenance in 09/2023. Progression documented on CT at 08/2024 with enlargement of hepatic lesions and new ascites.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 deleterious germline mutation", "biomarker": "CA19-9 elevated (1200 U/mL)", "treatment": "FOLFIRINOX followed by olaparib maintenance", "response": "initial partial response then progression", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 62-year-old man diagnosed with cutaneous melanoma of the right forearm, pathologic stage IIIC after positive sentinel lymph node. BRAF testing was not performed and PD-L1 was not reported. He underwent wide local excision and completion lymphadenectomy and was started on adjuvant nivolumab. Surveillance PET/CT demonstrates no distant uptake. Current status: no evidence of disease while on adjuvant immunotherapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "nivolumab (adjuvant)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 63-year-old with metastatic colorectal adenocarcinoma who initially presented with obstructing sigmoid tumor and multiple hepatic metastases. Molecular profile: KRAS G12D positive; tumor testing reported MSI-H. First-line therapy was FOLFOX plus bevacizumab with initial minor shrinkage, but subsequent CT at 4 months demonstrated new pulmonary nodules and overall progression. He was switched to pembrolizumab for MSI-H disease but imaging after 3 cycles showed further enlargement of liver lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX + bevacizumab followed by pembrolizumab", "response": "progression", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed lung adenocarcinoma. Presenting with cough and weight loss. Staging workup demonstrated T2N3M1 with multiple parenchymal nodules and two cerebellar metastases \u2014 overall stage IV. Molecular testing: EGFR L858R positive; PD-L1 tumor proportion score 10%. Started first-line osimertinib 80 mg daily in June. Interim CT and brain MRI at 8 weeks show decrease in size of pulmonary lesions and resolution of one cerebellar lesion on stereotactic radiosurgery follow-up.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old male underwent right hemicolectomy for a 3.2 cm colon adenocarcinoma. Pathology: T2 N0 M0, stage I. Molecular panel detected KRAS G12D; microsatellite testing reported MSI-stable. No adjuvant chemotherapy recommended and patient is under surveillance with current status no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "I", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "surgery (right hemicolectomy)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old female with newly progressive metastatic lung adenocarcinoma. Initial biopsy identified EGFR L858R; after progression on first-line erlotinib a repeat tissue biopsy demonstrated EGFR T790M. PD-L1 reported at 10%. Imaging shows multiple cerebral and osseous lesions. She was started on osimertinib and received stereotactic radiosurgery to two brain metastases. Interval CT at 8 weeks shows decrease in size of pulmonary nodules and partial response clinically.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 10%", "treatment": "osimertinib and stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "35-year-old woman with FIGO stage IB1 squamous cell carcinoma of the cervix. She underwent radical hysterectomy with pelvic lymphadenectomy; final pathology negative for nodal metastasis. HPV 16 positive on PCR. No molecular sequencing was performed. Patient is doing well at 6-month follow-up with no clinical evidence of disease.", "output": {"cancer_type": "squamous cell carcinoma of the cervix", "stage": "IB1", "gene_mutation": null, "biomarker": "HPV 16 positive", "treatment": "radical hysterectomy with pelvic lymphadenectomy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with metastatic castration-resistant prostate cancer (mCRPC), stage IV with predominant bone metastases. Germline BRCA2 pathogenic variant identified on genetic testing. Baseline PSA was 86 ng/mL. He received leuprolide and docetaxel, with subsequent biochemical progression; olaparib was started and PSA fell, however follow-up imaging showed progression of a sacral bone lesion.", "output": {"cancer_type": "prostate cancer (mCRPC)", "stage": "IV", "gene_mutation": "BRCA2", "biomarker": "PSA 86 ng/mL (baseline)", "treatment": "leuprolide, docetaxel, then olaparib", "response": "mixed response (biochemical PSA response, radiographic progression)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with stage IV lung adenocarcinoma harboring EGFR L858R mutation. Staging CT and brain MRI demonstrate multiple cerebral metastases; PD-L1 reported at 10%. She was started on osimertinib 80 mg daily in June and underwent stereotactic radiosurgery to a left frontal lesion. Imaging after 8 weeks shows shrinkage of pulmonary and intracranial disease consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology clinic note: 34-year-old with a 1.2 cm pigmented lesion on the left forearm. Excisional biopsy revealed superficial spreading melanoma, Breslow 0.6 mm, no ulceration, margins clear \u2014 staged as IA (stage I). Sentinel node not indicated. BRAF testing returned positive for V600E, but no systemic therapy recommended; patient to undergo routine surveillance.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision (surgical)", "response": "no evidence of disease / surveillance", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman presented with a 4 cm left breast mass. Core biopsy: invasive ductal carcinoma, ER positive, PR positive, HER2 amplified by FISH. Tumor NGS returned PIK3CA H1047R. Clinical stage at presentation cT3N1 (clinical IIIB). She received neoadjuvant carboplatin/docetaxel with trastuzumab and pertuzumab followed by mastectomy; pathology reported no residual invasive carcinoma (pathologic complete response). No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant carboplatin and docetaxel with trastuzumab and pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female diagnosed with pancreatic ductal adenocarcinoma by EUS-guided biopsy. She underwent a pancreaticoduodenectomy (Whipple) and completed adjuvant gemcitabine plus nab-paclitaxel. Surveillance CTs over the past year show no evidence of recurrence and the patient remains clinically stable. Molecular testing was not performed.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IIA", "gene_mutation": null, "biomarker": null, "treatment": "surgery (Whipple) and adjuvant gemcitabine plus nab-paclitaxel", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic colorectal adenocarcinoma to the liver. Molecular testing returned BRAF V600E and high tumor mutational burden (TMB-high); PCR shows MSI-H. He received 8 cycles of FOLFOX plus bevacizumab and was later transitioned to pembrolizumab; interval imaging demonstrates a partial response of hepatic metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX and bevacizumab, then pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 69-year-old who underwent sigmoidectomy for adenocarcinoma of the colon. Pathology: stage IV disease with synchronous liver metastases. Tumor profiling: KRAS G12D and microsatellite instability-high (MSI-H) with TMB-high. Given the MSI-H status, pembrolizumab was initiated as first-line systemic therapy. On interval imaging after 3 cycles there is radiographic stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology summary: 47-year-old woman with locally advanced left breast invasive ductal carcinoma, clinical stage IIIB. Tumor was ER negative, PR negative, HER2 3+ by IHC and confirmed HER2 amplification by FISH. Patient received neoadjuvant docetaxel/carboplatin with dual HER2 blockade (trastuzumab and pertuzumab) x6 cycles prior to mastectomy. Surgical specimen demonstrates no residual invasive carcinoma \u2014 pathologic complete response (pCR).", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel and carboplatin with trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 48-year-old with stage IIIC cutaneous melanoma of the right thigh. BRAF V600E mutation identified on PCR. Patient was started on adjuvant dabrafenib plus trametinib. Despite an initial response, surveillance CT later demonstrated new bilateral pulmonary nodules and biopsy confirmed metastatic melanoma consistent with progression. Tumor profiling reported high tumor mutational burden.", "output": {"cancer_type": "melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old with metastatic colorectal adenocarcinoma, liver-dominant disease at presentation. Tumor tested BRAF V600E positive and was MSI-High with high tumor mutational burden. First-line therapy was FOLFOX plus bevacizumab with initial partial response, but progressed after 8 months and was transitioned to encorafenib plus cetuximab with disease stabilization.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; encorafenib + cetuximab", "response": "partial response then stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 55-year-old with stage IIIB cutaneous melanoma of the upper back with multiple involved regional lymph nodes. Molecular testing returned BRAF V600E mutation. Patient started adjuvant therapy with dabrafenib and trametinib. Follow-up PET/CT demonstrates no FDG-avid disease in the chest, abdomen or pelvis and shrinking of the nodal deposits.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib (adjuvant)", "response": "complete response / no evidence of metabolically active disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced invasive ductal carcinoma of the breast, clinical stage IIIB. Tumor is ER-negative, PR-negative and HER2-amplified on FISH. She received neoadjuvant doxorubicin/cyclophosphamide followed by paclitaxel with concurrent trastuzumab and pertuzumab, then underwent modified radical mastectomy and adjuvant radiation. Surgical pathology showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "neoadjuvant doxorubicin/cyclophosphamide \u2192 paclitaxel with trastuzumab and pertuzumab; surgery; radiation", "response": "pathologic complete response (no evidence of residual disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with locally advanced pancreatic ductal adenocarcinoma involving the head of the pancreas and encasement of the superior mesenteric artery. Staging consistent with unresectable stage III disease. Comprehensive next-generation sequencing did not identify actionable somatic mutations and PD-L1 IHC was negative. She was treated with FOLFIRINOX for six cycles followed by consolidative radiation with concurrent capecitabine. Surveillance imaging at three months demonstrated interval progression with increased primary tumor burden and new vascular involvement.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "FOLFIRINOX followed by radiation with concurrent capecitabine", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma, initial diagnosis stage IV with multiple liver and pulmonary metastases. Tumor profiling: BRAF V600E mutation and MSI-H; TMB-high was also reported. First-line therapy was FOLFOX plus bevacizumab with radiographic progression after four months. He was switched to the BRAF/EGFR combination encorafenib plus cetuximab and subsequently achieved a partial response in liver lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab (first-line); encorafenib + cetuximab (subsequent)", "response": "partial response (after encorafenib + cetuximab)", "metastasis_site": "liver and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology: invasive ductal carcinoma of the right breast, clinical stage II (cT2N0M0). IHC: ER positive, PR positive; HER2 testing by FISH shows HER2 amplification. Patient underwent breast-conserving surgery with negative sentinel nodes. Adjuvant plan: paclitaxel followed by trastuzumab for one year and start tamoxifen. Six-month clinic follow-up: physical exam and mammogram show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": null, "biomarker": "ER+; PR+; HER2 amplification", "treatment": "breast-conserving surgery (lumpectomy); adjuvant paclitaxel; trastuzumab; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with cutaneous melanoma, biopsy positive for BRAF V600E. At presentation there was palpable nodal disease and the tumor was staged as IIIC. He was started on dabrafenib and trametinib. Initially there was a good partial response in the nodal basin, but at 8 months surveillance CT showed new pulmonary nodules consistent with disease progression.", "output": {"cancer_type": "melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced invasive ductal carcinoma of the right breast, clinical stage IIIB. Core biopsy: ER-negative, PR-negative, HER2 3+ by IHC with HER2 amplification confirmed by FISH. No distant mets on CT. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab. Underwent mastectomy; pathology showed no residual invasive carcinoma consistent with a pathologic complete response.", "output": {"cancer_type": "invasive ductal carcinoma (breast)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "neoadjuvant paclitaxel, trastuzumab, pertuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 62-year-old female with metastatic pancreatic ductal adenocarcinoma, initial diagnosis with liver metastases (multiple hypodense lesions). Germline and tumor testing revealed pathogenic BRCA2 mutation. Initial regimen gemcitabine/nab-paclitaxel produced transient clinical benefit, but restaging showed growth of hepatic lesions and rising CA 19-9. Patient was transitioned to platinum-containing combination then started on olaparib maintenance for BRCA2; currently evidence of radiographic progression in the liver.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "CA 19-9 elevated", "treatment": "gemcitabine/nab-paclitaxel; platinum-based chemotherapy; olaparib maintenance", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic colorectal adenocarcinoma presenting with multiple hepatic lesions. Molecular testing: KRAS G12D mutation detected. Tumor is MSI-H and TMB-high. Given MSI-H/TMB-high status he was started on pembrolizumab monotherapy. Interval imaging at 12 weeks shows a sustained partial response in the liver lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48F with ER+/PR+ invasive ductal carcinoma of the left breast. FISH demonstrated HER2 amplification. She presented with worsening hip pain and PET/CT showed an isolated lytic metastasis in the right femur. Staged as IV. No reportable somatic gene mutation was returned in the chart. She was started on trastuzumab and pertuzumab with docetaxel; restaging after three cycles revealed stable disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER+, PR+", "treatment": "trastuzumab, pertuzumab, docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Referral: 45-year-old male with cutaneous melanoma, biopsy proven and BRAF V600E positive. He was started on pembrolizumab as first-line immunotherapy but progressed after 4 months. Subsequently initiated on dabrafenib plus trametinib with marked regression of multiple pulmonary nodules on follow-up CT. Disease was staged as IV due to lung metastases.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab; dabrafenib and trametinib", "response": "progression on pembrolizumab; partial response to dabrafenib/trametinib", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op oncology note: 45-year-old woman with left breast invasive ductal carcinoma, clinically T4bN2M0 (stage IIIB). Core biopsy: ER negative, PR negative, HER2 IHC 3+. Tumor NGS identified PIK3CA H1047R. She completed neoadjuvant docetaxel, carboplatin and trastuzumab x6 cycles with marked reduction in tumor size; breast-conserving surgery planned. Cardiac function remains within normal limits.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 IHC 3+; ER negative; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin and trastuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old male with newly diagnosed prostate adenocarcinoma after elevated PSA and transrectal biopsy showing Gleason 4+4=8. Clinical exam and imaging consistent with T2cN0M0 (high-risk localized disease). He was started on androgen deprivation therapy with leuprolide and is planned for definitive external beam radiation. No molecular sequencing or biomarker testing recorded in the chart; no evidence of distant metastasis.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide (androgen deprivation therapy); external beam radiation (planned)", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with newly diagnosed metastatic lung adenocarcinoma (stage IV). Molecular testing returned EGFR L858R mutation. PD-L1 tumor proportion score was 10%. He received stereotactic radiosurgery to a solitary cerebellar metastasis and was started on osimertinib 80 mg daily. Three-month restaging CT chest and brain MRI show marked decrease in size of pulmonary nodules and near-complete resolution of the brain lesion; known T8 bone lesion is smaller.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old female with newly diagnosed lung adenocarcinoma. Biopsy confirmed adenocarcinoma; molecular testing identified EGFR L858R. Staging workup shows multiple cerebral metastases and lytic lesions in the spine consistent with bone mets; overall stage IV. PD-L1 by IHC 22C3 reported at 5%. Patient started osimertinib 80 mg daily; first restaging CT/MRI at 8 weeks demonstrates decrease in size of several lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with left breast mass. Core biopsy: invasive ductal carcinoma, ER-positive, PR-positive, HER2-amplified by FISH. Clinical exam and imaging consistent with locally advanced disease, cT4bN1, clinical stage IIIB. Next-generation sequencing detected PIK3CA H1047R. She received neoadjuvant paclitaxel, carboplatin and dual HER2 blockade with trastuzumab and pertuzumab. Surgery showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "neoadjuvant paclitaxel and carboplatin; trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old woman with high-grade serous ovarian carcinoma, FIGO stage IIIC, presenting with bulky peritoneal disease and ascites. Germline testing identified a pathogenic BRCA1 variant. CA-125 markedly elevated at diagnosis. She underwent optimal cytoreductive surgery followed by combination carboplatin and paclitaxel with bevacizumab. A complete clinical and radiographic response was documented post-chemotherapy and she was placed on maintenance olaparib for BRCA1. Surveillance CT at 18 months noted recurrent peritoneal implants.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "CA-125 elevated", "treatment": "debulking surgery; carboplatin and paclitaxel; bevacizumab; maintenance olaparib", "response": "complete clinical response after chemo then recurrence at 18 months", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 59-year-old man with metastatic colorectal adenocarcinoma, liver-dominant disease. Biopsy-confirmed Stage IV colon cancer. Molecular profile: KRAS G12D; microsatellite stable (MSS). Started FOLFOX plus bevacizumab; interval CT shows stable disease after 4 cycles. Tumor markers down modestly.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with stage II (T2N1) invasive ductal breast carcinoma. Tumor is ER positive, PR positive and HER2 amplified by FISH. She completed neoadjuvant doxorubicin and cyclophosphamide x4 followed by paclitaxel x12 with concurrent trastuzumab. Lumpectomy pathology returned with no residual invasive carcinoma (pathologic complete response). No distant disease on staging PET/CT.", "output": {"cancer_type": "breast cancer", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant doxorubicin and cyclophosphamide then paclitaxel with trastuzumab; lumpectomy", "response": "complete pathological response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female diagnosed with invasive ductal carcinoma of the left breast. Tumor is ER+/PR+, HER2 IHC 3+ with confirmed HER2 amplification by FISH. PIK3CA H1047R identified on NGS. Pathologic stage T1cN0M0 (stage I). She underwent breast-conserving surgery with sentinel lymph node biopsy followed by adjuvant AC x4 then paclitaxel; trastuzumab planned for 1 year and started tamoxifen. Post-operative imaging shows no evidence of disease.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "I", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "lumpectomy (breast-conserving surgery) with sentinel node biopsy; adjuvant doxorubicin + cyclophosphamide (AC) then paclitaxel; trastuzumab; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with sigmoid colon adenocarcinoma, underwent low anterior resection \u2014 pathology T3N1 (stage III). Tumor testing: MSI-H by PCR with loss of MLH1 and PMS2 on IHC consistent with MMR deficiency. He completed adjuvant FOLFOX; surveillance CT at 12 months shows no evidence of recurrent disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H / MMR deficient (loss of MLH1/PMS2)", "treatment": "surgical resection (low anterior resection); adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with colorectal adenocarcinoma of the ascending colon now with peritoneal carcinomatosis and ascites. Molecular testing returned KRAS G12D and microsatellite stable (MSS). He completed 6 cycles of FOLFOX plus bevacizumab but CT shows increasing omental caking and worsening ascites. Oncology assessment documents clinical and radiographic progression and plans for second-line irinotecan-based therapy.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "49-year-old with metastatic cutaneous melanoma, BRAF V600E\u2013positive. Baseline CT showed multiple liver lesions consistent with metastases. PD-L1 10% and tumor mutational burden reported as TMB-high. Initially treated with pembrolizumab but progressed after 3 cycles; subsequently started dabrafenib plus trametinib with a documented partial radiographic response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%; TMB-high", "treatment": "pembrolizumab (progressed), then dabrafenib + trametinib", "response": "progression on pembrolizumab; partial response to dabrafenib + trametinib", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with newly diagnosed prostate adenocarcinoma, Gleason 3+4=7, clinical stage IIA. Baseline PSA was 8.2 ng/mL. He underwent radical prostatectomy; pelvic nodes were negative and margins were clear. Post-op PSA is undetectable and no adjuvant systemic therapy has been given.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IIA", "gene_mutation": null, "biomarker": "PSA 8.2 ng/mL (pre-op)", "treatment": "radical prostatectomy", "response": "no evidence of disease / undetectable PSA", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male with sigmoid colon adenocarcinoma, underwent sigmoidectomy\u2014final pathology pT3N1 (stage III). Molecular panel demonstrates KRAS G12D mutation; tumor is microsatellite stable (MSS) and BRAF wild-type. Patient completed six months of adjuvant FOLFOX chemotherapy without significant complications. Surveillance scans at 12 months show no radiographic evidence of metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "surgical resection (sigmoidectomy); adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "53-year-old man with a 1.2 mm superficial spreading melanoma on the right forearm (Breslow 1.2 mm, no ulceration). Sentinel lymph node biopsy negative. Pathology and staging consistent with stage II (T2aN0M0). Molecular testing detected BRAF V600E. Wide local excision performed with clear margins; no adjuvant systemic therapy was given. Surveillance skin checks and nodal exam have shown no recurrence to date.", "output": {"cancer_type": "superficial spreading melanoma", "stage": "II", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no recurrence / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 59-year-old male with metastatic colorectal adenocarcinoma, KRAS G12D identified on PCR-based assay. CT shows multiple hepatic metastases; diagnosis is stage IV. Patient was started on FOLFOX plus bevacizumab three months ago. Restaging after 3 cycles demonstrates no new lesions and minimal decrease in size of target lesions \u2014 overall assessment: stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma presenting with right upper quadrant pain. Molecular panel: KRAS G12D positive; microsatellite status: microsatellite stable (MSS). Multiple liver lesions on CT consistent with metastatic disease. Treated with FOLFOX plus bevacizumab; imaging after 6 cycles showed increase in size and number of hepatic lesions (disease progression).", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "microsatellite stable (MSS)", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Recurrent metastatic melanoma with BRAF V600E detected by PCR on prior biopsy. Patient was started on dabrafenib plus trametinib and reports symptomatic improvement; chest CT shows decrease in size of multiple pulmonary nodules consistent with partial response. No formal AJCC stage recorded in the outside clinic note. PD-L1 was 10% on archival tissue.", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old woman presented with progressive cough and headache. Imaging revealed a left upper lobe mass and multiple enhancing lesions on brain MRI consistent with metastases. Biopsy confirmed lung adenocarcinoma. Plasma NGS detected EGFR L858R. PD-L1 TPS reported as 1%. Staged as IV. Patient was started on osimertinib 80 mg daily; first follow-up CT and brain MRI at 8 weeks showed decreased size of both primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op note: Invasive ductal carcinoma of the right breast, clinically T2N1 \u2014 staged as IIIA. ER 80%+, PR 20%+, HER2 by FISH shows amplification. Patient received neoadjuvant docetaxel and carboplatin with trastuzumab followed by lumpectomy and sentinel node biopsy. Pathology from surgery reports no residual invasive carcinoma (pCR). No distant disease on staging scans.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel and carboplatin with trastuzumab, followed by surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man diagnosed with metastatic lung adenocarcinoma (stage IV) in November 2023. Molecular testing identified EGFR L858R mutation. PD-L1 tumor proportion score reported as 10%. Imaging shows brain and bone metastases. Patient was started on osimertinib 80 mg daily with radiologic partial response on first follow-up; intracranial lesions also decreased in size.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "82-year-old man diagnosed with pancreatic ductal adenocarcinoma causing SMA encasement and considered locally advanced, unresectable (clinical stage III). Limited molecular testing did not identify actionable alterations. He was started on palliative FOLFIRINOX; after two cycles his performance status declined and CT shows new hypoattenuating lesions in the liver consistent with interval progression.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "FOLFIRINOX (palliative)", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma. Staging workup consistent with stage IV disease with known brain and bone metastases. NGS detected EGFR L858R mutation. PD-L1 tumor proportion score 5%. Patient started osimertinib 80 mg daily; first restaging CT/MRI demonstrates decrease in size of pulmonary and brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma, optimally debulked at laparotomy; surgical stage IIIC with omental and multiple peritoneal implants. Germline testing detected a deleterious BRCA1 mutation. Patient completed six cycles of carboplatin and paclitaxel and was started on maintenance olaparib. Follow-up CA-125 and CT scans demonstrate no radiographic progression and clinical status is stable. Tumor genomic profiling reported homologous recombination deficiency (HRD) positive.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": "HRD-positive", "treatment": "debulking surgery; carboplatin + paclitaxel; maintenance olaparib", "response": "stable disease", "metastasis_site": "peritoneum, omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Case review: 57-year-old male diagnosed with metastatic colorectal adenocarcinoma, liver-dominant disease. Primary tumor testing: BRAF V600E mutation; mismatch repair testing reported MSI-H and tumor mutational burden described as TMB-high. He received first-line mFOLFOX6 plus bevacizumab with initial disease control (stable disease) but subsequently progressed in the liver. He was started on encorafenib plus cetuximab on a clinical protocol but imaging after two months documented new hepatic lesions consistent with progression. Stage IV with liver metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "mFOLFOX6 + bevacizumab; then encorafenib + cetuximab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced invasive ductal carcinoma of the right breast, clinical Stage IIIB. Core biopsy shows HER2 amplification by FISH and a concurrent PIK3CA H1047R mutation; ER and PR are negative. She received neoadjuvant docetaxel, carboplatin and trastuzumab with marked tumor shrinkage but residual disease on post-treatment imaging.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "docetaxel, carboplatin and trastuzumab (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma, right-sided primary. CT shows multiple liver metastases (stage IV). Tumor profiling: BRAF V600E and high microsatellite instability (MSI-H). He was started on pembrolizumab given MSI-H status with an initial partial response in the liver; after 9 months there was radiographic progression and therapy was switched to encorafenib plus cetuximab.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab followed by encorafenib + cetuximab", "response": "initial partial response then progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old female with stage IV lung adenocarcinoma harboring EGFR L858R mutation. MRI brain demonstrates two small parenchymal metastases and PET/CT shows osseous lesions. PD-L1 tumor proportion score 5%. Patient was started on osimertinib 80 mg daily as first-line targeted therapy and interval scans at 8 weeks show marked tumor shrinkage consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed lung adenocarcinoma, stage IV at presentation with bone and brain metastases. Core needle biopsy shows EGFR L858R and TP53 R273H. PD-L1 22C3 tumor proportion score 20%; TMB 15 mut/Mb (reported as TMB-high). He started osimertinib with a partial response in the chest but developed progressive liver lesions after 8 months. He was transitioned to pembrolizumab in combination with carboplatin and pemetrexed, with a subsequent partial radiographic response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R, TP53 R273H", "biomarker": "PD-L1 20% (22C3), TMB-high (15 mut/Mb)", "treatment": "osimertinib; later pembrolizumab + carboplatin and pemetrexed", "response": "partial response to osimertinib; progression in liver; partial response to pembrolizumab + carboplatin/pemetrexed", "metastasis_site": "bone, brain, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colon cancer presenting with multiple liver lesions and peritoneal carcinomatosis. Tumor profiling returned BRAF V600E mutation, MSI-H and TMB-high. Clinical stage IV at presentation. Initial therapy with FOLFOX plus bevacizumab produced only stable disease and peritoneal progression after 4 months; therapy was switched to pembrolizumab with interval CT showing a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "partial response", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old female with metastatic colorectal adenocarcinoma of the sigmoid colon, stage IV with multiple bilobar liver metastases. NGS demonstrated a KRAS G12C mutation; tumor testing reported microsatellite stable (MSS). She received FOLFOX plus bevacizumab and achieved a partial radiographic response after 4 cycles.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX; bevacizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with nodular melanoma of the right calf, Breslow depth 3.2 mm. Sentinel node negative but multiple in-transit deposits were excised; overall stage III. Tumor NGS identified NRAS Q61K and a high tumor mutational burden (TMB-high). She completed adjuvant combination immunotherapy with nivolumab and ipilimumab. Follow-up PET/CT and skin exam show no evidence of disease.", "output": {"cancer_type": "melanoma", "stage": "III", "gene_mutation": "NRAS Q61K", "biomarker": "TMB-high", "treatment": "nivolumab and ipilimumab", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed lung adenocarcinoma. CT chest/abdomen shows bulky right lower lobe mass with multiple bilateral pulmonary nodules and enhancing lesions in the cerebellum. Biopsy confirmed adenocarcinoma; molecular testing positive for EGFR L858R. PD-L1 tumor proportion score 5%. Patient was started on osimertinib 80 mg daily as first-line therapy. After 8 weeks of therapy there is reduction in size of pulmonary lesions and decreased enhancement of the cerebellar lesion on MRI consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, lung (bilateral pulmonary nodules)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with invasive ductal carcinoma of the right breast, clinical stage IIA (T2N0). Tumor is ER+/PR+, HER2 amplified by FISH. She underwent lumpectomy with sentinel lymph node biopsy followed by adjuvant paclitaxel and trastuzumab. No actionable somatic mutations were identified on the 50-gene panel. Current surveillance imaging and exam show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER+/PR+", "treatment": "lumpectomy, paclitaxel, trastuzumab", "response": "complete response / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 62-year-old woman with metastatic lung adenocarcinoma diagnosed 09/2023. Staging at diagnosis was IV with CNS and osseous involvement. Molecular testing returned EGFR exon 19 deletion. PD-L1 tumor proportion score 25%. She started first-line osimertinib and has had shrinkage of the dominant right lower lobe mass and improvement of several brain metastases on the 8-week CT/MRI \u2014 overall partial response by RECIST.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 25% (TPS)", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman presented with right upper quadrant pain and was found to have metastatic colorectal adenocarcinoma. CT abdomen demonstrated multiple liver lesions; overall clinical stage IV. Tumor testing: MSI-H and BRAF V600E mutation (KRAS wild-type). Given MSI-H status she was started on pembrolizumab monotherapy. First restaging at 12 weeks showed shrinkage of liver lesions (~40% by RECIST) consistent with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with newly diagnosed lung adenocarcinoma presented with cough and headaches. Staging workup consistent with metastatic disease (multiple cerebellar lesions and lytic lesions in the thoracic spine) \u2014 overall stage IV. Molecular testing detected EGFR L858R mutation. PD-L1 TPS reported at 15%. He was started on osimertinib 80 mg daily; after intracranial progression received second-line carboplatin and pemetrexed. Most recent scan shows decrease in size of the dominant pulmonary mass and partial response clinically.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib; carboplatin and pemetrexed", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient presents with symptomatic sigmoid mass and multiple liver lesions. Biopsy confirmed colon adenocarcinoma. Molecular testing identified KRAS G12D and the tumor is mismatch repair proficient (MSI-stable). He was started on first-line FOLFOX with bevacizumab; interval CT after three cycles shows stable disease of the hepatic metastases.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old male with colorectal adenocarcinoma presenting with multiple liver metastases. Staged as IV at diagnosis. Tumor RAS testing positive for KRAS G12D; MSI testing reported microsatellite stable. First-line therapy was FOLFOX with bevacizumab; imaging after 3 months showed stable disease, but repeat scans documented progression in hepatic lesions after 6 months.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "microsatellite stable (MSI-stable)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease then progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old female presented with abdominal distension and ascites. Surgery and pathology confirmed high-grade serous ovarian carcinoma, stage IV with peritoneal carcinomatosis and liver implants. Germline testing identified a deleterious BRCA1 pathogenic variant. Baseline CA-125 was markedly elevated. She underwent optimal debulking followed by carboplatin and paclitaxel with bevacizumab added; given BRCA1 positivity she was transitioned to maintenance olaparib after induction. Restaging CT after three cycles showed reduction in omental and hepatic disease burden consistent with a partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IV", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "elevated CA-125", "treatment": "debulking surgery; carboplatin and paclitaxel with bevacizumab; maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with sigmoid colon adenocarcinoma, underwent left hemicolectomy. Pathology staged as stage III with two positive pericolic nodes (pT3N1). Tumor testing returned MSI-H; patient completed 6 months of adjuvant FOLFOX without major complications and remains without radiographic recurrence on surveillance CT.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "left hemicolectomy; adjuvant FOLFOX", "response": "disease-free / no radiographic recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with palpable left breast mass. Core biopsy: invasive ductal carcinoma, ER negative, PR negative, HER2 amplified by FISH. Nodal staging: one suspicious axillary node on ultrasound (clinical stage II). Tumor sequencing revealed PIK3CA H1047R mutation. She received neoadjuvant paclitaxel and carboplatin with trastuzumab; underwent lumpectomy and sentinel node biopsy. Surgical pathology reported no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant paclitaxel and carboplatin with trastuzumab, followed by surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Melanoma, metastatic to the brain and spine. Molecular profiling identified BRAF V600E mutation. Patient was started on combination targeted therapy with dabrafenib and trametinib. After 6 months of therapy intracranial lesions enlarged on MRI and extracranial disease progressed despite corticosteroids \u2014 treatment failure with progressive disease; plan is to review for clinical trial or switch to immunotherapy.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progressive disease", "metastasis_site": "brain, spine"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 48-year-old woman with metastatic melanoma with BRAF V600E mutation. Initially presented with multiple pulmonary nodules and hepatic lesions; PET/CT consistent with widespread disease \u2014 stage IV. She began combination targeted therapy with dabrafenib and trametinib; after 3 months scans showed interval shrinkage of liver and lung lesions but at month 7 there was radiographic progression in the liver and bone with worsening pain. Immunotherapy was discussed as next-line, patient bridged to palliative radiation for bony mets.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; palliative radiation", "response": "initial response followed by progression", "metastasis_site": "liver; bone; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman diagnosed with invasive ductal carcinoma of the left breast. Tumor was ER positive, PR positive and HER2 amplified by FISH. Pathology stage pT2N1 (stage IIA). She underwent breast-conserving surgery with sentinel lymph node biopsy followed by adjuvant doxorubicin/cyclophosphamide x4 then paclitaxel with concurrent trastuzumab; endocrine therapy with tamoxifen was started. She remains on trastuzumab maintenance with no evidence of disease on latest mammogram.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": null, "biomarker": "ER+, PR+, HER2 amplification", "treatment": "lumpectomy; adjuvant doxorubicin/cyclophosphamide then paclitaxel with trastuzumab; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with metastatic colorectal adenocarcinoma. Initial molecular workup: BRAF V600E positive and MSI-H on PCR. He presented with multiple liver lesions and peritoneal nodularity on CT. First-line therapy was FOLFOX plus bevacizumab; after progression he was switched to pembrolizumab on protocol but interval imaging demonstrated progressive disease in the liver and new ascites.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "progressive disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma presenting with bilobar liver metastases. Molecular testing: MSI-H and TMB-high; BRAF V600E mutation identified. Initially treated with FOLFOX plus bevacizumab but progressed after 4 months, then transitioned to pembrolizumab monotherapy with a complete radiographic response noted and durable remission at 12-month follow-up.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H, TMB-high", "treatment": "FOLFOX and bevacizumab, then pembrolizumab", "response": "complete response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma, liver-dominant disease. Tumor sequencing identified a KRAS G12D mutation; anti-EGFR therapy was withheld. Patient received FOLFOX plus bevacizumab; after four cycles there is radiographic progression in the liver. No additional predictive biomarkers were reported in the chart.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX + bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Young man with metastatic cutaneous melanoma diagnosed after an excision of a nodular lesion. Molecular testing positive for BRAF V600E. Baseline brain MRI revealed a 1.2 cm cerebellar metastasis. He received combination targeted therapy (dabrafenib and trametinib) and stereotactic radiosurgery to the cerebellar lesion. PET/CT shows decrease in extracranial disease burden; intracranial lesion responded as well.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Young adult with a 0.8 mm superficial spreading melanoma on the right forearm, no ulceration, negative sentinel node biopsy \u2014 staged as IA. No molecular testing was performed at this time. Managed with wide local excision and routine dermatologic follow-up; healing uncomplicated and no recurrence at 6-month visit.", "output": {"cancer_type": "cutaneous melanoma (superficial spreading)", "stage": "I (IA)", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision", "response": "no evidence of recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 70-year-old male with metastatic colon adenocarcinoma presented with new right upper quadrant pain. CT shows multiple hepatic lesions; biopsy confirms colorectal primary. Stage IV at diagnosis. Molecular: KRAS G12D positive; MSI testing returns microsatellite stable. CEA at diagnosis 12 ng/mL (elevated). He completed 8 cycles of FOLFOX with bevacizumab with radiographic stable disease and symptom palliation.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable, CEA 12 ng/mL", "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with pancreatic ductal adenocarcinoma, clinical stage IIB (T3N1) diagnosed by EUS-guided biopsy. CA 19-9 at diagnosis was 1,200 U/mL. No molecular profiling was performed. He initiated systemic therapy with gemcitabine plus nab-paclitaxel; after four cycles the CT scan showed interval enlargement of the primary pancreatic mass consistent with progression. No distant metastases were identified on the scan.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IIB", "gene_mutation": null, "biomarker": "CA 19-9 1,200 U/mL", "treatment": "gemcitabine and nab-paclitaxel", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with newly diagnosed lung adenocarcinoma. Biopsy-confirmed stage IV disease with MRI showing multiple cerebellar metastases and PET positive bone lesions. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score 15%. Patient was started on osimertinib 80 mg daily and underwent stereotactic radiosurgery to the dominant brain lesion. On first restaging CT at 8 weeks she had a marked reduction in pulmonary nodules and decreased size of bone lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female underwent lumpectomy for a 1.2 cm invasive ductal carcinoma, margins negative. Pathology: ER positive, PR positive, HER2 negative by IHC/FISH. PIK3CA H1047R mutation identified on panel. Tumor staged as I (pT1cN0). She declined chemotherapy and was started on adjuvant tamoxifen. Follow-up mammogram and clinical exam at 12 months show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive, PR positive, HER2 negative", "treatment": "lumpectomy; adjuvant tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology note: 68-year-old with locally advanced pancreatic ductal adenocarcinoma causing pain and gastric outlet symptoms. Imaging consistent with stage III unresectable disease. The patient was treated with combination gemcitabine plus nab-paclitaxel and concurrent hypofractionated radiotherapy as a neoadjuvant/consolidation approach. No actionable mutations were reported on the initial panel and PD-L1 testing was not performed. Restaging showed progression of the primary with encasement of the superior mesenteric vessels.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine and nab-paclitaxel with concurrent radiotherapy", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology consult: 40-year-old man with metastatic cutaneous melanoma. Tumor testing positive for BRAF V600E and a high tumor mutational burden (TMB-high). He was started on combination targeted therapy with dabrafenib and trametinib. Brain MRI showed a single 8 mm asymptomatic metastasis treated with stereotactic radiosurgery. Interval PET/CT demonstrates a partial response in pulmonary and nodal disease after 3 months of systemic therapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib; stereotactic radiosurgery to brain lesion", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with ulcerated primary melanoma of the right back, sentinel lymph node positive, staged as IIIB. BRAF testing identified V600E. He was started on adjuvant dabrafenib plus trametinib; interval PET/CT demonstrates decreased FDG uptake in the axillary and right paraspinal nodes with overall reduction in nodal burden.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib", "response": "partial response", "metastasis_site": "regional lymph nodes (axillary; paraspinal)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with newly diagnosed metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Molecular testing shows MSI-H by PCR and a BRAF V600E mutation on NGS. Started systemic therapy with FOLFOX plus bevacizumab. Interval imaging after 3 cycles documented enlargement of hepatic lesions and new ascites consistent with progression of disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old woman with metastatic invasive ductal carcinoma of the breast, ER+/PR+, HER2-amplified by FISH. At presentation she had multiple hepatic metastases and was staged as IV. Tumor sequencing identified a PIK3CA E545K mutation. She received 6 cycles of docetaxel with trastuzumab and pertuzumab, then transitioned to T-DM1 for residual disease. Follow-up CT shows interval reduction in liver lesions consistent with partial response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "docetaxel with trastuzumab and pertuzumab; followed by T-DM1", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma diagnosed after exploratory laparoscopy. Germline testing revealed a pathogenic BRCA1 185delAG mutation. Imaging demonstrated bilateral adnexal masses with omental caking and diffuse peritoneal implants; ascites present. Patient underwent interval debulking after 3 cycles of carboplatin and paclitaxel and is currently on olaparib maintenance. CA-125 has normalized and recent CT shows stable disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 185delAG", "biomarker": "CA-125 elevated (now normalized)", "treatment": "carboplatin and paclitaxel followed by olaparib maintenance", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old female with metastatic disease referred to oncology. Biopsy of right lower lobe confirmed lung adenocarcinoma. Molecular testing identified EGFR L858R mutation by PCR. PD-L1 TPS reported at 10%. Patient was started on osimertinib 80 mg daily with rapid symptomatic improvement. First CT at 8 weeks demonstrated a partial response. Bone scan positive for lumbar spine metastasis.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with palpable left breast mass. Core biopsy: invasive ductal carcinoma, ER+, PR+, HER2 amplification by FISH. Staging workup consistent with T2N1 (stage II). She underwent lumpectomy with sentinel node biopsy followed by adjuvant paclitaxel and trastuzumab; endocrine therapy (tamoxifen) planned for 5 years. Post-op imaging shows no residual disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": null, "biomarker": "ER+, PR+, HER2 amplification", "treatment": "lumpectomy; adjuvant paclitaxel and trastuzumab; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with newly diagnosed metastatic colorectal adenocarcinoma. Tumor sequencing identified KRAS G12D and the tumor was mismatch repair proficient (MSI-stable). Baseline CT shows multiple hepatic lesions. He was started on FOLFOX with bevacizumab; interval imaging after 3 cycles demonstrated enlargement of the dominant liver lesion and new hepatic nodularity consistent with radiographic progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX plus bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old woman with high-grade serous ovarian carcinoma, upfront surgical staging showed stage IIIC disease with omental and peritoneal implants. Germline testing identified a pathogenic BRCA1 185delAG mutation and tumor was HRD-positive. She completed debulking surgery followed by six cycles of carboplatin and paclitaxel with excellent clinical response and was started on maintenance olaparib. CA-125 normalized and CT scan at 12 weeks showed no measurable disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 185delAG", "biomarker": "HRD-positive", "treatment": "debulking surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "clinical complete response / no measurable disease", "metastasis_site": "peritoneum and omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old man with metastatic lung adenocarcinoma presented with progressive dyspnea. Biopsy confirmed lung adenocarcinoma, stage IV with brain and bone metastases. Molecular testing demonstrated KRAS G12C mutation; PD-L1 by IHC 60%; tumor mutational burden reported as TMB-high. He was started on combination therapy with pembrolizumab plus carboplatin and paclitaxel. After three cycles imaging showed a partial response with shrinkage of the primary and decreased FDG uptake in bone lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": "PD-L1 60%, TMB-high", "treatment": "pembrolizumab + carboplatin and paclitaxel", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Record: 45F with locally advanced breast cancer (invasive ductal carcinoma), clinical stage IIIB. ER/PR negative, HER2 amplification on FISH. Genomic profiling identified PIK3CA H1047R. Neoadjuvant regimen: weekly paclitaxel with trastuzumab and pertuzumab for 12 weeks. Imaging showed reduction in tumor size consistent with a partial response prior to surgery.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "paclitaxel with trastuzumab and pertuzumab (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man underwent sigmoid resection for pT3N1 colon adenocarcinoma (stage III). Tumor NGS returned KRAS G12D. He completed adjuvant FOLFOX for 6 months. Surveillance imaging at one year shows no radiographic evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "surgery (sigmoid resection), adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Tumor NGS showed KRAS G12D mutation; tumor was MSI-stable and PD-L1 negative. He was treated first-line with FOLFOX plus bevacizumab. At 4-month restaging CT there was interval hepatic progression and he was transitioned to an irinotecan-based regimen.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma presented with right upper quadrant pain. CT abdomen demonstrates multiple hepatic lesions consistent with metastases. Tumor sequencing revealed KRAS G12D. Plan is to start systemic therapy with FOLFOX plus bevacizumab. Follow-up imaging after three months shows overall measurements unchanged from baseline.", "output": {"cancer_type": "colon (colorectal) adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female presenting with high-grade serous ovarian carcinoma, FIGO stage IV with peritoneal carcinomatosis and liver metastases. Germline BRCA1 mutation identified. CA-125 markedly elevated pre-treatment. She underwent optimal cytoreductive surgery followed by carboplatin and paclitaxel; CT shows partial response and she was placed on maintenance olaparib. Progression documented at 8 months.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IV", "gene_mutation": "BRCA1 mutation", "biomarker": "CA-125 elevated", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "initial partial response then progression at 8 months", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 55-year-old with metastatic cutaneous melanoma. NGS showed BRAF V600E mutation. PD-L1 by IHC was 5% and tumor mutational burden was reported as high. He was started on combination targeted therapy with dabrafenib plus trametinib. Brain MRI at 8 weeks showed shrinkage of several pulmonary nodules but new enhancing foci in the cerebellum, described in the notes as a mixed response with intracranial progression requiring stereotactic radiosurgery.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%; TMB-high", "treatment": "dabrafenib + trametinib; stereotactic radiosurgery to cerebellar lesions", "response": "mixed response (systemic regression with intracranial progression)", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "32-year-old with history of cutaneous melanoma previously excised, now presents with multiple bilateral pulmonary nodules on chest CT consistent with metastatic recurrence. Genomic testing identified BRAF V600E. Patient was started on combination targeted therapy with dabrafenib and trametinib; chest imaging after 8 weeks demonstrates complete radiographic resolution of the lung lesions. PD-L1 testing was not performed.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib", "response": "complete response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy of the breast demonstrates invasive ductal carcinoma, ER-negative, PR-negative, HER2 amplified by FISH. Clinical staging cT4bN1 consistent with stage IIIB. Patient received neoadjuvant trastuzumab and pertuzumab with docetaxel x6 cycles, with significant reduction in tumor bulk but persistent nodal disease on exam. No distant metastases on staging PET/CT; plan for modified radical mastectomy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "trastuzumab + pertuzumab + docetaxel (neoadjuvant)", "response": "partial response (residual nodal disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old man with newly symptomatic metastatic prostate adenocarcinoma. Bone scan and CT show multiple sclerotic lesions in the spine and pelvis consistent with osseous metastases. Clinical stage IV. He was started on androgen-deprivation therapy with leuprolide and received docetaxel 75 mg/m2 q3w. PSA has stabilized on therapy and imaging demonstrates radiographic stable disease. Limited molecular testing performed previously showed no actionable alterations.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old woman diagnosed with high-grade serous ovarian carcinoma, FIGO stage IIIC with bulky peritoneal disease. Germline testing revealed a pathogenic BRCA1 5382insC variant; HRD assay reported positive. She received carboplatin and paclitaxel with interval debulking surgery and was subsequently started on olaparib maintenance. Postoperative imaging after three cycles showed a partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 5382insC (germline)", "biomarker": "HRD positive", "treatment": "carboplatin and paclitaxel; interval debulking surgery; olaparib maintenance", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old with newly diagnosed metastatic colorectal adenocarcinoma. Colonoscopy removed primary tumor in sigmoid; CT shows multiple liver lesions and omental nodularity consistent with peritoneal disease (stage IV). Tumor testing: KRAS G12D mutation, MSI-stable. Patient was started on FOLFOX with bevacizumab. After three cycles there is radiographic progression in the liver.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX; bevacizumab", "response": "progression", "metastasis_site": "liver; peritoneum"}}
